
<html lang="en"     class="pb-page"  data-request-id="a4659a25-f6d5-493c-8bd0-3d706ec01e6a"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;website:website:acspubs;article:article:10.1021/acs.jmedchem.9b01346;issue:issue:10.1021/jmcmar.2019.62.issue-21;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Discovery of a Series of 5-Azaquinazolines as Orally Efficacious IRAK4 Inhibitors Targeting MyD88L265P Mutant Diffuse Large B Cell Lymphoma" /></meta><meta name="dc.Creator" content="Sébastien L.  Degorce" /></meta><meta name="dc.Creator" content="Rana  Anjum" /></meta><meta name="dc.Creator" content="Andrew  Bloecher" /></meta><meta name="dc.Creator" content="Rodrigo J.  Carbajo" /></meta><meta name="dc.Creator" content="Keith S.  Dillman" /></meta><meta name="dc.Creator" content="Lisa  Drew" /></meta><meta name="dc.Creator" content="Christopher T.  Halsall" /></meta><meta name="dc.Creator" content="Eva M.  Lenz" /></meta><meta name="dc.Creator" content="Nicola A.  Lindsay" /></meta><meta name="dc.Creator" content="Michele F.  Mayo" /></meta><meta name="dc.Creator" content="Jennifer H.  Pink" /></meta><meta name="dc.Creator" content="Graeme R.  Robb" /></meta><meta name="dc.Creator" content="Alan  Rosen" /></meta><meta name="dc.Creator" content="James S.  Scott" /></meta><meta name="dc.Creator" content="Yafeng  Xue" /></meta><meta name="dc.Description" content="In this article, we report the discovery of a series of 5-azaquinazolines as selective IRAK4 inhibitors. From modestly potent quinazoline 4, we introduced a 5-aza substitution to mask the 4-NH hydr..." /></meta><meta name="Description" content="In this article, we report the discovery of a series of 5-azaquinazolines as selective IRAK4 inhibitors. From modestly potent quinazoline 4, we introduced a 5-aza substitution to mask the 4-NH hydr..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="October 17, 2019" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.9b01346" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="Copyright © 2019 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.9b01346" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.9b01346" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.9b01346" /></link>
        
    
    

<title>Discovery of a Series of 5-Azaquinazolines as Orally Efficacious IRAK4 Inhibitors Targeting MyD88L265P Mutant Diffuse Large B Cell Lymphoma | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.9b01346" /></meta><meta property="og:title" content="Discovery of a Series of 5-Azaquinazolines as Orally Efficacious IRAK4 Inhibitors Targeting MyD88L265P Mutant Diffuse Large B Cell Lymphoma" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-21/acs.jmedchem.9b01346/20191108/images/large/jm9b01346_0005.jpeg" /></meta><meta property="og:description" content="In this article, we report the discovery of a series of 5-azaquinazolines as selective IRAK4 inhibitors. From modestly potent quinazoline 4, we introduced a 5-aza substitution to mask the 4-NH hydrogen bond donor (HBD). This allowed us to substitute the core with a 2-aminopyrazole, which showed large gains in cellular potency despite the additional formal HBD. Further optimization led to 6-cyanomethyl-5-azaquinazoline 13, a selective IRAK4 inhibitor, which proved efficacious in combination with ibrutinib, while showing very little activity as a single agent up to 100 mg/kg. This contrasted to previously reported IRAK4 inhibitors that exhibited efficacy in the same model as single agents and was attributed to the enhanced specificity of 13 toward IRAK4." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.9b01346"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.9b01346">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.9b01346&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.9b01346&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.9b01346&amp;href=/doi/10.1021/acs.jmedchem.9b01346" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2019</span><span class="cit-fg-volume">, 62</span><span class="cit-fg-issue">, 21</span><span class="cit-fg-pageRange">, 9918-9930</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/62/21" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.9b01324" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.9b01369" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Discovery of a Series of 5-Azaquinazolines as Orally Efficacious IRAK4 Inhibitors Targeting MyD88<sup>L265P</sup> Mutant Diffuse Large B Cell Lymphoma</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Sébastien L. Degorce</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Sébastien L. Degorce</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Medicinal Chemistry, Oncology R&D, AstraZeneca, Cambridge Science Park, Unit 310 Darwin Building, Cambridge CB4 0WG, U.K.</div></div><span class="conrtib-corresp"><strong>*</strong>E-mail: <a href="/cdn-cgi/l/email-protection#1d6e787f7c6e697478733379787a726f7e785d7c6e696f7c677873787e7c337e7270"><span class="__cf_email__" data-cfemail="4f3c2a2d2e3c3b262a21612b2a28203d2c2a0f2e3c3b3d2e352a212a2c2e612c2022">[email protected]</span></a></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=S%C3%A9bastien+L.++Degorce">Sébastien L. Degorce</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-9478-5106" title="Orcid link">http://orcid.org/0000-0002-9478-5106</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Rana Anjum</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Rana Anjum</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Bioscience, Oncology R&D, AstraZeneca, Boston, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Rana++Anjum">Rana Anjum</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Andrew Bloecher</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Andrew Bloecher</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Bioscience, Oncology R&D, AstraZeneca, Boston, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Andrew++Bloecher">Andrew Bloecher</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Rodrigo J. Carbajo</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Rodrigo J. Carbajo</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Medicinal Chemistry, Oncology R&D, AstraZeneca, Cambridge Science Park, Unit 310 Darwin Building, Cambridge CB4 0WG, U.K.</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Rodrigo+J.++Carbajo">Rodrigo J. Carbajo</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Keith S. Dillman</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Keith S. Dillman</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Bioscience, Oncology R&D, AstraZeneca, Boston, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Keith+S.++Dillman">Keith S. Dillman</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Lisa Drew</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Lisa Drew</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Bioscience, Oncology R&D, AstraZeneca, Boston, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Lisa++Drew">Lisa Drew</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Christopher T. Halsall</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Christopher T. Halsall</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Medicinal Chemistry, Oncology R&D, AstraZeneca, Cambridge Science Park, Unit 310 Darwin Building, Cambridge CB4 0WG, U.K.</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Christopher+T.++Halsall">Christopher T. Halsall</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Eva M. Lenz</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Eva M. Lenz</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Medicinal Chemistry, Oncology R&D, AstraZeneca, Cambridge Science Park, Unit 310 Darwin Building, Cambridge CB4 0WG, U.K.</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Eva+M.++Lenz">Eva M. Lenz</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Nicola A. Lindsay</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Nicola A. Lindsay</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Medicinal Chemistry, Oncology R&D, AstraZeneca, Cambridge Science Park, Unit 310 Darwin Building, Cambridge CB4 0WG, U.K.</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Nicola+A.++Lindsay">Nicola A. Lindsay</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Michele F. Mayo</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Michele F. Mayo</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Bioscience, Oncology R&D, AstraZeneca, Boston, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Michele+F.++Mayo">Michele F. Mayo</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Jennifer H. Pink</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jennifer H. Pink</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Medicinal Chemistry, Oncology R&D, AstraZeneca, Cambridge Science Park, Unit 310 Darwin Building, Cambridge CB4 0WG, U.K.</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jennifer+H.++Pink">Jennifer H. Pink</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Graeme R. Robb</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Graeme R. Robb</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Medicinal Chemistry, Oncology R&D, AstraZeneca, Cambridge Science Park, Unit 310 Darwin Building, Cambridge CB4 0WG, U.K.</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Graeme+R.++Robb">Graeme R. Robb</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-4531-4375" title="Orcid link">http://orcid.org/0000-0002-4531-4375</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Alan Rosen</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Alan Rosen</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Bioscience, Oncology R&D, AstraZeneca, Boston, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Alan++Rosen">Alan Rosen</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">James S. Scott</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">James S. Scott</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Medicinal Chemistry, Oncology R&D, AstraZeneca, Cambridge Science Park, Unit 310 Darwin Building, Cambridge CB4 0WG, U.K.</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=James+S.++Scott">James S. Scott</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-2263-7024" title="Orcid link">http://orcid.org/0000-0002-2263-7024</a></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">Yafeng Xue</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Yafeng Xue</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Discovery Sciences, R&D, AstraZeneca, Gothenburg SE-431 83, Mölndal, Sweden</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Yafeng++Xue">Yafeng Xue</a></span></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.9b01346&amp;href=/doi/10.1021%2Facs.jmedchem.9b01346" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2019</span></span><span class="cit-volume">, 62</span><span class="cit-issue">, 21</span><span class="cit-pageRange">, 9918–9930</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">October 17, 2019</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>15 August 2019</li><li><span class="item_label"><b>Published</b> online</span>17 October 2019</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 14 November 2019</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.9b01346" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b01346</a></div><div class="article_header-article-copyright"><strong>Copyright © 2019 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D9918%26pageCount%3D13%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DS%25C3%25A9bastien%2BL.%2BDegorce%252C%2BRana%2BAnjum%252C%2BAndrew%2BBloecher%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D62%26issueNum%3D21%26contentID%3Dacs.jmedchem.9b01346%26title%3DDiscovery%2Bof%2Ba%2BSeries%2Bof%2B5-Azaquinazolines%2Bas%2BOrally%2BEfficacious%2BIRAK4%2BInhibitors%2BTargeting%2BMyD88L265P%2BMutant%2BDiffuse%2BLarge%2BB%2BCell%2BLymphoma%26numPages%3D13%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D9930%26publicationDate%3DNovember%2B2019">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.9b01346"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">1860</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">7</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.9b01346" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Discovery of a Series of 5-Azaquinazolines as Orally Efficacious IRAK4 Inhibitors Targeting MyD88L265P Mutant Diffuse Large B Cell Lymphoma&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Sébastien&quot;,&quot;last_name&quot;:&quot;L. Degorce&quot;},{&quot;first_name&quot;:&quot;Rana&quot;,&quot;last_name&quot;:&quot;Anjum&quot;},{&quot;first_name&quot;:&quot;Andrew&quot;,&quot;last_name&quot;:&quot;Bloecher&quot;},{&quot;first_name&quot;:&quot;Rodrigo&quot;,&quot;last_name&quot;:&quot;J. Carbajo&quot;},{&quot;first_name&quot;:&quot;Keith&quot;,&quot;last_name&quot;:&quot;S. Dillman&quot;},{&quot;first_name&quot;:&quot;Lisa&quot;,&quot;last_name&quot;:&quot;Drew&quot;},{&quot;first_name&quot;:&quot;Christopher&quot;,&quot;last_name&quot;:&quot;T. Halsall&quot;},{&quot;first_name&quot;:&quot;Eva&quot;,&quot;last_name&quot;:&quot;M. Lenz&quot;},{&quot;first_name&quot;:&quot;Nicola&quot;,&quot;last_name&quot;:&quot;A. Lindsay&quot;},{&quot;first_name&quot;:&quot;Michele&quot;,&quot;last_name&quot;:&quot;F. Mayo&quot;},{&quot;first_name&quot;:&quot;Jennifer&quot;,&quot;last_name&quot;:&quot;H. Pink&quot;},{&quot;first_name&quot;:&quot;Graeme&quot;,&quot;last_name&quot;:&quot;R. Robb&quot;},{&quot;first_name&quot;:&quot;Alan&quot;,&quot;last_name&quot;:&quot;Rosen&quot;},{&quot;first_name&quot;:&quot;James&quot;,&quot;last_name&quot;:&quot;S. Scott&quot;},{&quot;first_name&quot;:&quot;Yafeng&quot;,&quot;last_name&quot;:&quot;Xue&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2019&quot;,&quot;month&quot;:&quot;10&quot;,&quot;day&quot;:&quot;17&quot;,&quot;issue&quot;:&quot;21&quot;,&quot;volume&quot;:&quot;62&quot;,&quot;pages&quot;:&quot;9918-9930&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.9b01346&quot;},&quot;abstract&quot;:&quot;In this article, we report the discovery of a series of 5-azaquinazolines as selective IRAK4 inhibitors. From modestly potent quinazoline 4, we introduced a 5-aza substitution to mask the 4-NH hydrogen bond donor (HBD). This allowed us to substitute the core with a 2-aminopyrazole, which showed large gains in cellular potency despite the additional formal HBD. Further optimization led to 6-cyanomethyl-5-azaquinazoline 13, a selective IRAK4 inhibitor, which proved efficacious in combination with ibrutinib, while showing very little activity as a single agent up to 100 mg/kg. This contrasted to previously reported IRAK4 inhibitors that exhibited efficacy in the same model as single agents and was attributed to the enhanced specificity of 13 toward IRAK4.&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.9b01346&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b01346" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.9b01346&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b01346" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.9b01346&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b01346" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.9b01346&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b01346&amp;href=/doi/10.1021/acs.jmedchem.9b01346" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.9b01346" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.9b01346" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (4 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b01346&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.9b01346%26sid%3Dliteratum%253Aachs%26pmid%3D31622099%26genre%3Darticle%26aulast%3DDegorce%26date%3D2019%26atitle%3DDiscovery%2Bof%2Ba%2BSeries%2Bof%2B5-Azaquinazolines%2Bas%2BOrally%2BEfficacious%2BIRAK4%2BInhibitors%2BTargeting%2BMyD88L265P%2BMutant%2BDiffuse%2BLarge%2BB%2BCell%2BLymphoma%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D62%26issue%3D21%26spage%3D9918%26epage%3D9930%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (2)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=292365" title="Electromagnetic radiation">Electromagnetic radiation</a>,</li><li><a href="/action/doSearch?ConceptID=292464" title="Rodent models">Rodent models</a>,</li><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a>,</li><li><a href="/action/doSearch?ConceptID=291793" title="Inhibition">Inhibition</a>,</li><li><a href="/action/doSearch?ConceptID=292349" title="Alkyls">Alkyls</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/62/21" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-21/jmcmar.2019.62.issue-21/20191114/jmcmar.2019.62.issue-21.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-21/acs.jmedchem.9b01346/20191108/images/medium/jm9b01346_0005.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-21/acs.jmedchem.9b01346/20191108/images/large/jm9b01346_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01346&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">In this article, we report the discovery of a series of 5-azaquinazolines as selective IRAK4 inhibitors. From modestly potent quinazoline <b>4</b>, we introduced a 5-aza substitution to mask the 4-NH hydrogen bond donor (HBD). This allowed us to substitute the core with a 2-aminopyrazole, which showed large gains in cellular potency despite the additional formal HBD. Further optimization led to 6-cyanomethyl-5-azaquinazoline <b>13</b>, a selective IRAK4 inhibitor, which proved efficacious in combination with ibrutinib, while showing very little activity as a single agent up to 100 mg/kg. This contrasted to previously reported IRAK4 inhibitors that exhibited efficacy in the same model as single agents and was attributed to the enhanced specificity of <b>13</b> toward IRAK4.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_41366" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_41366" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">Activated B cell-like diffuse large B cell lymphoma (ABC-DLBCL) is an aggressive type of DLBCL that has been associated with constitutively active nuclear factor-kappa B (NFκB) signaling. Recurrent oncogenic mutations in myeloid differentiation primary response gene 88 (MyD88), an adaptor protein, have been identified in ABC-DLBCL, and a specific L265P mutation has been observed in almost 30% of cases of ABC-DLBC, sometimes accompanied by co-occurring mutations of the B cell receptor (BCR) transmembrane protein partner, cluster of differentiation 79 (CD79).<a onclick="showRef(event, 'ref1 ref2'); return false;" href="javascript:void(0);" class="ref ref1 ref2">(1,2)</a> While BCR signaling can be inhibited clinically with Bruton’s tyrosine kinase (BTK) inhibitors such as ibrutinib<a onclick="showRef(event, 'ref3 ref4'); return false;" href="javascript:void(0);" class="ref ref3 ref4">(3,4)</a> or acalabrutinib,<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> cellular signaling driven by mutant MyD88<sup>L265P</sup> results in the constitutive activation of interleukin-1 receptor-associated kinase 4 (IRAK4). Activation of IRAK4 leads to phosphorylation of inhibitor of kappa B (IκBα) and downstream activation of NFκB signaling.<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> IRAK4 kinase activity has been shown to be necessary for MyD88<sup>L265P</sup>-driven survival signaling in DLBCL in addition to the Toll-like receptor (TLR)/interleukin 1B receptor (IL-1b)-mediated innate immune response.<a onclick="showRef(event, 'ref2 ref7'); return false;" href="javascript:void(0);" class="ref ref2 ref7">(2,7)</a> Oncology groups, including ourselves, have reported IRAK4 inhibitors that demonstrated tumor growth inhibition (TGI) in double-mutant (MyD88<sup>L265P</sup>/CD79<sup>MUT</sup>) ABC-DLBCL models in combination with ibrutinib.<a onclick="showRef(event, 'ref8 ref9 ref10'); return false;" href="javascript:void(0);" class="ref ref8 ref9 ref10">(8−10)</a> Multiple other IRAK4 inhibitors are currently being evaluated in preclinical and early clinical phases,<a onclick="showRef(event, 'ref11 ref12'); return false;" href="javascript:void(0);" class="ref ref11 ref12">(11,12)</a> with the most advanced molecule PF-06650833 in phase 2.<a onclick="showRef(event, 'ref13 ref14'); return false;" href="javascript:void(0);" class="ref ref13 ref14">(13,14)</a> Our efforts focused on the identification of potent and selective IRAK4 inhibitors to assess the combined effect of IRAK4 and BTK inhibitions against double-mutant (MyD88<sup>L265P</sup>/CD79<sup>MUT</sup>) DLBCL.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Synthesis</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_53356" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_53356" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Previously unreported disubstituted quinazolines <b>4</b> and <b>9</b> were prepared via S<sub>N</sub>Ar displacement of the corresponding 4-chloroquinazoline with methyl 4-(<i>trans</i>-4-aminocyclohexyl)piperazine-1-carboxylate (<a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>). <named-content content-type="anchor" rid="sch2" type="simple"></named-content>Trisubstituted quinazolines <b>6</b> and <b>7</b> were synthesized following a regioselective C4 displacement of 2,4-dichloroquinazoline-6-carbonitrile followed either by acid-catalyzed C2 displacement or by RuPhos-catalyzed cross-coupling with 1-methyl-4-aminopyrazole. Similarly, 6-methyl-2,4-dicholoro-5-azaquinazoline was treated with methyl 4-(<i>trans</i>-4-aminocyclohexyl)piperazine-1-carboxylate to give 2-chloroquinazoline intermediate <b>10a</b> that either yielded <b>10</b> after hydrogenolysis of the 2-Cl or <b>12</b> after C2 displacement with 1-methyl-4-aminopyrazole. 2,4,6-Tricholoro-5-azaquinazoline was used in an analogous fashion to synthesize <b>13</b> after Suzuki cross-coupling with 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)isoxazole followed by potassium fluoride-induced ring opening of the isoxazole as the last two steps.<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a></div><figure id="sch1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-21/acs.jmedchem.9b01346/20191108/images/medium/jm9b01346_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-21/acs.jmedchem.9b01346/20191108/images/large/jm9b01346_0008.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of Quinazolines <b>4</b>, <b>6</b>, <b>7</b>, and <b>9</b> and 5-Azaquinazolines <b>10</b> and <b>12</b>–<b>13</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-21/acs.jmedchem.9b01346/20191108/images/large/jm9b01346_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01346&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) methyl 4-(<i>trans</i>-4-aminocyclohexyl)piperazine-1-carboxylate or 1-(4-(<i>trans</i>-4-aminocyclohexyl)piperazin-1-yl)ethanone, DIPEA, <i>n</i>-BuOH or <i>i</i>-PrOH or NMP, 60–150 °C, 3 h (37–84%); (b) 1-methyl-4-aminopyrazole, RuPhos-Pd-G3, Cs<sub>2</sub>CO<sub>3</sub>, 1,4-dioxane, 100 °C, 16 h (<b>6</b>, 49%); (c) 1-methyl-4-aminopyrazole, TsOH, EtOH, 90 °C, 3 h (32–97%); (d) Pd/C, H<sub>2</sub>, dimethylformamide (DMF)/EtOH, room temperature (RT), 18 h (28%); (e) XPhos-Pd-G2, 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)isoxazole, KF, dimethyl sulfoxide (DMSO), 100 °C, 2 h (94%); and (f) KF, MeOH, 100 °C, 2 h (51%).</p></p></figure><div class="NLM_p">2,6-Dicholoro-5-azaquinazolin-4-one was used to make <b>14</b> by condensation with ethyl 2-cyanopropanoate, followed by C2 displacement with 1-methyl-4-aminopyrazole and PyBop-mediated coupling at C4 (<a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>). Other analogues reported required building the 5-azaquinazoline core from the appropriate 3-aminopyridine. In the case of 6-cyano-5-azaquinazoline <b>11</b>, the sequence involved cyanation of 3-amino-6-chloro-2-pyridinecarboxamide with zinc cyanide, cyclization with triphosgene, activation with phosphorous oxychloride, and C4 and C2 couplings as described above. Likewise, <b>15</b> and <b>16</b> were prepared using the commercially available 2-(5-amino-2-pyridinyl)-2-methylpropanenitrile or 1-(5-amino-2-pyridinyl)cyclopropanecarbonitrile. These required bromination followed by reaction with zinc cyanide and subsequent hydrolysis to give the carboxamide precursors to the 5-azaquinazoline core. An analogous sequence as used for <b>12</b> then gave the corresponding C2- and C4-activated 5-azaquinazolines, which were coupled as described above to give the final products.</div><figure id="sch2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-21/acs.jmedchem.9b01346/20191108/images/medium/jm9b01346_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-21/acs.jmedchem.9b01346/20191108/images/large/jm9b01346_0015.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of 5-Azaquinazolines <b>11</b> and <b>14</b>–<b>16</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-21/acs.jmedchem.9b01346/20191108/images/large/jm9b01346_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01346&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) ethyl 2-cyanopropanoate, <i>t</i>-BuONa, DMF, 80 °C, 48 h (61%); (b) methyl 4-(<i>trans</i>-4-aminocyclohexyl)piperazine-1-carboxylate, DIPEA, PyBOP, DMF, RT, 16 h (19%); (c) 1-methyl-4-aminopyrazole, HCl, EtOH, 60 °C, 30 min (72%); (d) Br<sub>2</sub>, NaOAc, AcOH, RT, 30 min (86–90%); (e) Zn(CN)<sub>2</sub>, Pd(PPh<sub>3</sub>)<sub>4</sub>, DMF, 100 °C, 21 h (94–95%); (f) H<sub>2</sub>O<sub>2</sub>, K<sub>2</sub>CO<sub>3</sub>, DMSO, 0–20 °C, 2–3 h (94–95%); (g) (i) triphosgene, 1,4-dioxane, 100 °C, 3 h; (ii) POCl<sub>3</sub>, DIPEA, toluene, 100 °C, 16 h (<b>11</b>, 49% over two steps); (h) thiophosgene, 1,4-dioxane, RT-reflux, 2 h (<b>15</b>–<b>16</b>, 78–83%); (j) (i) methyl 4-(<i>trans</i>-4-aminocyclohexyl)piperazine-1-carboxylate, DIPEA, <i>i</i>-PrOH, 100 °C, 1 h; (ii) 1-methyl-4-aminopyrazole, TsOH, EtOH, 80 °C, 2 h (<b>11</b>, 11% over two steps); and (k) (i) 1-methyl-4-aminopyrazole, HCl, EtOH, 70–80 °C, 1 h; (ii) methyl 4-(<i>trans</i>-4-aminocyclohexyl)piperazine-1-carboxylate, DIPEA, PyBOP, DMF, RT, 16 h (<b>15</b>–<b>16</b>, 8–35%, over two steps).</p></p></figure></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i6">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_08211" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_08211" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">We and others<a onclick="showRef(event, 'ref16 ref17'); return false;" href="javascript:void(0);" class="ref ref16 ref17">(16,17)</a> have independently discovered quinazolines exemplified by 2–3 as potentially useful inhibitors of IRAK4 (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>). Our own investigation originated from previously reported pyrrolotriazine <b>1</b>,<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> a known quinazoline bioisostere, whose natural evolution led us to quinazoline <b>4</b> after an optimization campaign similar to that reported by Smith et al.<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> While in terms of potency and pharmacology, quinazolines <b>2</b>–<b>4</b> were very similar, we found <b>4</b> to be superior in terms of permeability and absorption owing to the presence of a methyl carbamate-capped piperazine, in agreement with our previous observations.<a onclick="showRef(event, 'ref8 ref10'); return false;" href="javascript:void(0);" class="ref ref8 ref10">(8,10)</a> In addition, <b>4</b> exhibited lower clearance in rat compared to both <b>2</b> and <b>3</b> (CL = 7.4 vs 20 and 19 mL/min/kg, respectively) and superior bioavailability relative to <b>2</b> (<i>F</i>% > 100 vs 29%, respectively). We obtained a crystal structure of <b>4</b>, which had a binding mode consistent with that of previously published 6-nitroquinazoline <b>8</b>,<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> as shown in <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>. In addition to the standard “hinge” interactions with Val263 and Met265, <b>4</b> makes hydrogen-bonding interactions with both Asp272 and Lys213. Two solvent molecules are also directly coordinated by <b>4</b>: one through the cyano group and one through the nitrogen donor substituent at the 4-position of the quinazoline. The addition of a 1-methyl-4-aminopyrazole group, a common motif in kinase inhibitors,<a onclick="showRef(event, 'ref18 ref19'); return false;" href="javascript:void(0);" class="ref ref18 ref19">(18,19)</a> at the 2-position of the quinazoline provided up to 100-fold improvement in enzyme potency but only 5-fold improvement in cell potency in previously reported analogue <b>5</b>,<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> as well as in <b>6</b>–<b>7</b>. The resulting increased enzyme:cell drop-off is in line with the loss of intrinsic permeability and increased efflux, presumably due to the additional hydrogen bond donor (HBD) to the hinge. This was particularly pronounced in matched pair quinazolines <b>3</b> and <b>6</b>, where efflux increased by about 17-fold. Methyl carbamate in <b>7</b> improved efflux relative to <b>6</b>, but low permeability and high efflux resulted in low oral bioavailability and precluded progression into in vivo models.</div><figure id="fig1" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-21/acs.jmedchem.9b01346/20191108/images/medium/jm9b01346_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-21/acs.jmedchem.9b01346/20191108/images/large/jm9b01346_0003.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. X-ray crystallographic structures of quinazoline <b>4</b> (orange, PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6RFI">6RFI</a>) relative to <b>8</b> (cyan, PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5T1T">5T1T</a>). Solvent molecules are only shown for 6RFI.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-21/acs.jmedchem.9b01346/20191108/images/large/jm9b01346_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01346&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Selected Quinazoline Examples of IRAK4 Inhibitors</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-21/acs.jmedchem.9b01346/20191108/images/medium/jm9b01346_0006.gif" alt="" id="fx1" /></img><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="left" /></col><col align="left" /></col><col align="char" char="/" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">entry</th><th class="colsep0 rowsep0" align="center"><i>X</i></th><th class="colsep0 rowsep0" align="center" char=".">enz IRAK4 IC<sub>50</sub><a class="ref internalNav" href="#t1fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center" char=".">cell pIRAK4 IC<sub>50</sub><a class="ref internalNav" href="#t1fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center" char=".">log <i>D</i><sub>7.4</sub><a class="ref internalNav" href="#t1fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center" char=".">hu/rat heps CL<sub>int</sub><a class="ref internalNav" href="#t1fn3" aria-label="c">c</a></th><th class="colsep0 rowsep0" align="center">Caco2 A2B P<sub>app</sub><a class="ref internalNav" href="#t1fn4" aria-label="d">d</a></th><th class="colsep0 rowsep0" align="center">Caco2 efflux ratio<a class="ref internalNav" href="#t1fn5" aria-label="e">e</a></th><th class="colsep0 rowsep0" align="center" char="/">rat CL/<i>F</i>%<a class="ref internalNav" href="#t1fn6" aria-label="f">f</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>2</b><a onclick="showRef(event, 'ref16 ref17'); return false;" href="javascript:void(0);" class="ref ref16 ref17">(16,17)</a></td><td class="colsep0 rowsep0" align="left">O</td><td class="colsep0 rowsep0" align="char" char=".">0.046</td><td class="colsep0 rowsep0" align="char" char=".">0.25</td><td class="colsep0 rowsep0" align="char" char=".">1.6</td><td class="colsep0 rowsep0" align="char" char="."><1.2/3.4</td><td class="colsep0 rowsep0" align="left">18</td><td class="colsep0 rowsep0" align="left">1.6</td><td class="colsep0 rowsep0" align="char" char="/">20/29%</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>3</b><a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a></td><td class="colsep0 rowsep0" align="left">NAc</td><td class="colsep0 rowsep0" align="char" char=".">0.122</td><td class="colsep0 rowsep0" align="char" char=".">0.42</td><td class="colsep0 rowsep0" align="char" char=".">1.4</td><td class="colsep0 rowsep0" align="char" char="."><1/<1</td><td class="colsep0 rowsep0" align="left">4.2</td><td class="colsep0 rowsep0" align="left">19</td><td class="colsep0 rowsep0" align="char" char="/">19/-</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>4</b></td><td class="colsep0 rowsep0" align="left">NCO<sub>2</sub>Me</td><td class="colsep0 rowsep0" align="char" char=".">0.037</td><td class="colsep0 rowsep0" align="char" char=".">0.16</td><td class="colsep0 rowsep0" align="char" char=".">2.2</td><td class="colsep0 rowsep0" align="char" char="."><1/<1.6</td><td class="colsep0 rowsep0" align="left">20</td><td class="colsep0 rowsep0" align="left">1.7</td><td class="colsep0 rowsep0" align="char" char="/">7.4/>100%</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>5</b><a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a></td><td class="colsep0 rowsep0" align="left">O</td><td class="colsep0 rowsep0" align="char" char=".">0.002</td><td class="colsep0 rowsep0" align="char" char=".">0.059</td><td class="colsep0 rowsep0" align="char" char=".">2.6</td><td class="colsep0 rowsep0" align="char" char="."><1/18</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">94</td><td class="colsep0 rowsep0" align="char" char="/">31/5%</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>6</b></td><td class="colsep0 rowsep0" align="left">NAc</td><td class="colsep0 rowsep0" align="char" char=".">0.001</td><td class="colsep0 rowsep0" align="char" char=".">0.40</td><td class="colsep0 rowsep0" align="char" char=".">2.3</td><td class="colsep0 rowsep0" align="char" char="."><1/3.2</td><td class="colsep0 rowsep0" align="left"><0.2</td><td class="colsep0 rowsep0" align="left">323</td><td class="colsep0 rowsep0" align="char" char="/">17/-</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>7</b></td><td class="colsep0 rowsep0" align="left">NCO<sub>2</sub>Me</td><td class="colsep0 rowsep0" align="char" char=".">0.001</td><td class="colsep0 rowsep0" align="char" char=".">0.034</td><td class="colsep0 rowsep0" align="char" char=".">3.2</td><td class="colsep0 rowsep0" align="char" char="."><1/5.4</td><td class="colsep0 rowsep0" align="left">3</td><td class="colsep0 rowsep0" align="left">46</td><td class="colsep0 rowsep0" align="char" char="/">11/10%</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup><sup>a</sup></sup><p class="last">All IC<sub>50</sub> data are expressed in micromolar (μM) and are the means of <i>n</i> ≥ 2 independent measurements. Each has an SEM ± 0.2 log units. Enzymatic IRAK4 ([ATP] = 5 mM ∼10 × <i>K</i><sub>m</sub>) and cell pIRAK4 potencies were measured as previously reported by our group.</p></div><div class="footnote" id="t1fn2"><sup><sup>b</sup></sup><p class="last">Measured using shake-flask methodology with a buffer/octanol volume ratio of 100:1.</p></div><div class="footnote" id="t1fn3"><sup><sup>c</sup></sup><p class="last">Hepatocyte intrinsic clearance (μL/min/10<sup>6</sup> cells).<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a></p></div><div class="footnote" id="t1fn4"><sup><sup>d</sup></sup><p class="last">Intrinsic permeability (10<sup>–6</sup> cm/s) using Caco2 cells.<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a></p></div><div class="footnote" id="t1fn5"><sup><sup>e</sup></sup><p class="last">Efflux ratio measured in Caco2 cells.</p></div><div class="footnote" id="t1fn6"><sup><sup>f</sup></sup><p class="last">Rat clearance (mL/min/kg) and bioavailability following a 0.5 mg/kg iv dose and 1 mg/kg po dose, respectively.</p></div></div></div><div class="NLM_p">To improve permeability, we decided to introduce a nitrogen atom into the core to give 5-azaquinazolines in which the HBD at C4 would be masked by an intramolecular H-bond (IHB). Our first C2-unsubstituted matched pair <b>9</b>–<b>10</b> (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>) indicated an acceptable loss of potency in the cell (∼4-fold) with the co-occurring lipophilicity drop resulting in a similar cellular ligand lipophilic efficiency (cell LLE). The comparison between the two enzyme:cell drop-offs of <b>9</b> and <b>10</b> (17- and 4-folds, respectively) also suggested that the desired masking of the HBD was partially successful, although this was not evident from the Caco2 measurements.</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. C6<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a> Exploration of 5-Azaquinazolines<a class="ref internalNav" href="#t2fn2" aria-label="b">b</a><sup>,</sup><a class="ref internalNav" href="#t2fn3" aria-label="c">c</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-21/acs.jmedchem.9b01346/20191108/images/medium/jm9b01346_0013.gif" alt="" id="fx2" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-21/acs.jmedchem.9b01346/20191108/images/medium/jm9b01346_0007.gif" alt="" id="fx3" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup><sup>a</sup></sup><p class="last">Experimental assays as per <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a> unless otherwise specified.</p></div><div class="footnote" id="t2fn2"><sup><sup>b</sup></sup><p class="last">Cell LLE = pIRAK4 cell pIC<sub>50</sub> – log <i>D</i><sub>7.4</sub>.</p></div><div class="footnote" id="t2fn3"><sup><sup>c</sup></sup><p class="last"><i>N</i> = 1.</p></div></div><div></div></div><div class="NLM_p">NMR experiments combined with computational models suggested that the preferred conformations in solution for <b>9</b> and <b>10</b> are similar (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>). For quinazoline <b>9</b>, a strong through-space nuclear Overhauser effect (NOE) was observed between the 4-N–H and the 5-C–H and a weaker one between the 2-C–H and the C–H of the cyclohexyl. The preferred conformation for <b>10</b> is supported by NOEs observed between the 4-N–H and the 6-CH<sub>3</sub> groups, as well as between the 2-C–H and the C–H of the cyclohexyl. In contrast, no NOE was observed between 4-N–H and 2-C–H for either <b>9</b> or <b>10</b>, nor between 5-C–H and the cyclohexyl C–H for <b>9</b>, indicating that both likely adopt in solution the preferred conformations shown in <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>. The presence of an IHB between the 4-N–H and the 5-aza in <b>10</b> was quantitatively assessed via the variation of the chemical shift of the exchangeable proton measured in CDCl<sub>3</sub> and DMSO-<i>d</i><sub>6</sub> using NMR-derived hydrogen bond acidity or <i>A</i><sub>NMR</sub>.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> An <i>A</i><sub>NMR</sub> value below 0.05 is usually characteristic of a strong IHB, while a value higher than 0.15 is usually indicative of no IHB. For <b>10</b>, an <i>A</i><sub>NMR</sub> value of 0.11 was measured experimentally, suggesting that the 4-N–H is forming a weak IHB with the lone pairs of the nitrogen atom in the 5-position of the 5-azaquinazoline core. These conclusions were supported by quantum mechanics (QM) conformational energy calculations, which determined the relative strain while rotating the 4-substituent rigidly through 360° and optimizing to the local minimum. Results supported the presence of a hydrogen bond in solution, shown in <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>A, between 4-N–H and the 5-aza (defined as 0°). The strain energy required to twist the substituent group out of plane by ±90° and breaking the interaction increased from 10.2 kcal/mol for <b>9</b> to 12.8 kcal/mol for <b>10</b>. A similar calculation was performed without a solvent model, representing a nonaqueous environment, such as the cell membrane. Here, the internal hydrogen bond is implied to be stronger, shown in <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>B. The energy required to break the interaction was predicted to be 13.2 kcal/mol for <b>10</b>, rising from 7.4 kcal/mol for <b>9</b> (when the hydrogen bond is absent). We hypothesized that some of the surface polarity is effectively masked while in the membrane, permitting permeation to occur more easily.</div><figure id="fig2" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-21/acs.jmedchem.9b01346/20191108/images/medium/jm9b01346_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-21/acs.jmedchem.9b01346/20191108/images/large/jm9b01346_0014.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Predicted solution conformations of quinazoline <b>9</b> and 5-azaquinazoline <b>10</b> based on experimental NMR data and computational models.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-21/acs.jmedchem.9b01346/20191108/images/large/jm9b01346_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01346&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig3" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-21/acs.jmedchem.9b01346/20191108/images/medium/jm9b01346_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-21/acs.jmedchem.9b01346/20191108/images/large/jm9b01346_0001.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Predicted torsion profiles for indicated C–N bond of quinazoline <b>9</b> and 5-azaquinazoline <b>10</b> based on QM calculations, representing molecules (A) solvated in water and (B) in nonaqueous environment (e.g., cell membrane).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-21/acs.jmedchem.9b01346/20191108/images/large/jm9b01346_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01346&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Introduction of the 6-cyano group onto the 5-azaquinazoline core resulted in potent compound <b>11</b> with seemingly good properties, but was found to give rise to reactive metabolites in a human microsome-mediated glutathione (GSH) trapping assay<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> (a ratio of 44% of GSH adducts relative to the control clozapine was observed [MSG + H]<sup>+</sup> = 796.3), through a presumed reaction on the 2-cyanopyridine. 6-Methyl analogue <b>12</b> showed significantly less reactive metabolites (8%, [MSG + H]<sup>+</sup> = 785.4), confirming the 2-cyanopyridine motif as the culprit for the formation of reactive metabolites. The benefit of the weak IHB was more evident in C2-substituted 5-azaquinazoline <b>12</b>. Although not a direct matched pair to <b>7</b>, it nonetheless exhibited improved intrinsic permeability and lower efflux (2.5- and 54-fold improvements, respectively) despite a lower log <i>D</i> (Δlog <i>D</i><sub>7.4</sub> = −0.6). Compared to C2-unsubstituted <b>10</b>, the addition of the 1-methyl-4-aminopyrazole at C2 in <b>12</b> showed similar benefits in potency to the <b>4</b>/<b>7</b> matched pair (i.e., ∼30-fold in the enzyme and ∼5-fold in the cell). The addition of a methylene spacer between the core and the cyano group in <b>13</b> solved the reactive metabolite issue (<1% reactive metabolites were detected in the GSH assay) and maintained good potency and properties. An X-ray crystal structure for <b>13</b> was obtained (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>), which shows the aminopyrazole making an additional hydrogen bond acceptor interaction to the hinge (Met265). The acetonitrile group maintains an interaction with Lys213, but places the acceptor in a very different location, compromising the geometry and thus the strength of the interaction. However, in doing so, this places the methylene with two polarized hydrogens within 3.5 Å of Tyr262, the gatekeeper residue. This results in a positive interaction with the π-cloud of the aromatic ring and compensates for the loss of the more direct hydrogen bond to Lys213.</div><figure id="fig4" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-21/acs.jmedchem.9b01346/20191108/images/medium/jm9b01346_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-21/acs.jmedchem.9b01346/20191108/images/large/jm9b01346_0012.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. X-ray crystallographic structures of 5-azaquinazoline <b>13</b> (green, PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6RFJ">6RFJ</a>) relative to <b>4</b> (orange).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-21/acs.jmedchem.9b01346/20191108/images/large/jm9b01346_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01346&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Metabolism of <b>13</b> in human hepatocytes was moderate (in line with the 6-methyl analogue <b>12</b>). We observed in the <sup>1</sup>H NMR of <b>13</b> that the methylene protons were potentially acidic (δ = 4.23 ppm) and thus decided to attempt blocking this position through the addition of a single methyl in <b>14</b>, a gem dimethyl in <b>15</b>, or a cyclopropyl unit in <b>16</b>. Unfortunately, all three compounds lost cell potency while also displaying higher lipophilicity, which resulted in significantly lower cell LLEs compared to <b>13</b> (LLE = 5.0), all in keeping with the observed binding mode of <b>13</b>. Overall, based on its combined profile, we deemed <b>13</b> to be a viable candidate for in vivo experiments, and thus it was profiled further.</div><div class="NLM_p"><named-content content-type="anchor" rid="fig5" type="simple"></named-content><named-content content-type="anchor" rid="tbl3" type="simple"></named-content>In terms of kinome selectivity (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>), our starting quinazoline <b>4</b> inhibited 5 of 125 kinases with >50% inhibition when tested at 1 μM: IRAK4 (97%), CDK9 (84%), ULK2 (58%), CK1g1 (53%), and MLK1 (51%). When tested in concentration responses (<a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>), the activity against the CLK family (except CLK3) and CDK8 and CDK9 was confirmed and consistent with data previously reported for <b>1</b>.<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> In contrast, 5-azaquinazoline <b>13</b> only inhibited 2 of 350 kinases with >50% inhibition when tested at 0.1 μM (0.1 μM was chosen over 1 μM to give a meaningful comparison to <b>4</b> given <b>13</b> was 10-fold more potent against IRAK4): IRAK4 (104%) and IRAK1 (70%). We were delighted to observe that in concentration responses, <b>13</b> showed improved margins against both the CDK and the CLK families. In particular, selectivity over CDK8 was improved by >1000-fold, indicating that <b>13</b> is a potent and selective IRAK4 inhibitor with modest activity against IRAK1.</div><figure id="fig5" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-21/acs.jmedchem.9b01346/20191108/images/medium/jm9b01346_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-21/acs.jmedchem.9b01346/20191108/images/large/jm9b01346_0009.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Kinome selectivity of <b>4</b> (A, 1 μM) and <b>13</b> (B, 0.1 μM).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-21/acs.jmedchem.9b01346/20191108/images/large/jm9b01346_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01346&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Enzyme Inhibitory Concentrations for <b>4</b> and <b>13</b> in Selected Kinases<a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="left"> </th><th class="colsep0 rowsep0" align="left" char="."> </th><th class="rowsep1 colsep0" colspan="2" align="center"><b>4</b></th><th class="rowsep1 colsep0" colspan="2" align="center"><b>13</b></th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="left">kinase</th><th class="colsep0 rowsep0" align="left" char=".">[ATP] (μM)</th><th class="colsep0 rowsep0" align="center">IC<sub>50</sub> (μM)</th><th class="colsep0 rowsep0" align="center">selectivity (fold)</th><th class="colsep0 rowsep0" align="center">IC<sub>50</sub> (μM)</th><th class="colsep0 rowsep0" align="center">selectivity (fold)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">IRAK4</td><td class="colsep0 rowsep0" align="char" char=".">5000</td><td class="colsep0 rowsep0" align="left">0.032</td><td class="colsep0 rowsep0" align="left">1.0</td><td class="colsep0 rowsep0" align="left">0.004</td><td class="colsep0 rowsep0" align="left">1.0</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">IRAK1</td><td class="colsep0 rowsep0" align="char" char=".">25</td><td class="colsep0 rowsep0" align="left">0.044</td><td class="colsep0 rowsep0" align="left">1.4</td><td class="colsep0 rowsep0" align="left">0.027</td><td class="colsep0 rowsep0" align="left">6.8</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CLK1*</td><td class="colsep0 rowsep0" align="char" char=".">25</td><td class="colsep0 rowsep0" align="left">1.7</td><td class="colsep0 rowsep0" align="left">53</td><td class="colsep0 rowsep0" align="left">3.1</td><td class="colsep0 rowsep0" align="left">775</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CLK2*</td><td class="colsep0 rowsep0" align="char" char=".">25</td><td class="colsep0 rowsep0" align="left">0.36</td><td class="colsep0 rowsep0" align="left">11</td><td class="colsep0 rowsep0" align="left">1.4</td><td class="colsep0 rowsep0" align="left">350</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CLK3*</td><td class="colsep0 rowsep0" align="char" char=".">150</td><td class="colsep0 rowsep0" align="left">>10</td><td class="colsep0 rowsep0" align="left">>300</td><td class="colsep0 rowsep0" align="left">>10</td><td class="colsep0 rowsep0" align="left">>2500</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CLK4*</td><td class="colsep0 rowsep0" align="char" char=".">5</td><td class="colsep0 rowsep0" align="left">0.61</td><td class="colsep0 rowsep0" align="left">19</td><td class="colsep0 rowsep0" align="left">1.0</td><td class="colsep0 rowsep0" align="left">250</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CDK7</td><td class="colsep0 rowsep0" align="char" char=".">35</td><td class="colsep0 rowsep0" align="left">3.1</td><td class="colsep0 rowsep0" align="left">97</td><td class="colsep0 rowsep0" align="left">17</td><td class="colsep0 rowsep0" align="left">4250</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CDK8*</td><td class="colsep0 rowsep0" align="char" char=".">5</td><td class="colsep0 rowsep0" align="left">0.068</td><td class="colsep0 rowsep0" align="left">2.1</td><td class="colsep0 rowsep0" align="left">>10</td><td class="colsep0 rowsep0" align="left">>2500</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CDK9</td><td class="colsep0 rowsep0" align="char" char=".">10</td><td class="colsep0 rowsep0" align="left">0.37</td><td class="colsep0 rowsep0" align="left">12</td><td class="colsep0 rowsep0" align="left">13</td><td class="colsep0 rowsep0" align="left">3250</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup><sup>a</sup></sup><p class="last">* Denotes assays ran externally at Thermo-Fisher.</p></div></div></div><div id="sec3_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i10" class="anchor-spacer"></div><h3 class="article-section__title" id="_i10"> Pharmacokinetics</h3><div class="NLM_p"><named-content content-type="anchor" rid="tbl4" type="simple"></named-content>Plasma pharmacokinetic parameters for compounds <b>4</b> and <b>13</b> were determined in Han Wistar rats (<a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>). Compound <b>4</b> showed low clearance and good absorption (<i>F</i><sub>abs</sub> > 100%), whereas <b>13</b> showed higher clearance and lower absorption (<i>F</i><sub>abs</sub> = 15%). Similarly, in SCID mice, <b>4</b> showed superior exposure, but when related to the free pIRAK4 cell IC<sub>50</sub>, both compounds showed similar duration of cover (approximately 12 h; <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>), and thus both were progressed to in vivo efficacy studies to interrogate their different pharmacology profiles.</div><figure id="fig6" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-21/acs.jmedchem.9b01346/20191108/images/medium/jm9b01346_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-21/acs.jmedchem.9b01346/20191108/images/large/jm9b01346_0010.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Mouse exposure following a 50 mg/kg oral dose, normalized as a free cover over the pIRAK4 cell IC<sub>50</sub> for <b>4</b> (blue) and <b>13</b> (green).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-21/acs.jmedchem.9b01346/20191108/images/large/jm9b01346_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01346&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. PK Parameters of Quinazoline <b>4</b> and Selected 5-Azaquinazoline <b>13</b> in Rat<a class="ref internalNav" href="#t4fn1" aria-label="a">a</a> and Mouse</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="char" char="." /></col><col align="left" /></col><col align="left" /></col><col align="char" char="." /></col><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center" char=".">entry</th><th class="colsep0 rowsep0" align="center">rat/mouse/human %free<a class="ref internalNav" href="#t4fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center">rat CL<a class="ref internalNav" href="#t4fn3" aria-label="c">c</a></th><th class="colsep0 rowsep0" align="center" char=".">rat Vdss<a class="ref internalNav" href="#t4fn4" aria-label="d">d</a></th><th class="colsep0 rowsep0" align="center">rat <i>F</i>%<a class="ref internalNav" href="#t4fn5" aria-label="e">e</a></th><th class="colsep0 rowsep0" align="center" char=".">mouse AUC<a class="ref internalNav" href="#t4fn6" aria-label="f">f</a></th><th class="colsep0 rowsep0" align="center" char=".">solubility<a class="ref internalNav" href="#t4fn7" aria-label="g">g</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char="."><b>4</b></td><td class="colsep0 rowsep0" align="left">5/28/23</td><td class="colsep0 rowsep0" align="left">7.4</td><td class="colsep0 rowsep0" align="char" char=".">1.3</td><td class="colsep0 rowsep0" align="left">>100</td><td class="colsep0 rowsep0" align="char" char=".">390</td><td class="colsep0 rowsep0" align="char" char=".">130</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char="."><b>13</b></td><td class="colsep0 rowsep0" align="left">23/44/30</td><td class="colsep0 rowsep0" align="left">25</td><td class="colsep0 rowsep0" align="char" char=".">4.5</td><td class="colsep0 rowsep0" align="left">10</td><td class="colsep0 rowsep0" align="char" char=".">23</td><td class="colsep0 rowsep0" align="char" char=".">29</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t4fn1"><div class="footnote" id="t4fn1"><sup><sup>a</sup></sup><p class="last">Rat PK: male Han Wistar rats were dosed at 1.0 or 1.5 μmol/kg iv and 2.0 or 2.5 μmol/kg po.</p></div><div class="footnote" id="t4fn2"><sup><sup>b</sup></sup><p class="last">Plasma protein binding was assessed by equilibrium dialysis in the appropriate species plasma at 37 °C.<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a></p></div><div class="footnote" id="t4fn3"><sup><sup>c</sup></sup><p class="last">Plasma clearance expressed in mL/min/kg.</p></div><div class="footnote" id="t4fn4"><sup><sup>d</sup></sup><p class="last">Volume of distribution at steady state in L/kg.</p></div><div class="footnote" id="t4fn5"><sup><sup>e</sup></sup><p class="last">Oral bioavailability (%).</p></div><div class="footnote" id="t4fn6"><sup><sup>f</sup></sup><p class="last">AUC (μM.h) following a 50 mg/kg unique po dose in SCID mice.</p></div><div class="footnote" id="t4fn7"><sup><sup>g</sup></sup><p class="last">Aqueous solubility (μM) measured in a pH 7.4 phosphate buffer.<sup>14</sup></p></div></div></div></div><div id="sec3_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i12" class="anchor-spacer"></div><h3 class="article-section__title" id="_i12"> Efficacy</h3><div class="NLM_p">In vitro, <b>4</b> and <b>13</b> used as single agents led to a dose-dependent decrease in pIκBα in OCI-LY10 cells, which have mutations in both CD79A (deletion of ITAM) and MYD88<sup>L265P</sup>. <b>13</b> decreased levels of pIκBα (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>B) more potently than compound <b>4</b> (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>A), consistent with its superior IRAK4 potency. Ibrutinib alone also led to a dose-dependent reduction of pIκBα but did not show complete depletion, while the combination with both IRAK4 inhibitors <b>4</b> and <b>13</b> gave rise to the synergistic inhibition of IκBα phosphorylation. In combination with ibrutinib, 5-azaquinazoline <b>13</b> at a concentration of 0.3 μM resulted in the complete suppression of IκBα phosphorylation.</div><figure id="fig7" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-21/acs.jmedchem.9b01346/20191108/images/medium/jm9b01346_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-21/acs.jmedchem.9b01346/20191108/images/large/jm9b01346_0011.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. In vitro synergistic suppression of IκBα phosphorylation: OCI-LY10 cells were treated with increasing concentrations of compound <b>4</b> (A) or compound <b>13</b> (B) and ibrutinib for 14 h. Vinculin served as a loading control.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-21/acs.jmedchem.9b01346/20191108/images/large/jm9b01346_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01346&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">In addition, the combination of ibrutinib and <b>13</b> in a 6 × 6 matrix format showed potent growth inhibition of OCI-LY10 cells in a 3 day viability assay (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>A). While <b>13</b> only led to modest growth inhibition up to 3.3 μM, the combination with 4 nM of ibrutinib led to the death of OCI-LY10 cells. In contrast, the combination profiled in OCI-LY19 cells (germinal center B cell-like cells expressing a double wild-type genetic background for MYD88 and CD79B) showed no synergistic inhibition of cell growth (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>B). On the basis of these combined in vitro results, both <b>4</b> and <b>13</b> were progressed to in vivo xenograft studies.</div><figure id="fig8" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-21/acs.jmedchem.9b01346/20191108/images/medium/jm9b01346_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-21/acs.jmedchem.9b01346/20191108/images/large/jm9b01346_0002.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. (A) combination of <b>13</b> and ibrutinib leads to synergistic growth inhibition in OCI-LY10 cells (ABC-DLBCL double CD79<sup>MUT</sup>/MYD88<sup>L265P</sup> cell line). (B) Lack of combination benefit in OCI-LY19 cells (GCB-DLBCL double CD79<sup>WT</sup>/MYD88<sup>WT</sup> cell line). Numbers represent the percent growth inhibition in a 6 × 6 dose matrix in a 3 day growth assay, where 0–100 signifies increasing cell growth inhibition and >100 signifies increasing cell death.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-21/acs.jmedchem.9b01346/20191108/images/large/jm9b01346_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01346&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Oral dosing of both compound <b>4</b> (50 mg/kg QD; <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>A) and compound <b>13</b> (100 mg/kg QD; <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>B) to mice bearing OCI-LY10 xenografts led to modest tumor growth inhibition in separate studies as single agents. This was particularly marked with 5-azaquinazoline <b>13</b> and contrasted to our previous results obtained using earlier lead IRAK4 inhibitors, which showed single-agent activity.<a onclick="showRef(event, 'ref8 ref10'); return false;" href="javascript:void(0);" class="ref ref8 ref10">(8,10)</a> We attributed this to the enhanced selectivity of <b>13</b> compared to that of, e.g., <b>1</b>. Ibrutinib alone (12 mg/kg QD) led to tumor stasis in both studies, while the combination with either <b>4</b> or <b>13</b> resulted in robust tumor regressions. Tumors regressed during the entire dosing period (especially with <b>13</b>) and, upon cessation of treatment, started to regrow at a similar pace to the ibrutinib alone arm of the studies. These results confirmed that the dual inhibition of BTK and IRAK4 led to synergistic tumor growth inhibition in CD79/MYD88 double-mutant models.<named-content content-type="anchor" rid="fig6" type="simple"></named-content><named-content content-type="anchor" rid="fig7" type="simple"></named-content><named-content content-type="anchor" rid="fig8" type="simple"></named-content><named-content content-type="anchor" rid="fig9" type="simple"></named-content></div><figure id="fig9" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-21/acs.jmedchem.9b01346/20191108/images/medium/jm9b01346_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-21/acs.jmedchem.9b01346/20191108/images/large/jm9b01346_0004.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Efficacy of quinazoline <b>4</b> (A) and 5-azaquinazoline <b>13</b> (B) in combination with ibrutinib in OCI-LY10 xenografts.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-21/acs.jmedchem.9b01346/20191108/images/large/jm9b01346_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01346&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i13">Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_18108" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_18108" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">We have discovered a series of selective IRAK4 inhibitors through optimization of the quinazoline core of <b>4</b>. The introduction of a 5-aza substituent to minimize permeability issues, through intramolecular masking of a formal hydrogen bond donor, allowed us to install a C2 1-methyl-4-aminopyrazole to gain ∼5-fold potency in cells. Subsequent optimization of the 6-substituent led to 6-cyanomethyl-5-azaquinazoline <b>13</b>, which proved efficacious in combination with ibrutinib, while showing very little activity as a single agent. We attributed this to the enhanced selectivity of <b>13</b> compared to our previously reported IRAK4 lead molecules showing some efficacy in the same model as single agents. We therefore believe that selective IRAK4 inhibitors, when used as single agents, should show limited activity in MyD88<sup>L265P</sup> mutant DLBCL.</div></div><div id="sec5" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i14">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_00614" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_00614" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec5_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i15" class="anchor-spacer"></div><h3 class="article-section__title" id="_i15"> General Procedures</h3><div class="NLM_p">All solvents and chemicals used were reagent grade. Anhydrous solvents tetrahydrofuran, dichloromethane (DCM), and DMF were purchased from Sigma-Aldrich. Microwave reactions were run in a Biotage “Initiator Robot 60” (100-120/220-240V, 50-60 Hz, 100 VA). Flash column chromatography was carried out using prepacked silica cartridges (from 4 g up to 330 g) from Grace, Redisep, or Silicycle and eluted using an Isco Companion system. Purity and characterization of compounds were established by a combination of liquid chromatography–mass spectroscopy (LC–MS) and NMR analytical techniques, and purity was >95% for all test compounds.</div><div class="NLM_p"><sup>1</sup>H NMR was recorded on a Varian INOVA (600 MHz), Varian Gemini 2000 (300 MHz), Bruker Avance 700 (700 MHz), Bruker Avance 500 (500 MHz), or Bruker Avance DPX400 (400 MHz) and was determined in CDCl<sub>3</sub>, DMSO-<i>d</i><sub>6</sub>, or MeOH-<i>d</i><sub>4</sub>. Chemical shifts are reported in ppm relative to TMS (0.00 ppm) or solvent peaks as the internal reference. Splitting patterns are indicated as follows: s, singlet; d, doublet; t, triplet; m, multiplet; br, broad peak.</div><div class="NLM_p">Analytical LC–MS was carried out using a suitable system, such as a Waters 2790/95 LC system with a 2996 PDA and a 2000 amu ZQ single quadrupole mass spectrometer, or a UPLC system utilizing a Waters Aquity Binary pump with sample manager, Aquity PDA, and SQD mass spectrometer.</div><div class="NLM_p">Accurate mass and MSMS fragmentation data were obtained using a Thermo Scientific hybrid LTQ-FT mass spectrometer with an Agilent 1100 Quaternary pump with PDA and autosampler; 5 μL of the sample dissolved in 50:50 acetonitrile/water 0.1% formic acid was injected onto a Thermo Scientific Hypersil Gold 50 × 2.1 mm<sup>2</sup> 5 μm particle LC column and eluted with a gradient of 5–100% B over 17 min with a 3 min re-equilibration time at 5% B. The flow rate was 0.5 mL/min with A being 0.1% formic acid in water and B 0.1% formic acid in acetonitrile. The MS and MSMS spectra were obtained in ESI +ve mode in both the ion trap and ion cyclotron resonance (ICR) cell using helium as the collision gas at a normalized collision energy of 35 eV. The ICR cell was run at resolution settings of 25 000 in MS mode and 12 500 in MSMS mode.</div><div class="NLM_p">All IC<sub>50</sub> data are quoted as geometric mean values, and statistical analysis is available in the <a href="/doi/suppl/10.1021/acs.jmedchem.9b01346/suppl_file/jm9b01346_si_001.pdf" class="ext-link">Supporting Information</a>.</div><div class="NLM_p last">All experimental activities involving animals were carried out in accordance with AstraZeneca animal welfare protocols, which are consistent with Elsevier ethical guidelines.</div></div><div id="sec5_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i16" class="anchor-spacer"></div><h3 class="article-section__title" id="_i16"> Chemistry</h3><div id="sec5_2_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i17" class="anchor-spacer"></div><h4 class="article-section__title" id="_i17"> Methyl 4-(<i>Trans</i>-4-[(6-cyano-4-quinazolinyl)amino]cyclohexyl)-1-piperazinecarboxylate (<b>4</b>)</h4><div class="NLM_p">4-Chloroquinazoline-6-carbonitrile (520 mg, 2.7 mmol), methyl 4-(<i>trans</i>-4-aminocyclohexyl)piperazine-1-carboxylate (695 mg, 2.9 mmol), and DIPEA (1.4 mL, 8.2 mmol) were suspended in NMP (15 mL) and sealed into a microwave tube. The reaction was heated to 100 °C for 18 h under microwave irradiation and then cooled to RT. The reaction mixture was purified by ion-exchange chromatography, using an SCX column, eluting with 1 M NH<sub>3</sub> in MeOH, and fractions were evaporated. The residue was further purified by preparative high-performance liquid chromatography (HPLC; Waters XBridge Prep C18 OBD column, 5 μm silica, 30 mm diameter, 100 mm length), using decreasingly polar mixtures of water (containing 1% NH<sub>3</sub>) and MeCN as eluents. Fractions containing the desired compound were evaporated to dryness and triturated with Et<sub>2</sub>O to afford the title compound (398 mg, 37%) as a colorless solid.</div><div class="NLM_p last"><sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>, 300 K) 1.29–1.51 (4H, m), 1.85 (2H, dd, <i>J</i> 9.9), 1.98–2.08 (2H, m), 2.35 (1H, qd, <i>J</i> 7.6, 3.4), 2.47 (4H, m), 3.32–3.37 (4H, m), 3.59 (3H, s), 4.12 (1H, tdt, <i>J</i> 11.4, 7.7, 4.0), 7.75 (1H, d, <i>J</i> 8.6), 8.05 (1H, dd, <i>J</i> 8.6, 1.8), 8.27 (1H, d, <i>J</i> 7.5), 8.55 (1H, s), 8.93 (1H, d, <i>J</i> 1.8). <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>, 300 K) 26.6, 30.8, 43.9, 49.6, 48.4, 52.2, 62.1, 107.3, 114.7, 118.6, 128.8, 129.7, 133.7, 151.4, 155.0, 157.8, 158.3. HRMS (ESI<sup>+</sup>): Anal. calcd. for C<sub>21</sub>H<sub>27</sub>N<sub>6</sub>O (M + H)<sup>+</sup>: 395.2190; found: 395.2182.</div></div><div id="sec5_2_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i18" class="anchor-spacer"></div><h4 class="article-section__title" id="_i18"> 4-([<i>Trans</i>-4-(4-acetyl-1-piperazinyl)cyclohexyl]amino)-2-[(1-methyl-1<i>H</i>-pyrazol-4-yl)amino]-6-quinazolinecarbonitrile (<b>6</b>)</h4><div class="NLM_p">2,4-Dichloroquinazoline-6-carbonitrile (350 mg, 1.6 mmol), 1-(4-(<i>trans</i>-4-aminocyclohexyl)piperazin-1-yl)ethanone (370 mg, 1.6 mmol), and DIPEA (1.4 mL, 7.8 mmol) were suspended in <i>n</i>-BuOH (7 mL) and sealed into a microwave tube. The reaction was heated to 150 °C for 3 h under microwave irradiation and then cooled to RT. The crude product was purified by flash silica chromatography, eluting with a gradient of 0–15% 1 M NH<sub>3</sub>/MeOH and DCM. Pure fractions were evaporated to dryness, triturated with ether/heptane, and filtered to give 4-([<i>trans</i>-4-(4-acetylpiperazin-1-yl)cyclohexyl]amino)-2-chloroquinazoline-6-carbonitrile (360 mg, 56%) as a cream solid.</div><div class="NLM_p"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>, 300 K) 1.16–1.35 (5H, m), 1.53 (3H, m), 2.06 (7H, m), 3.01–3.21 (2H, m), 3.52–3.81 (2H, m), 4.10 (1H, s), 7.72 (1H, d, <i>J</i> 8.7), 8.10 (1H, dd, <i>J</i> 1.7, 8.6), 8.82 (1H, d, <i>J</i> 7.0), 9.01 (1H, d, <i>J</i> 1.5). <i>m</i>/<i>z</i>: ES<sup>+</sup> [M + H]<sup>+</sup> 413.</div><div class="NLM_p">Ruphos third-generation catalyst (30 mg, 0.04 mmol) and dicyclohexyl(2′,6′-diisopropoxy-[1,1′-biphenyl]-2-yl)phosphine (17 mg, 0.04 mmol) were added to a solution of 4-([<i>trans</i>-4-(4-acetylpiperazin-1-yl)cyclohexyl]amino)-2-chloroquinazoline-6-carbonitrile (150 mg, 0.4 mmol), 1-methyl-1<i>H</i>-pyrazol-4-amine HCl (54 mg, 0.4 mmol), and cesium carbonate (473 mg, 1.5 mmol) in dioxane (7 mL) at RT under nitrogen. The resulting mixture was stirred at 100 °C for 16 h, after which the crude product was purified by flash silica chromatography eluting with a gradient of 0–20% 1 M NH<sub>3</sub>/MeOH and DCM. Pure fractions were evaporated to dryness, triturated with ether, and filtered to afford the title compound (85 mg, 49%) as a cream solid.</div><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>, 300 K) 1.32–1.59 (4H, m), 1.95 (2H, dd, <i>J</i> 15.3, 4.7), 1.99 (3H, s), 2.07–2.19 (2H, m), 2.35–2.46 (1H, m), 2.52–2.61 (4H, m), 3.37–3.52 (4H, m), 3.82 (3H, s), 4.09 (1H, dt, <i>J</i> 7.5, 3.9), 7.38 (1H, d, <i>J</i> 8.7), 7.57 (1H, d, <i>J</i> 0.7), 7.69 (1H, s), 7.72 (1H, dd, <i>J</i> 8.7, 1.8), 7.89 (1H, s), 8.62 (1H, d, <i>J</i> 1.8), 8.86 (1H, s). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>, 300 K) 20.3, 26.7, 30.3, 38.0, 48.3, 49.4, 61.7, 101.1, 118.7, 120.3, 123.0, 125.4, 128.8, 130.0, 133.0, 154.2, 157.8, 167.5 (3C missing). HRMS (ESI<sup>+</sup>): Anal. calcd. for C<sub>25</sub>H<sub>32</sub>N<sub>9</sub>O (M + H)<sup>+</sup>: 474.2724; found: 474.2717.</div></div><div id="sec5_2_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i19" class="anchor-spacer"></div><h4 class="article-section__title" id="_i19"> Methyl 4-(<i>Trans</i>-4-((6-cyano-2-[(1-methyl-1<i>H</i>-pyrazol-4-yl)amino]-4-quinazolinyl)amino)cyclohexyl)-1-piperazinecarboxylate (<b>7</b>)</h4><div class="NLM_p">2,4-Dichloroquinazoline-6-carbonitrile (200 mg, 0.9 mmol), methyl 4-(<i>trans-</i>4-aminocyclohexyl)piperazine-1-carboxylate (237 mg, 1.0 mmol), and DIPEA (0.468 mL, 2.7 mmol) were suspended in <i>i</i>-PrOH (10 mL). The reaction was stirred at 60 °C for 3 h and then cooled to RT, and the solvent was removed under reduced pressure. The crude product was washed with water to give methyl 4-(<i>trans</i>-4-((2-chloro-6-cyanoquinazolin-4-yl)amino)cyclohexyl)piperazine-1-carboxylate (300 mg, 78%) as a yellow solid.</div><div class="NLM_p"><sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>, 300 K) 1.30–1.56 (4H, m), 1.81–1.92 (2H, m), 1.93–2.08 (2H, m), 2.36–2.47 (1H, m), 2.47–2.70 (4H, m), 3.09–3.38 (4H, m), 3.60 (3H, s), 4.00–4.13 (1H, m), 7.71 (1H, d), 8.16 (1H, d), 8.71 (1H, d), 8.95 (1H, d). <i>m</i>/<i>z</i>: ES<sup>+</sup> [M + H]<sup>+</sup> 429.</div><div class="NLM_p">TsOH (67 mg, 0.4 mmol) was added to a solution of methyl 4-(<i>trans</i>-4-((2-chloro-6-cyanoquinazolin-4-yl)amino)cyclohexyl)piperazine-1-carboxylate (300 mg, 0.7 mmol) and 1-methyl-1<i>H</i>-pyrazol-4-amine (82 mg, 0.8 mmol) in EtOH (10 mL). The resulting mixture was stirred at 90 °C for 3 h, after which the solvent was removed under reduced pressure. The crude product was purified by preparative HPLC (Waters XBridge Prep C18 OBD column, 5 μm silica, 30 mm diameter, 100 mm length), using decreasingly polar mixtures of water (containing 1% NH<sub>3</sub>) and MeCN as eluents. Pure fractions were evaporated to dryness to afford the title compound (240 mg, 70%) as a yellow solid.</div><div class="NLM_p last"><sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>, 373 K) 1.32–1.58 (4H, m), 1.93 (2H, d, <i>J</i> 12.1), 2.12 (2H, d, <i>J</i> 12.3), 2.34–2.44 (1H, m), 2.50–2.56 (4H, m), 3.32–3.42 (4H, m), 3.62 (3H, s), 3.82 (3H, s), 4.09 (1H, dtt, <i>J</i> 11.3, 7.7, 4.0), 7.38 (1H, d, <i>J</i> 8.7), 7.57 (1H, d, <i>J</i> 0.8), 7.68 (1H, s), 7.72 (1H, dd, <i>J</i> 8.7, 1.8), 7.89 (1H, s), 8.62 (1H, d, <i>J</i> 1.8), 8.85 (1H, s). <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>, 373 K) 26.7, 30.3, 38.0, 43.7, 48.0, 49.4, 51.5, 61.7, 101.1, 118.7, 120.3, 123.0, 125.4, 128.8, 130.0, 133.0, 154.2, 154.6, 157.8, 158.7. HRMS (ESI<sup>+</sup>): Anal. calcd. for C<sub>25</sub>H<sub>32</sub>N<sub>9</sub>O<sub>2</sub> (M + H)<sup>+</sup>: 490.2673; found: 490.2662.</div></div><div id="sec5_2_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i20" class="anchor-spacer"></div><h4 class="article-section__title" id="_i20"> Methyl 4-(<i>Trans</i>-4-((6-methylquinazolin-4-yl)amino)cyclohexyl)piperazine-1-carboxylate (<b>9</b>)</h4><div class="NLM_p">4-Chloro-6-methylquinazoline (50 mg, 0.3 mmol), methyl 4-(<i>trans</i>-4-aminocyclohexyl)piperazine-1-carboxylate (370 mg, 1.6 mmol), and DIPEA (0.15 mL, 0.8 mmol) were suspended in <i>n</i>-BuOH (1 mL) and sealed into a microwave tube. The reaction was heated to 150 °C for 3 h under microwave irradiation and then cooled to RT and evaporated to dryness. The crude product was purified by preparative HPLC (Waters XBridge Prep C18 OBD column, 5 μm silica, 30 mm diameter, 100 mm length), using decreasingly polar mixtures of water (containing 1% NH<sub>3</sub>) and MeCN as eluents. Fractions containing the desired compound were evaporated to dryness, and the resulting residue was further purified by flash silica chromatography, elution gradient 0–4% 7 N NH<sub>3</sub>/MeOH in DCM. Pure fractions were evaporated to dryness to afford the title compound (45 mg, 41%) as a colorless solid.</div><div class="NLM_p last"><sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>, 300 K) 1.40 (4H, dtd, <i>J</i> 24.2, 12.1, 3.1), 1.84 (2H, dt, <i>J</i> 11.9, 2.7), 1.97–2.07 (2H, m), 2.28–2.4 (1H, m), 2.45 (3H, s), 2.47 (4H, m), 3.34 (4H, t, <i>J</i> 5.0), 3.59 (3H, s), 4.11 (1H, dtd, <i>J</i> 11.0, 7.3, 3.7), 7.51–7.61 (2H, m), 7.75 (1H, d, <i>J</i> 7.7), 8.09 (1H, s), 8.38 (1H, s). <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>, 300 K) 21.1, 26.8, 31.0, 43.9, 48.4, 49.1, 52.2, 62.3, 114.7, 121.8, 127.2, 134.0, 134.8, 147.4, 154.3, 155.0, 158.3. HRMS (ESI<sup>+</sup>): Anal. calcd. for C<sub>21</sub>H<sub>30</sub>N<sub>5</sub>O<sub>2</sub> (M + H)<sup>+</sup>: 384.2394; found: 384.2394.</div></div><div id="sec5_2_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i21" class="anchor-spacer"></div><h4 class="article-section__title" id="_i21"> Methyl 4-(<i>Trans</i>-4-((2-chloro-6-methylpyrido[3,2-<i>d</i>]pyrimidin-4-yl)amino)cyclohexyl)piperazine-1-carboxylate (<b>10a</b>)</h4><div class="NLM_p">2,4-Dichloro-6-methyl-5-azaquinazoline (200 mg, 0.9 mmol), methyl 4-(<i>trans</i>-4-aminocyclohexyl)piperazine-1-carboxylate (225 mg, 0.9 mmol), and DIPEA (0.4 mL, 2.3 mmol) were suspended in <i>i</i>-PrOH (5 mL) and sealed into a microwave tube. The reaction was heated to 140 °C for 3 h under microwave irradiation and then cooled to RT and evaporated to dryness. The crude product was purified by flash silica chromatography, eluting with a gradient of 0–10% MeOH in DCM. Pure fractions were evaporated to dryness to afford the title intermediate (268 mg, 69%) as a yellow foam.</div><div class="NLM_p last"><sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>, 300 K) 1.31–1.47 (2H, m), 1.61 (2H, q, <i>J</i> 11.3, 12.4), 1.84 (2H, d, <i>J</i> 11.9), 1.95 (2H, d, <i>J</i> 10.5), 2.28–2.39 (2H, m), 2.48 (3H, s), 2.67 (3H, s), 3.31–3.39 (4H, m), 3.60 (3H, s), 3.95–4.11 (1H, m), 7.71 (1H, d, <i>J</i> 8.6), 7.92 (1H, d, <i>J</i> 8.6), 8.27 (1H, d, <i>J</i> 8.1). <i>m</i>/<i>z</i>: ES<sup>+</sup> [M + H]<sup>+</sup> 419.</div></div><div id="sec5_2_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i22" class="anchor-spacer"></div><h4 class="article-section__title" id="_i22"> Methyl 4-(<i>Trans</i>-4-((6-methylpyrido[3,2-<i>d</i>]pyrimidin-4-yl)amino)cyclohexyl)piperazine-1-carboxylate (<b>10</b>)</h4><div class="NLM_p">10% Palladium on carbon (31 mg, 0.3 mmol) was added to a solution of methyl 4-(<i>trans</i>-4-((2-chloro-6-methylpyrido[3,2-<i>d</i>]pyrimidin-4-yl)amino)cyclohexyl)piperazine-1-carboxylate (66 mg, 0.2 mmol) in DMF/EtOH (1:2, 15 mL), and the reaction mixture was stirred under an atmosphere of hydrogen at RT for 18 h. The catalyst was removed by filtration through celite, and the filtrate was concentrated to give a yellow gum (56 mg), which was purified by preparative HPLC (Waters XBridge Prep C18 OBD column, 5 μm silica, 30 mm diameter, 100 mm length), using decreasingly polar mixtures of water (containing 1% NH<sub>3</sub>) and MeCN as eluents. Fractions containing the desired compound were evaporated to dryness to afford the title compound (17 mg, 28%) as a colorless solid.</div><div class="NLM_p last"><sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>, 300 K) 1.3–1.42 (2H, m), 1.55 (2H, qd, <i>J</i> 12.7, 3.2), 1.80–1.88 (2H, m), 1.94–2.02 (2H, m), 2.27–2.37 (1H, m), 2.45–2.49 (4H, m), 2.66 (3H, s), 3.34 (4H, t, <i>J</i> 5.0), 3.59 (3H, s), 4.07 (1H, dtd, <i>J</i> 11.7, 7.9, 4.2), 7.68 (1H, d, <i>J</i> 8.6), 7.75 (1H, d, <i>J</i> 8.5), 7.97 (1H, d, <i>J</i> 8.5), 8.43 (1H, s). <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>, 300 K) 24.3, 26.8, 30.7, 43.9, 48.4, 48.9, 52.2, 62.1, 128.7, 130.4, 135.5, 142.4, 154.9, 155.0, 157.2, 158.1. HRMS (ESI<sup>+</sup>): Anal. calcd. for C<sub>20</sub>H<sub>29</sub>N<sub>6</sub>O<sub>2</sub> (M + H)<sup>+</sup>: 385.2347; found: 385.2337.</div></div><div id="sec5_2_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i23" class="anchor-spacer"></div><h4 class="article-section__title" id="_i23"> 3-Amino-6-cyanopicolinamide (<b>11a</b>)</h4><div class="NLM_p">3-Amino-6-chloropicolinamide (2.4 g, 14 mmol), zinc cyanide (2.5 g, 21 mmol), Pd<sub>2</sub>dba<sub>3</sub> (1.3 g, 1.40), zinc (91 mg, 1.4 mmol), DPPF (1.6 g, 2.8 mmol), and Zn(AcO)<sub>2</sub> (256 mg, 1.4 mmol) were suspended in DMF/H<sub>2</sub>O (50 mL) and sealed into a microwave tube. The reaction was heated to 120 °C for 2 h under microwave irradiation and cooled to RT. The reaction mixture was filtered, and the solvents were removed under reduced pressure. The resulting residue was purified by flash silica chromatography, eluting with a gradient of 50% EtOAc in petroleum ether. Pure fractions were evaporated to dryness to afford the title intermediate (1.9 g, 84%) as an orange solid.</div><div class="NLM_p last"><sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>, 300 K) 7.22 (2H, d), 7.57 (1H, s), 7.70 (2H, d), 8.00 (1H, s). <i>m</i>/<i>z</i>: ES<sup>+</sup> [M + H]<sup>+</sup> 163.</div></div><div id="sec5_2_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i24" class="anchor-spacer"></div><h4 class="article-section__title" id="_i24"> 2,4-Dichloropyrido[3,2-<i>d</i>]pyrimidine-6-carbonitrile (<b>11b</b>)</h4><div class="NLM_p">Triphosgene (1.0 g, 3.4 mmol) was added to 3-amino-6-cyanopicolinamide (1.1 g, 6.8 mmol) in 1,4-dioxane (50 mL) at 25 °C under nitrogen, and the resulting suspension was stirred at 100 °C for 3 h. The reaction mixture was filtered and evaporated to afford a residue, which was washed with water and dried under vacuum to afford 2,4-dihydroxypyrido[3,2-<i>d</i>]pyrimidine-6-carbonitrile (950 mg, 74%) as a black solid, which was used without further purification.</div><div class="NLM_p"><sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>, 300 K) 7.69 (1H, d), 8.15 (1H, d), 11.64 (1H, s), 11.78 (1H, s). <i>m</i>/<i>z</i>: ES<sup>+</sup> [M + H]<sup>+</sup> 189.</div><div class="NLM_p">DIPEA (1.6 mL, 9 mmol) was added to a solution of 2,4-dihydroxypyrido[3,2-<i>d</i>]pyrimidine-6-carbonitrile (850 mg, 4.5 mmol) and POCl<sub>3</sub> (2.1 mL, 23 mmol) in toluene (20 mL) at 25 °C under nitrogen. The resulting suspension was stirred at 100 °C for 16 h, then evaporated to dryness, and partitioned between EtOAc (50 mL) and saturated NaHCO<sub>3</sub> (20 mL). The organic layer was washed with brine (3 × 50 mL), then dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and evaporated to afford the title intermediate (660 mg, 65%) as a black solid, which was used without further purification.</div><div class="NLM_p last"><sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>, 300 K) 8.26 (1H, d), 8.37 (1H, d). <i>m</i>/<i>z</i>: ES<sup>+</sup> [M + H]<sup>+</sup> 225.</div></div><div id="sec5_2_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i25" class="anchor-spacer"></div><h4 class="article-section__title" id="_i25"> Methyl 4-(<i>Trans</i>-4-((6-cyano-2-((1-methyl-1<i>H</i>-pyrazol-4-yl)amino)pyrido[3,2-<i>d</i>]pyrimidin-4-yl)amino)cyclohexyl)piperazine-1-carboxylate (<b>11</b>)</h4><div class="NLM_p">2,4-Dichloropyrido[3,2-<i>d</i>]pyrimidine-6-carbonitrile (450 mg, 2 mmol), methyl 4-(<i>trans</i>-4-aminocyclohexyl)piperazine-1-carboxylate (579 mg, 2.4 mmol), and DIPEA (0.7 mL, 4 mmol) were suspended in <i>i</i>-PrOH (5 mL), and the reaction mixture was heated to 100 °C for 1 h. It was then evaporated to dryness, and the residue was partitioned between EtOAc (50 mL) and brine (20 mL). The organic layer was with brine (2 × 20 mL), then dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and evaporated to afford methyl 4-(<i>trans</i>-4-((2-chloro-6-cyanopyrido[3,2-<i>d</i>]pyrimidin-4-yl)amino)cyclohexyl)piperazine-1-carboxylate (600 mg, 70%) as a black solid, which was used without further purification.</div><div class="NLM_p"><i>m</i>/<i>z</i>: ES<sup>+</sup> [M + H]<sup>+</sup> 430.</div><div class="NLM_p">TsOH (24 mg, 0.1 mmol) was added to a solution of methyl 4-(<i>trans</i>-4-((2-chloro-6-cyanopyrido[3,2-<i>d</i>]pyrimidin-4-yl)amino)cyclohexyl)piperazine-1-carboxylate (300 mg, 0.7 mmol) and 1-methyl-1<i>H</i>-pyrazol-4-amine (69 mg, 0.7 mmol) in EtOH (15 mL). The resulting mixture was stirred at 80 °C for 2 h, after which the solvent was removed under reduced pressure. The crude product was purified by preparative HPLC (Waters XBridge Prep C18 OBD column, 5 μm silica, 30 mm diameter, 100 mm length), using decreasingly polar mixtures of water (containing 1% NH<sub>3</sub>) and MeCN as eluents. Pure fractions were evaporated to dryness to afford the title compound (51 mg, 15%) as a yellow solid.</div><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>, 373 K) 1.33–1.46 (2H, m), 1.60 (2H, qd, <i>J</i> 12.8, 3.3), 1.93 (2H, d, <i>J</i> 12.6), 2.08 (2H, d, <i>J</i> 12.5), 2.31–2.46 (1H, m), 2.52 (4H, m), 3.32–3.45 (4H, m), 3.62 (3H, s), 3.82 (3H, s), 4.05 (1H, qt, <i>J</i> 8.0, 4.1), 7.60 (1H, d, <i>J</i> 0.7), 7.69 (1H, d, <i>J</i> 8.1), 7.78 (1H, d, <i>J</i> 8.6), 7.92 (1H, s), 7.93 (1H, d, <i>J</i> 8.6), 9.13 (1H, s). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>, 373 K) 26.6, 30.1, 38.1, 43.7, 48.0, 51.5, 61.5, 117.2, 120.6, 122.7, 123.2, 130.2, 130.5, 132.4, 148.0, 154.6. HRMS (ESI<sup>+</sup>): Anal. calcd. for C<sub>24</sub>H<sub>30</sub>N<sub>10</sub>O<sub>2</sub> (M + H)<sup>+</sup>: 491.2626; found: 491.2626.</div></div><div id="sec5_2_10" class="NLM_sec NLM_sec_level_3"><div id="ac_i26" class="anchor-spacer"></div><h4 class="article-section__title" id="_i26"> Methyl 4-(<i>Trans</i>-4-((6-methyl-2-((1-methyl-1<i>H</i>-pyrazol-4-yl)amino)pyrido[3,2-<i>d</i>]pyrimidin-4-yl)amino)cyclohexyl)piperazine-1-carboxylate (<b>12</b>)</h4><div class="NLM_p">TsOH (22 mg, 0.1 mmol) was added to a solution of methyl 4-(<i>trans-</i>4-((2-chloro-6-methylpyrido[3,2-<i>d</i>]pyrimidin-4-yl)amino)cyclohexyl)piperazine-1-carboxylate (106 mg, 0.25 mmol) and 1-methyl-1<i>H</i>-pyrazol-4-ylamine hydrochloride (41 mg, 0.3 mmol) in EtOH (10 mL) and sealed into a microwave tube. The reaction was heated to 90 °C for 5 h under microwave irradiation and then cooled to RT. The mixture was then diluted with EtOAc (20 mL) and washed with saturated aq. Na<sub>2</sub>CO<sub>3</sub> (20 mL). The aqueous layer was washed with EtOAc (50 mL), and the combined organic layers were dried over Na<sub>2</sub>SO<sub>4</sub>, concentrated in vacuo, and adsorbed onto silica. The resulting residue was purified by flash silica chromatography, eluting with a gradient of 0–10% MeOH in DCM and then by preparative HPLC (Waters XBridge Prep C18 OBD column, 5 μm silica, 30 mm diameter, 100 mm length), using decreasingly polar mixtures of water (containing 1% NH<sub>3</sub>) and MeCN as eluents. Pure fractions were evaporated to dryness to afford the title compound (39 mg, 32%) as an off-white solid.</div><div class="NLM_p last"><sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>, 373 K) 1.34–1.46 (2H, m), 1.46–1.59 (2H, m), 1.87–1.97 (2H, m), 2.14 (2H, d, <i>J</i> 12.2), 2.41 (1H, ddt, <i>J</i> 3.6, 7.5, 11.2), 2.53 (4H, m), 3.34–3.48 (4H, m), 3.62 (3H, s), 3.81 (3H, s), 4.00 (1H, dtd, <i>J</i> 4.1, 7.5, 11.3), 7.14 (1H, d, <i>J</i> 8.1), 7.44 (1H, d, <i>J</i> 8.5), 7.56 (1H, d, <i>J</i> 0.7), 7.63 (1H, d, <i>J</i> 8.5), 7.91 (1H, d, <i>J</i> 0.8), 8.52 (1H, s). <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>, 373 K) 24.2, 27.6, 31.6, 39.0, 44.7, 49.0, 49.7, 52.5, 62.6, 120.9, 124.7, 128.2, 128.5, 130.7, 133.4, 145.1, 152.1, 155.6, 156.9, 159.3. HRMS (ESI<sup>+</sup>): Anal. calcd. for C<sub>24</sub>H<sub>34</sub>N<sub>9</sub>O<sub>2</sub> (M + H)<sup>+</sup>: 480.2830; found: 480.2817.</div></div><div id="sec5_2_11" class="NLM_sec NLM_sec_level_3"><div id="ac_i27" class="anchor-spacer"></div><h4 class="article-section__title" id="_i27"> Methyl 4-(<i>Trans</i>-4-((2,6-dichloropyrido[3,2-<i>d</i>]pyrimidin-4-yl)amino)cyclohexyl)piperazine-1-carboxylate (<b>13a</b>)</h4><div class="NLM_p">2,4,6-Trichloro-5-azaquinazoline (300 mg, 1.3 mmol), methyl 4-(<i>trans</i>-4-aminocyclohexyl)piperazine-1-carboxylate (309 mg, 1.3 mmol), and DIPEA (0.7 mL, 3.8 mmol) were suspended in <i>i</i>-PrOH (10 mL), and the resulting mixture was stirred at 80 °C for 1 h, after which the solvent was removed under reduced pressure. The crude residue was triturated with water to give a solid, which was collected by filtration and dried under vacuum to give the title compound (470 mg, 84%) as a beige solid.</div><div class="NLM_p last"><sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>, 303 K) 1.26–1.45 (2H, m), 1.53–1.72 (2H, m), 1.77–1.95 (4H, m), 2.25–2.36 (1H, m), 2.43–2.50 (4H, m), 3.32–3.38 (4H, m), 3.58 (3H, s), 3.98–4.10 (1H, m), 7.88 (1H, d), 8.07 (1H, d), 8.69 (1H, d). <i>m</i>/<i>z</i> (ES<sup>+</sup>) [M + H]<sup>+</sup> 439.</div></div><div id="sec5_2_12" class="NLM_sec NLM_sec_level_3"><div id="ac_i28" class="anchor-spacer"></div><h4 class="article-section__title" id="_i28"> Methyl 4-(<i>Trans</i>-4-((6-chloro-2-((1-methyl-1<i>H</i>-pyrazol-4-yl)amino)pyrido[3,2-<i>d</i>]pyrimidin-4-yl)amino)cyclohexyl)piperazine-1-carboxylate (<b>13b</b>)</h4><div class="NLM_p">1-Methyl-1<i>H</i>-pyrazol-4-amine hydrochloride (137 mg, 1.0 mmol) was added to methyl 4-(<i>trans</i>-4-((2,6-dichloropyrido[3,2-<i>d</i>]pyrimidin-4-yl)amino)cyclohexyl)piperazine-1-carboxylate (450 mg, 1.0 mmol) in EtOH (15 mL) at room temperature. The resulting mixture was stirred at 50 °C for 16 h, and the solvent was removed under reduced pressure. The crude reaction mixture was purified by flash C18-flash chromatography, elution gradient 0–90% MeOH in water (containing 10 mmol/L NH<sub>4</sub>HCO<sub>3</sub>). Pure fractions were evaporated to dryness to afford the title compound (495 mg, 97%) as a beige solid.</div><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>, 303 K) 1.27–1.44 (2H, m), 1.51–1.65 (2H, m), 1.78–2.09 (4H, m), 2.28–2.39 (1H, m), 2.43–2.50 (4H, m), 3.33–3.39 (4H, m), 3.59 (3H, s), 3.81 (3H, s), 3.95–4.12 (1H, m), 7.51–7.91 (4H, m), 8.09 (1H, br), 9.17 (1H, s). <i>m</i>/<i>z</i> (ES<sup>+</sup>) [M + H]<sup>+</sup> 500.</div></div><div id="sec5_2_13" class="NLM_sec NLM_sec_level_3"><div id="ac_i29" class="anchor-spacer"></div><h4 class="article-section__title" id="_i29"> Methyl 4-(<i>Trans</i>-4-((6-(cyanomethyl)-2-((1-methyl-1<i>H</i>-pyrazol-4-yl)amino)pyrido[3,2-<i>d</i>]pyrimidin-4-yl)amino)cyclohexyl)piperazine-1-carboxylate (<b>13</b>)</h4><div class="NLM_p">Chloro(2-dicyclohexylphosphino-2′,4′,6′-triisopropyl-1,1′-biphenyl)[2-(2′-amino-1,1′-biphenyl)]palladium(II) (XPhos-Pd-G2, 24 mg, 0.03 mmol) was added to methyl 4-(<i>trans</i>-4-((6-chloro-2-((1-methyl-1<i>H</i>-pyrazol-4-yl)amino)pyrido[3,2-<i>d</i>]pyrimidin-4-yl)amino)cyclohexyl)piperazine-1-carboxylate (150 mg, 0.3 mmol), 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)isoxazole (88 mg, 0.45 mmol), and 1 M aqueous potassium fluoride (0.9 mL, 0.9 mmol) in DMSO (5 mL) at room temperature under nitrogen. The resulting mixture was stirred at 100 °C for 2 h. The crude reaction mixture was purified by flash C18-flash chromatography, elution gradient 0–60% MeOH in water (containing 10 mmol/L NH<sub>4</sub>HCO<sub>3</sub>). Pure fractions were evaporated to dryness to afford methyl 4-(<i>trans</i>-4-((6-(isoxazol-4-yl)-2-((1-methyl-1<i>H</i>-pyrazol-4-yl)amino)pyrido[3,2-<i>d</i>]pyrimidin-4-yl)amino)cyclohexyl)piperazine-1-carboxylate (150 mg, 94%) as a yellow solid.</div><div class="NLM_p"><sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>, 303 K) 1.32–1.63 (4H, m), 1.92–2.01 (2H, m), 2.04–2.10 (1H, m), 2.13–2.25 (1H, m), 2.67–2.82 (5H, m), 3.40–3.50 (4H, m), 3.60 (3H, s), 3.80 (3H, s), 3.92 - 4.05 (1H, m), 6.99 (1H, s), 7.39–7.66 (3H, m), 7.98 (1H, s), 8.55–8.70 (1H, m), 9.05 (1H, s), 9.19 (1H, s). <i>m</i>/<i>z</i> (ES<sup>+</sup>) [M + H]<sup>+</sup> 533.</div><div class="NLM_p">1 M Aqueous potassium fluoride (1.3 mL, 1.3 mmol) was added to methyl 4-(<i>trans</i>-4-((6-(isoxazol-4-yl)-2-((1-methyl-1<i>H</i>-pyrazol-4-yl)amino)pyrido[3,2-<i>d</i>]pyrimidin-4-yl)amino)cyclohexyl)piperazine-1-carboxylate (135 mg, 0.3 mmol) in MeOH (10 mL) at RT under nitrogen. The resulting mixture was stirred at 100 °C for 2 h, and the solvent was removed under reduced pressure. The resulting residue was purified by flash C18-flash chromatography, elution gradient 30–50% MeCN in water (containing 10 mM NH<sub>4</sub>HCO<sub>3</sub>). Pure fractions were evaporated to dryness to afford the title compound (65 mg, 51%) as a yellow solid.</div><div class="NLM_p last"><sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>, 300 K) 1.37 (2H, br d, <i>J</i> 11.5), 1.43–1.55 (2H, m), 1.88 (2H, br d, <i>J</i> 11.6), 2.07 (2H, br d, <i>J</i> 7.9), 2.38 (1H, s), 2.47–2.52 (4H, m), 3.31–3.39 (4H, m), 3.59 (3H, s), 3.80 (3H, s), 4.00 (1H, s), 4.22 (2H, s), 7.31 (1H, s), 7.51–7.57 (2H, m), 7.60 (2H, d, <i>J</i> 8.6), 7.78 (1H, s), 8.00 (1H, s), 9.03 (1H, s). <sup>13</sup>C NMR (151 MHz, DMSO-<i>d</i><sub>6</sub>, 300 K) 25.3, 26.7, 30.8, 38.5, 43.8, 48.3, 48.7, 52.0, 61.9, 118.0, 120.2, 123.7, 127.0, 127.9, 129.7, 133.9, 144.1, 145.7, 154.9, 156.3, 158.0. HRMS (ESI<sup>+</sup>): Anal. calcd. for C<sub>25</sub>H<sub>33</sub>N<sub>10</sub>O<sub>2</sub> (M + H)<sup>+</sup>: 505.2782; found: 505.2766.</div></div><div id="sec5_2_14" class="NLM_sec NLM_sec_level_3"><div id="ac_i30" class="anchor-spacer"></div><h4 class="article-section__title" id="_i30"> 2-(2-Chloro-4-hydroxypyrido[3,2-<i>d</i>]pyrimidin-6-yl)propanenitrile (<b>14a</b>)</h4><div class="NLM_p">Sodium <i>tert</i>-butoxide (445 mg, 4.6 mmol) was added to a solution of 2,6-dichloropyrido[3,2-<i>d</i>]pyrimidin-4-ol (500 mg, 2.3 mmol) and ethyl 2-cyanopropanoate (589 mg, 4.6 mmol) in DMF (10 mL) at RT under nitrogen. The resulting mixture was stirred at 80 °C for 48 h. The crude product was purified by flash chromatography, eluting with a gradient of 0–10% MeCN in water. Pure fractions were evaporated to dryness to the title compound (330 mg, 61%) as a brown solid.</div><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>, 300 K) 1.61 (3H, d), 4.48 (1H, q), 7.60 (1H, d), 7.77 (1H, d), 7.96 (1H, s). <i>m</i>/<i>z</i>: ES<sup>+</sup> [M + H]<sup>+</sup> 235.</div></div><div id="sec5_2_15" class="NLM_sec NLM_sec_level_3"><div id="ac_i31" class="anchor-spacer"></div><h4 class="article-section__title" id="_i31"> Methyl 4-(<i>Trans</i>-4-((6-(1-cyanoethyl)-2-((1-methyl-1<i>H</i>-pyrazol-4-yl)amino)pyrido[3,2-<i>d</i>]pyrimidin-4-yl)amino)cyclohexyl)piperazine-1-carboxylate (<b>14</b>)</h4><div class="NLM_p">1-Methyl-1<i>H</i>-pyrazol-4-amine HCl (100 mg, 0.75 mmol) was added to 2-(2-chloro-4-hydroxypyrido[3,2-<i>d</i>]pyrimidin-6-yl)propanenitrile (110 mg, 0.4 mmol) in <i>i-</i>PrOH (3 mL) at RT. The resulting mixture was stirred at 60 °C for 30 min, after which pH was adjusted to 7. The crude product was purified by flash chromatography, eluting with a gradient of 0–40% MeOH in (0.1% HCO<sub>2</sub>H) water. Pure fractions were evaporated to dryness to afford 2-(4-hydroxy-2-((1-methyl-1<i>H</i>-pyrazol-4-yl)amino)pyrido[3,2-<i>d</i>]pyrimidin-6-yl)propanenitrile (80 mg, 72%) as a brown solid.</div><div class="NLM_p"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>, 300 K) 1.62 (3H, d), 3.84 (3H, s), 4.42–4.55 (1H, m), 7.59 (1H, s), 7.71 (1H, d), 7.87 (1H, d), 8.10 (1H, s), 8.69 (1H, s), 11.25 (1H, s). <i>m</i>/<i>z</i>: ES<sup>+</sup> [M + H]<sup>+</sup> 296.</div><div class="NLM_p">DIPEA (0.18 mL, 1.0 mmol) was added to 2-(4-hydroxy-2-((1-methyl-1<i>H</i>-pyrazol-4-yl)amino)pyrido[3,2-<i>d</i>]pyrimidin-6-yl)propanenitrile (75 mg, 0.25 mmol), methyl 4-(<i>trans</i>-4-aminocyclohexyl)piperazine-1-carboxylate (74 mg, 0.3 mmol), and PyBOP (198 mg, 0.4 mmol) in DMF (2 mL). The resulting mixture was stirred at RT for 16 h, and the crude product was purified by flash chromatography, eluting with a gradient of 0–20% MeCN in (0.1% HCO<sub>2</sub>H) water and then by preparative HPLC (Waters XBridge Prep C18 OBD column, 5 μm silica, 19 mm diameter, 150 mm length). Fractions containing the desired compound were evaporated to dryness to afford the title compound (25 mg, 19%) as a yellow solid.</div><div class="NLM_p last"><sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>, 373 K) 1.32–1.47 (2H, m), 1.51 (1H, t, <i>J</i> 13.0), 1.69 (3H, d, <i>J</i> 7.2), 1.93 (3H, d, <i>J</i> 12.0), 2.16 (2H, d, <i>J</i> 12.4), 2.41 (1H, dq, <i>J</i> 11.0, 3.7), 2.51–2.59 (4H, m), 3.35–3.44 (5H, m), 3.62 (3H, s), 3.82 (3H, s), 3.9–4.14 (1H, m), 4.42 (1H, q, <i>J</i> 7.2), 7.14 (1H, d, <i>J</i> 8.0), 7.58 (1H, d, <i>J</i> 0.7), 7.66 (1H, d, <i>J</i> 8.7), 7.78 (1H, d, <i>J</i> 8.6), 7.92 (1H, s), 8.72 (1H, s). <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>, 373 K) 17.9, 26.5, 30.5, 31.8, 38.0, 43.7, 48.0, 48.8, 51.5, 61.5, 120.1, 120.6, 123.3, 125.3, 127.3,129.9, 133.6, 145.4, 148.5, 154.6, 156.5, 158.2. HRMS (ESI<sup>+</sup>): Anal. calcd. for C<sub>27</sub>H<sub>42</sub>N<sub>9</sub>O<sub>2</sub> (M + H)<sup>+</sup>: 519.2939; found: 519.2934.</div></div><div id="sec5_2_16" class="NLM_sec NLM_sec_level_3"><div id="ac_i32" class="anchor-spacer"></div><h4 class="article-section__title" id="_i32"> 3-Amino-6-(1-cyanocyclopropyl)picolinamide (<b>15a</b>)</h4><div class="NLM_p">Br<sub>2</sub> (0.64 mL, 12 mmol) was added dropwise to a solution of 2-(5-aminopyridin-2-yl)-2-methylpropanenitrile (2.0 g, 12 mmol) and sodium acetate (1.0 g, 12 mmol) in acetic acid (30 mL) at 0 °C under nitrogen. The resulting mixture was stirred at RT for 30 min and then quenched with saturated sodium thiosulfate (50 mL), basified with NaOH, and extracted with EtOAc (4 × 200 mL). The organic layer was dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and evaporated to afford a crude yellow solid, which was purified by flash silica chromatography, eluting with a gradient of 5–15% EtOAc in petroleum ether. Pure fractions were evaporated to dryness to afford 2-(5-amino-6-bromopyridin-2-yl)-2-methylpropanenitrile (2.6 g, 86%) as a light brown solid.</div><div class="NLM_p"><sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>, 300 K) 1.61 (6H, s), 5.64 (2H, s), 7.13 (1H, d), 7.30 (1H, d). <i>m</i>/<i>z</i>: ES<sup>+</sup> [M + H]<sup>+</sup> 240.</div><div class="NLM_p">Pd(PPh<sub>3</sub>)<sub>4</sub> (1.2 g, 1.0 mmol) was added to 2-(5-amino-6-bromopyridin-2-yl)-2-methylpropanenitrile (2.5 g, 10 mmol) and zinc cyanide (1.8 g, 16 mmol) in DMF (40 mL) at RT under nitrogen. The resulting mixture was stirred at 100 °C for 1.5 h, and the reaction mixture was filtered and washed with EtOAc. The filtrate was concentrated to dryness, and the resulting residue was purified by flash silica chromatography, eluting with a gradient of 0–38% MeCN in 10 mM aq. NH<sub>4</sub>CO<sub>3</sub>. Pure fractions were evaporated to dryness to afford 3-amino-6-(2-cyanopropan-2-yl)picolinonitrile (1.8 g, 95%) as a colorless solid.</div><div class="NLM_p"><sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>, 300 K) 1.61 (6H, s), 6.43 (2H, s), 7.28 (1H, d), 7.56 (1H, d). <i>m</i>/<i>z</i>: ES<sup>+</sup> [M + H]<sup>+</sup> 187.</div><div class="NLM_p">H<sub>2</sub>O<sub>2</sub> (0.66 mL, 6.5 mmol) was added to a solution of 3-amino-6-(2-cyanopropan-2-yl)picolinonitrile (0.81 g, 4.4 mmol) and K<sub>2</sub>CO<sub>3</sub> (0.30 g, 2.2 mmol) in DMSO (10 mL) at 0 °C, and the reaction was allowed to stir at 0–20 °C for 2 h. The crude product was purified by flash chromatography, eluting with a gradient of 0–25% MeCN in water (10 mmol NH<sub>4</sub>HCO<sub>3</sub>). Pure fractions were evaporated to dryness to afford the title intermediate (810 mg, 91%) as a colorless solid.</div><div class="NLM_p last"><sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>, 300 K) 1.65 (6H, s), 6.91 (2H, s), 7.21 (1H, d), 7.45 (2H, d), 7.81 (1H, s). <i>m</i>/<i>z</i>: ES<sup>+</sup> [M + H]<sup>+</sup> 205.</div></div><div id="sec5_2_17" class="NLM_sec NLM_sec_level_3"><div id="ac_i33" class="anchor-spacer"></div><h4 class="article-section__title" id="_i33"> 2-(2-Chloro-4-hydroxypyrido[3,2-<i>d</i>]pyrimidin-6-yl)-2-methylpropanenitrile (<b>15b</b>)</h4><div class="NLM_p">Thiophosgene (0.63 mL, 8.2 mmol) was added dropwise to 3-amino-6-(2-cyanopropan-2-yl)picolinamide (800 mg, 3.9 mmol) in 1,4-dioxane (10 mL), and the resulting mixture was allowed to stir at RT for 1 h and then brought to 70 °C for 1 h. The solvent was then removed under reduced pressure, and the residue was washed with Et<sub>2</sub>O (20 mL) and dried under vacuum to afford the title intermediate (760 mg, 78%) as a colorless solid, which was used without further purification.</div><div class="NLM_p last"><sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>, 300 K) 1.76 (6H, s), 8.05 (1H, d), 8.13 (1H, d), 13.65 (1H, s). <i>m</i>/<i>z</i>: ES<sup>+</sup> [M + H]<sup>+</sup> 249.</div></div><div id="sec5_2_18" class="NLM_sec NLM_sec_level_3"><div id="ac_i34" class="anchor-spacer"></div><h4 class="article-section__title" id="_i34"> Methyl 4-(<i>Trans</i>-4-((6-(2-cyanopropan-2-yl)-2-((1-methyl-1<i>H</i>-pyrazol-4-yl)amino)pyrido[3,2-<i>d</i>]pyrimidin-4-yl)amino)cyclohexyl)piperazine-1-carboxylate (<b>15</b>)</h4><div class="NLM_p">1-Methyl-1<i>H</i>-pyrazol-4-amine HCl (59 mg, 0.4 mmol) was added to a solution of 2-(2-chloro-4-hydroxypyrido[3,2-<i>d</i>]pyrimidin-6-yl)-2-methylpropanenitrile (100 mg, 0.4 mmol) in <i>i</i>-PrOH (2 mL), and the resulting mixture was stirred at 80 °C for 1 h. The mixture was then neutralized with 2 M NaOH, and the solvents were removed under reduced pressure. The crude sample of 2-(4-hydroxy-2-((1-methyl-1<i>H</i>-pyrazol-4-yl)amino)pyrido[3,2-<i>d</i>]pyrimidin-6-yl)-2-methylpropanenitrile (160 mg, quant.) was used without further purification.</div><div class="NLM_p"><sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>, 300 K) 1.73 (6H, s), 3.80 (3H, s), 7.48 (1H, s), 7.65–7.77 (2H, m), 8.04 (1H, s). <i>m</i>/<i>z</i>: ES<sup>+</sup> [M + H]<sup>+</sup> 310.</div><div class="NLM_p">DIPEA (0.17 mL, 1.0 mmol) was added to 2-(4-hydroxy-2-((1-methyl-1<i>H</i>-pyrazol-4-yl)amino)pyrido[3,2-<i>d</i>]pyrimidin-6-yl)-2-methylpropanenitrile (100 mg, 0.3 mmol), methyl 4-(<i>trans</i>-4-aminocyclohexyl)piperazine-1-carboxylate (94 mg, 0.4 mmol), and PyBOP (336 mg, 0.7 mmol) in DMF (4 mL). The resulting mixture was stirred at RT for 2 h, and the crude product was purified by flash chromatography, eluting with a gradient of 0–45% MeCN in (0.1% NaHCO<sub>3</sub>) water, and then by preparative HPLC (Waters XBridge Prep C18 OBD column, 5 μm silica, 19 mm diameter, 150 mm length). Fractions containing the desired compound were evaporated to dryness to afford the title compound (60 mg, 35%) as a yellow solid.</div><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>, 373 K) 1.42 (2H, dd, <i>J</i> 12.2, 3.0), 1.47–1.59 (2H, m), 1.79 (6H, s), 1.87–2.04 (2H, m), 2.17 (2H, d, <i>J</i> 12.1), 2.49 (1H, m), 2.51–2.60 (4H, m), 3.34–3.43 (4H, m), 3.62 (3H, s), 3.82 (3H, s), 4.02 (1H, dq, <i>J</i> 11.1, 3.5), 7.09 (1H, d, <i>J</i> 8.0), 7.58 (1H, d, <i>J</i> 0.7), 7.79 (2H, d, <i>J</i> 1.2), 7.93 (1H, s), 8.72 (1H, s). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>, 373 K) 26.5, 26.7, 30.5, 38.0, 38.4, 43.7, 48.0, 48.8, 51.5, 61.5, 120.1, 123.3, 123.4, 123.6, 126.8, 129.9, 133.6, 145.2, 151.8, 154.6, 156.5, 158.3. HRMS (ESI<sup>+</sup>): Anal. calcd. for C<sub>27</sub>H<sub>37</sub>N<sub>10</sub>O<sub>2</sub> (M + H)<sup>+</sup>: 533.3095; found: 533.3088.</div></div><div id="sec5_2_19" class="NLM_sec NLM_sec_level_3"><div id="ac_i35" class="anchor-spacer"></div><h4 class="article-section__title" id="_i35"> 3-Amino-6-(1-cyanocyclopropyl)picolinamide (<b>16a</b>)</h4><div class="NLM_p">Br<sub>2</sub> (1.4 mL, 27 mmol) was added dropwise to a solution of 1-(5-aminopyridin-2-yl)cyclopropane-1-carbonitrile (4.3 g, 27 mmol) and sodium acetate (2.216 g, 27.01 mmol) in acetic acid (45 mL) at 0 °C under nitrogen. The resulting mixture was stirred at RT for 30 min, then quenched with saturated sodium thiosulfate (100 mL), and extracted with EtOAc (3 × 100 mL). The organic layer was dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and evaporated to afford a crude yellow solid, which was purified by flash silica chromatography, eluting with a gradient of 5–15% EtOAc in petroleum ether. Pure fractions were evaporated to dryness to afford 1-(5-amino-6-bromopyridin-2-yl)cyclopropane-1-carbonitrile (5.8 g, 90%) as an orange solid.</div><div class="NLM_p"><sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>, 300 K) 1.43–1.58 (2H, m), 1.58–1.75 (2H, m), 5.58 (2H, s), 7.12 (1H, d), 7.27 (1H, d). <i>m</i>/<i>z</i>: ES<sup>+</sup> [M + H]<sup>+</sup> 238.</div><div class="NLM_p">Pd(PPh<sub>3</sub>)<sub>4</sub> (2.8 g, 2.4 mmol) was added to 1-(5-amino-6-bromopyridin-2-yl)cyclopropane-1-carbonitrile (5.8 g, 24 mmol) and zinc cyanide (4.3 g, 37 mmol) in DMF (80 mL) at RT under nitrogen. The resulting mixture was stirred at 100 °C for 21 h, and the reaction mixture was filtered and washed with EtOAc. The filtrate was concentrated to dryness, and the resulting residue was purified by flash silica chromatography, eluting with a gradient of 5–20% EtOAc in petroleum ether. Pure fractions were evaporated to dryness to afford 3-amino-6-(1-cyanocyclopropyl)picolinonitrile (4.2 g, 94%) as a pale yellow solid.</div><div class="NLM_p"><sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>, 300 K) 1.48–1.60 (2H, m), 1.60–1.75 (2H, m), 6.38 (2H, s), 7.27 (1H, d), 7.46 (1H, d). <i>m</i>/<i>z</i>: ES<sup>+</sup> [M + H]<sup>+</sup> 185.</div><div class="NLM_p">H<sub>2</sub>O<sub>2</sub> (0.55 mL, 5.4 mmol) was added to a solution of 3-amino-6-(1-cyanocyclopropyl)picolinonitrile (1.0 g, 5.4 mmol) and K<sub>2</sub>CO<sub>3</sub> (0.75 g, 5.4 mmol) in DMSO (10 mL) at 0 °C, and the reaction was allowed to stir at 0 °C for 2 h. The crude product was purified by flash chromatography, eluting with a gradient of 0–30% MeCN in water (10 mmol NH<sub>4</sub>HCO<sub>3</sub>). Pure fractions were evaporated to dryness to afford the title intermediate (670 mg, 61%) as a pale yellow solid.</div><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>, 300 K) 1.60–1.66 (2H, m), 1.67–1.73 (2H, m), 6.87 (2H, s), 7.20 (1H, d), 7.39 (1H, s), 7.41 (1H, d), 7.78 (1H, s). <i>m</i>/<i>z</i>: ES<sup>+</sup> [M + H]<sup>+</sup> 203.</div></div><div id="sec5_2_20" class="NLM_sec NLM_sec_level_3"><div id="ac_i36" class="anchor-spacer"></div><h4 class="article-section__title" id="_i36"> 1-(2-Chloro-4-hydroxypyrido[3,2-<i>d</i>]pyrimidin-6-yl)cyclopropane-1-carbonitrile (<b>16b</b>)</h4><div class="NLM_p">Thiophosgene (0.49 mL, 6.4 mmol) was added dropwise to 3-amino-6-(1-cyanocyclopropyl)picolinamide (620 mg, 3.1 mmol) in 1,4-dioxane (10 mL), and the resulting mixture was allowed to stir at RT for 1 h and then brought to reflux for 1 h. The solvent was then removed under reduced pressure, and the residue was washed with Et<sub>2</sub>O (50 mL) and dried under vacuum to afford the title intermediate (630 mg, 83%) as a brown solid, which was used without further purification.</div><div class="NLM_p last"><i>m</i>/<i>z</i>: ES<sup>+</sup> [M + H]<sup>+</sup> 247.</div></div><div id="sec5_2_21" class="NLM_sec NLM_sec_level_3"><div id="ac_i37" class="anchor-spacer"></div><h4 class="article-section__title" id="_i37"> Methyl 4-(<i>Trans</i>-4-((6-(1-cyanocyclopropyl)-2-((1-methyl-1<i>H</i>-pyrazol-4-yl)amino)pyrido[3,2-<i>d</i>]pyrimidin-4-yl)amino)cyclohexyl)piperazine-1-carboxylate (<b>16</b>)</h4><div class="NLM_p">1-Methyl-1<i>H</i>-pyrazol-4-amine HCl (512 mg, 3.8 mmol) was added to a solution of 1-(2-chloro-4-hydroxypyrido[3,2-<i>d</i>]pyrimidin-6-yl)cyclopropane-1-carbonitrile (630 mg, 2.6 mmol) in <i>i</i>-PrOH (10 mL), and the resulting mixture was stirred at 70 °C for 1 h. The solvent was then removed under reduced pressure, and the crude residue was purified by flash chromatography, eluting with a gradient of 0–40% MeCN in (0.1% HCO<sub>2</sub>H) water. Fractions containing the desired compound were evaporated to dryness to afford 1-(4-hydroxy-2-((1-methyl-1<i>H</i>-pyrazol-4-yl)amino)pyrido[3,2-<i>d</i>]pyrimidin-6-yl)cyclopropane-1-carbonitrile (130 mg, 17%) as a yellow solid.</div><div class="NLM_p"><sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>, 300 K) 1.72 (2H, q), 1.82 (2H, q), 3.83 (3H, s), 7.57 (1H, s), 7.76 (1H, d), 7.85 (1H, d), 8.10 (1H, s), 8.76 (1H, s), 11.32 (1H, s). <i>m</i>/<i>z</i>: ES<sup>+</sup> [M + H]<sup>+</sup> 308.</div><div class="NLM_p">DIPEA (0.21 mL, 1.0 mmol) was added to 1-(4-hydroxy-2-((1-methyl-1<i>H</i>-pyrazol-4-yl)amino)pyrido[3,2-<i>d</i>]pyrimidin-6-yl)cyclopropane-1-carbonitrile (120 mg, 0.4 mmol), methyl 4-(<i>trans</i>-4-aminocyclohexyl)piperazine-1-carboxylate (113 mg, 0.5 mmol), and PyBOP (305 mg, 0.6 mmol) in DMF (4 mL). The resulting mixture was stirred at RT for 5 h, and the crude product was purified by flash chromatography, eluting with a gradient of 0–45% MeCN in (0.1% NaHCO<sub>3</sub>) water. Fractions containing the desired compound were evaporated to dryness to afford the title compound (88 mg, 43%) as a yellow solid.</div><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>, 373 K) 1.31–1.47 (2H, m), 1.47–1.62 (2H, m), 1.73–1.8 (2H, m), 1.83–1.88 (2H, m), 1.93 (2H, dd, <i>J</i> 3.2, 12.3), 2.08–2.19 (2H, m), 2.41 (1H, ddt, <i>J</i> 3.5, 7.8, 11.3), 2.52–2.57 (4H, m), 3.32–3.42 (4H, m), 3.62 (3H, s), 3.81 (3H, s), 3.93–4.08 (1H, m), 7.10 (1H, br d, <i>J</i> 7.8), 7.57 (1H, d, <i>J</i> 0.7), 7.71 (1H, d, <i>J</i> 8.7), 7.77 (1H, d, <i>J</i> 8.7), 7.92 (1H, s), 8.66 (1H, br s). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>, 373 K) 14.8, 18.4, 26.6, 30.4, 38.0, 43.7, 48.0, 48.8, 51.5, 61.6, 120.0, 121.3, 123.4, 123.9, 127.4, 129.8, 133.4, 145.0, 147.0, 154.6, 156.3, 158.0. HRMS (ESI<sup>+</sup>): Anal. calcd. for C<sub>27</sub>H<sub>35</sub>N<sub>10</sub>O<sub>2</sub> (M + H)<sup>+</sup>: 531.2939; found: 531.2942.</div></div></div><div id="sec5_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i38" class="anchor-spacer"></div><h3 class="article-section__title" id="_i38"> Biology</h3><div id="sec5_3_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i39" class="anchor-spacer"></div><h4 class="article-section__title" id="_i39"> pIκBα Signaling Assay</h4><div class="NLM_p last">OCI-LY10 cells (in IMDM medium) were treated with increasing concentrations of compound <b>4</b> or <b>13</b> and ibrutinib along with DMSO as a control. Cells were incubated for 14 h at 37 °C with 0.003 μM ibrutinib alone and in combination with increasing concentrations of compound <b>4</b> or <b>13</b> (0.12, 0.37, 1.1, 3.3, and 10 μM). Cells were then lysed, and 30 μg of lysate was loaded onto 4–12% polyacrylamide gel. The gel was transferred to nitrocellulose membranes, and the membranes were Western-blotted following typical procedures with antibodies for pIκBα and vinculin (Cell Signaling Technology) following typical Western blotting procedures.</div></div><div id="sec5_3_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i40" class="anchor-spacer"></div><h4 class="article-section__title" id="_i40"> Cell Viability Assay</h4><div class="NLM_p last">A “6 × 6 dose matrix” was used to evaluate the combination effects between compound <b>13</b> and ibrutinib, where all possible mixtures of serially diluted single agents at the indicated concentrations were evaluated including zero in a growth assay. At the end of day 3, the viable cells were measured using Alamar blue reagent (a resazurin-based solution that functions as a cell health indicator using the reducing power of living cells to quantitatively measure viability). Fluorescence with an excitation wavelength at 530–560 nm and an emission wavelength at 590 nm was measured. Cell growth was determined at day zero (<i>V</i><sub>0</sub>) before compound dosing and after 72 h of treatment (<i>V</i>), after treatment with the compound T. A GI reading of 0% represents no growth inhibition, a GI of 100% represents complete growth inhibition (cytostatic effect), and a GI of 200% represents complete death of cells. Compounds reaching an activity plateau of GI 200% are considered cytotoxic (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>). Genedata screener calculates GI by applying the following test and equation<span class="NLM_disp-formula" id="ueq1"><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-21/acs.jmedchem.9b01346/20191108/images/medium/jm9b01346_m001.gif" alt="" id="_i41" /></img></span><span class="NLM_disp-formula" id="ueq2"><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-21/acs.jmedchem.9b01346/20191108/images/medium/jm9b01346_m002.gif" alt="" id="_i42" /></img></span>where <i>T</i> is the signal measure for a test article, <i>V</i> is the vehicle-treated control measure after 72 h, and <i>V</i><sub>0</sub> is the vehicle control measure at time zero.</div></div></div><div id="sec5_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i43" class="anchor-spacer"></div><h3 class="article-section__title" id="_i43"> In Vivo Efficacy Study</h3><div class="NLM_p last">The antitumor activity of compound <b>4</b>, compound <b>13</b>, ibrutinib, and combinations was evaluated in mice bearing OCI-LY10 tumors in two separate studies. Briefly, female CB.17 SCID mice, 5–6 weeks old, were obtained from Charles River Laboratories (Wilmington, MA). The mice were maintained in accordance with the Guide for the Care and Use of Laboratory Animals (National Research Council). OCI-LY10 cells were injected subcutaneously into the area under the right flank of each mouse. Thirty-four days after tumor cell inoculation, mice were randomized into treatment groups: vehicle control, <b>4</b> (50 mg/kg), ibrutinib (12 mg/kg), and a combination of <b>4</b> (50 mg/kg) and ibrutinib (12 mg/kg) in a study shown in <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>A. The second study included vehicle, <b>13</b> (100 mg/kg), ibrutinib (12 mg/kg), and a combination of <b>13</b> (50 mg/kg) and ibrutinib (12 mg/kg) shown in <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>B. Treatments were administered daily orally. Tumor volumes following the administration of the test articles, with time after tumor inoculation, are plotted in <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>. All treatments were well tolerated with no bodyweight loss as with vehicle control animals.</div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i44"><a href="/doi/suppl/10.1021/acs.jmedchem.9b01346" class="ext-link">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_43264" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_43264" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a href="/" class="ext-link">ACS Publications website</a> at DOI: <a href="/doi/abs/10.1021/acs.jmedchem.9b01346" class="ext-link">10.1021/acs.jmedchem.9b01346</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Assay statistical analyses; quantum mechanics calculations; crystallographic data (<a href="/doi/suppl/10.1021/acs.jmedchem.9b01346/suppl_file/jm9b01346_si_001.pdf" class="ext-link">PDF</a>)</p></li><li><p class="inline">Molecular formula strings (<a href="/doi/suppl/10.1021/acs.jmedchem.9b01346/suppl_file/jm9b01346_si_002.csv" class="ext-link">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b01346/suppl_file/jm9b01346_si_001.pdf">jm9b01346_si_001.pdf (242.47 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b01346/suppl_file/jm9b01346_si_002.csv">jm9b01346_si_002.csv (1.32 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.9b01346" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_82708" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_82708" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Sébastien L. Degorce</span> - <span class="hlFld-Affiliation affiliation">Medicinal
Chemistry, Oncology R&D, AstraZeneca, Cambridge Science Park, Unit 310 Darwin Building, Cambridge CB4
0WG, U.K.</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-9478-5106" title="Orcid link">http://orcid.org/0000-0002-9478-5106</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#a6d5c3c4c7d5d2cfc3c888c2c3c1c9d4c5c3e6c7d5d2d4c7dcc3c8c3c5c788c5c9cb"><span class="__cf_email__" data-cfemail="7e0d1b1c1f0d0a171b10501a1b19110c1d1b3e1f0d0a0c1f041b101b1d1f501d1113">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Rana Anjum</span> - <span class="hlFld-Affiliation affiliation">Bioscience,
Oncology R&D, AstraZeneca, Boston, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Andrew Bloecher</span> - <span class="hlFld-Affiliation affiliation">Bioscience,
Oncology R&D, AstraZeneca, Boston, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Rodrigo J. Carbajo</span> - <span class="hlFld-Affiliation affiliation">Medicinal
Chemistry, Oncology R&D, AstraZeneca, Cambridge Science Park, Unit 310 Darwin Building, Cambridge CB4
0WG, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Keith S. Dillman</span> - <span class="hlFld-Affiliation affiliation">Bioscience,
Oncology R&D, AstraZeneca, Boston, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Lisa Drew</span> - <span class="hlFld-Affiliation affiliation">Bioscience,
Oncology R&D, AstraZeneca, Boston, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Christopher T. Halsall</span> - <span class="hlFld-Affiliation affiliation">Medicinal
Chemistry, Oncology R&D, AstraZeneca, Cambridge Science Park, Unit 310 Darwin Building, Cambridge CB4
0WG, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Eva M. Lenz</span> - <span class="hlFld-Affiliation affiliation">Medicinal
Chemistry, Oncology R&D, AstraZeneca, Cambridge Science Park, Unit 310 Darwin Building, Cambridge CB4
0WG, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Nicola A. Lindsay</span> - <span class="hlFld-Affiliation affiliation">Medicinal
Chemistry, Oncology R&D, AstraZeneca, Cambridge Science Park, Unit 310 Darwin Building, Cambridge CB4
0WG, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Michele F. Mayo</span> - <span class="hlFld-Affiliation affiliation">Bioscience,
Oncology R&D, AstraZeneca, Boston, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jennifer H. Pink</span> - <span class="hlFld-Affiliation affiliation">Medicinal
Chemistry, Oncology R&D, AstraZeneca, Cambridge Science Park, Unit 310 Darwin Building, Cambridge CB4
0WG, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Graeme R. Robb</span> - <span class="hlFld-Affiliation affiliation">Medicinal
Chemistry, Oncology R&D, AstraZeneca, Cambridge Science Park, Unit 310 Darwin Building, Cambridge CB4
0WG, U.K.</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-4531-4375" title="Orcid link">http://orcid.org/0000-0002-4531-4375</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Alan Rosen</span> - <span class="hlFld-Affiliation affiliation">Bioscience,
Oncology R&D, AstraZeneca, Boston, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">James S. Scott</span> - <span class="hlFld-Affiliation affiliation">Medicinal
Chemistry, Oncology R&D, AstraZeneca, Cambridge Science Park, Unit 310 Darwin Building, Cambridge CB4
0WG, U.K.</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-2263-7024" title="Orcid link">http://orcid.org/0000-0002-2263-7024</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yafeng Xue</span> - <span class="hlFld-Affiliation affiliation">Discovery
Sciences, R&D, AstraZeneca, Gothenburg SE-431 83, Mölndal, Sweden</span></div></li></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="ack" id="ACK-d7e4054-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i45">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_15526" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_15526" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The authors would like to thank Sharon Tentarelli for the characterization of previously unreported molecules and Jeff Johannes for his help with this manuscript.</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations</td></tr><tr><td class="NLM_term">ABC</td><td class="NLM_def"><p class="first last">activated B cell-like</p></td></tr><tr><td class="NLM_term">BCR</td><td class="NLM_def"><p class="first last">B cell receptor</p></td></tr><tr><td class="NLM_term">BTK</td><td class="NLM_def"><p class="first last">Bruton’s tyrosine kinase</p></td></tr><tr><td class="NLM_term">CD79</td><td class="NLM_def"><p class="first last">cluster of differentiation 79</p></td></tr><tr><td class="NLM_term">CDK</td><td class="NLM_def"><p class="first last">cyclin-dependent kinase</p></td></tr><tr><td class="NLM_term">CLK</td><td class="NLM_def"><p class="first last">CDC-like kinase</p></td></tr><tr><td class="NLM_term">CK1g1</td><td class="NLM_def"><p class="first last">Casein kinase 1, γ 1</p></td></tr><tr><td class="NLM_term">DIPEA</td><td class="NLM_def"><p class="first last"><i>N</i>,<i>N</i>-diisopropylethylamine</p></td></tr><tr><td class="NLM_term">DLBCL</td><td class="NLM_def"><p class="first last">diffuse large B cell lymphoma</p></td></tr><tr><td class="NLM_term">GCB</td><td class="NLM_def"><p class="first last">germinal center B</p></td></tr><tr><td class="NLM_term">GSH</td><td class="NLM_def"><p class="first last">glutathione</p></td></tr><tr><td class="NLM_term">HBD</td><td class="NLM_def"><p class="first last">hydrogen bond donor</p></td></tr><tr><td class="NLM_term">IκBα</td><td class="NLM_def"><p class="first last">inhibitor of kappa B</p></td></tr><tr><td class="NLM_term">IHB</td><td class="NLM_def"><p class="first last">intramolecular hydrogen bond</p></td></tr><tr><td class="NLM_term">IL-1b</td><td class="NLM_def"><p class="first last">interleukin 1B receptor</p></td></tr><tr><td class="NLM_term">IRAK4</td><td class="NLM_def"><p class="first last">interleukin-1 receptor-associated kinase 4</p></td></tr><tr><td class="NLM_term">LLE</td><td class="NLM_def"><p class="first last">ligand lipophilicity efficiency</p></td></tr><tr><td class="NLM_term">MLK1</td><td class="NLM_def"><p class="first last">mixed lineage kinase 1</p></td></tr><tr><td class="NLM_term">MyD88</td><td class="NLM_def"><p class="first last">myeloid differentiation primary response gene 88</p></td></tr><tr><td class="NLM_term">NFκB</td><td class="NLM_def"><p class="first last">nuclear factor-kappa B</p></td></tr><tr><td class="NLM_term">NMP</td><td class="NLM_def"><p class="first last"><i>N</i>-methylpyrrolidone</p></td></tr><tr><td class="NLM_term">NOE</td><td class="NLM_def"><p class="first last">nuclear Overhauser effect</p></td></tr><tr><td class="NLM_term">prep.</td><td class="NLM_def"><p class="first last">preparative</p></td></tr><tr><td class="NLM_term">QM</td><td class="NLM_def"><p class="first last">quantum mechanics</p></td></tr><tr><td class="NLM_term">RT</td><td class="NLM_def"><p class="first last">room temperature</p></td></tr><tr><td class="NLM_term">SAR</td><td class="NLM_def"><p class="first last">structure–activity relationship</p></td></tr><tr><td class="NLM_term">SCID</td><td class="NLM_def"><p class="first last">severe combined immuno-deficient</p></td></tr><tr><td class="NLM_term">SNAr</td><td class="NLM_def"><p class="first last">nucleophilic aromatic substitution</p></td></tr><tr><td class="NLM_term">TGI</td><td class="NLM_def"><p class="first last">tumor growth inhibition</p></td></tr><tr><td class="NLM_term">TLR</td><td class="NLM_def"><p class="first last">Toll-like receptor</p></td></tr><tr><td class="NLM_term">ULK2</td><td class="NLM_def"><p class="first last">Unc-51-like kinase 2</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i47">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_43711" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_43711" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 23 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Camicia, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winkler, H. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hassa, P. O.</span></span> <span> </span><span class="NLM_article-title">Novel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive review</span>. <i>Mol. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">207</span>, <span class="refDoi"> DOI: 10.1186/s12943-015-0474-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01346&amp;key=10.1186%2Fs12943-015-0474-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01346&amp;key=26654227" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01346&amp;key=1%3ACAS%3A528%3ADC%252BC28Xpt1Olurk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2015&pages=207&author=R.+Camiciaauthor=H.+C.+Winklerauthor=P.+O.+Hassa&title=Novel+drug+targets+for+personalized+precision+medicine+in+relapsed%2Frefractory+diffuse+large+B-cell+lymphoma%3A+a+comprehensive+review&doi=10.1186%2Fs12943-015-0474-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Novel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive review</span></div><div class="casAuthors">Camicia, Rosalba; Winkler, Hans C.; Hassa, Paul O.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">207/1-207/62</span>CODEN:
                <span class="NLM_cas:coden">MCOACG</span>;
        ISSN:<span class="NLM_cas:issn">1476-4598</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Diffuse large B-cell lymphoma (DLBCL) is a clin. heterogeneous lymphoid malignancy and the most common subtype of non-Hodgkin's lymphoma in adults, with one of the highest mortality rates in most developed areas of the world.  More than half of DLBLC patients can be cured with std. R-CHOP regimens, however approx. 30 to 40 % of patients will develop relapsed/refractory disease that remains a major cause of morbidity and mortality due to the limited therapeutic options.  Recent advances in gene expression profiling have led to the identification of at least three distinct mol. subtypes of DLBCL: a germinal center B cell-like subtype, an activated B cell-like subtype, and a primary mediastinal B-cell lymphoma subtype.  Moreover, recent findings have not only increased our understanding of the mol. basis of chemotherapy resistance but have also helped identify mol. subsets of DLBCL and rational targets for drug interventions that may allow for subtype/subset-specific molecularly targeted precision medicine and personalized combinations to both prevent and treat relapsed/refractory DLBCL.  Novel agents such as lenalidomide, ibrutinib, bortezomib, CC-122, epratuzumab or pidilizumab used as single-agent or in combination with (rituximab-based) chemotherapy have already demonstrated promising activity in patients with relapsed/ refractory DLBCL.  Several novel potential drug targets have been recently identified such as the BET bromodomain protein (BRD)-4, phosphoribosyl-pyrophosphate synthetase (PRPS)-2, macrodomain-contg. mono-ADP-ribosyltransferase (ARTD)-9 (also known as PARP9), deltex-3-like E3 ubiquitin ligase (DTX3L) (also known as BBAP), NF-kappaB inducing kinase (NIK) and transforming growth factor beta receptor (TGFssR).  This review highlights the new insights into the mol. basis of relapsed/refractory DLBCL and summarizes the most promising drug targets and exptl. treatments for relapsed/refractory DLBCL, including the use of novel agents such as lenalidomide, ibrutinib, bortezomib, pidilizumab, epratuzumab, brentuximab-vedotin or CAR T cells, dual inhibitors, as well as mechanism-based combinatorial exptl. therapies.  We also provide a comprehensive and updated list of current drugs, drug targets and preclin. and clin. exptl. studies in DLBCL.  A special focus is given on STAT1, ARTD9, DTX3L and ARTD8 (also known as PARP14) as novel potential drug targets in distinct mol. subsets of DLBCL.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpJp4JiT_yM07Vg90H21EOLACvtfcHk0lhrvbk9v47I8g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xpt1Olurk%253D&md5=c4365573bf9b7d942ecdefadf08c7741</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1186%2Fs12943-015-0474-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs12943-015-0474-2%26sid%3Dliteratum%253Aachs%26aulast%3DCamicia%26aufirst%3DR.%26aulast%3DWinkler%26aufirst%3DH.%2BC.%26aulast%3DHassa%26aufirst%3DP.%2BO.%26atitle%3DNovel%2520drug%2520targets%2520for%2520personalized%2520precision%2520medicine%2520in%2520relapsed%252Frefractory%2520diffuse%2520large%2520B-cell%2520lymphoma%253A%2520a%2520comprehensive%2520review%26jtitle%3DMol.%2520Cancer%26date%3D2015%26volume%3D14%26spage%3D207%26doi%3D10.1186%2Fs12943-015-0474-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ngo, V. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmitz, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jhavar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lim, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kohlhammer, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaffer, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romesser, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wright, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Powell, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosenwald, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muller-Hermelink, H. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ott, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gascoyne, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Connors, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rimsza, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campo, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jaffe, E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delabie, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smeland, E. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fisher, R. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Braziel, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tubbs, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cook, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weisenburger, D. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Staudt, L. M.</span></span> <span> </span><span class="NLM_article-title">Oncogenically active MYD88 mutations in human lymphoma</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>470</i></span>,  <span class="NLM_fpage">115</span>– <span class="NLM_lpage">119</span>, <span class="refDoi"> DOI: 10.1038/nature09671</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01346&amp;key=10.1038%2Fnature09671" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01346&amp;key=21179087" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01346&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtVCksQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=470&publication_year=2011&pages=115-119&author=V.+N.+Ngoauthor=R.+M.+Youngauthor=R.+Schmitzauthor=S.+Jhavarauthor=W.+Xiaoauthor=K.+H.+Limauthor=H.+Kohlhammerauthor=W.+Xuauthor=Y.+Yangauthor=H.+Zhaoauthor=A.+L.+Shafferauthor=P.+Romesserauthor=G.+Wrightauthor=J.+Powellauthor=A.+Rosenwaldauthor=H.+K.+Muller-Hermelinkauthor=G.+Ottauthor=R.+D.+Gascoyneauthor=J.+M.+Connorsauthor=L.+M.+Rimszaauthor=E.+Campoauthor=E.+S.+Jaffeauthor=J.+Delabieauthor=E.+B.+Smelandauthor=R.+I.+Fisherauthor=R.+M.+Brazielauthor=R.+R.+Tubbsauthor=J.+R.+Cookauthor=D.+D.+Weisenburgerauthor=W.+C.+Chanauthor=L.+M.+Staudt&title=Oncogenically+active+MYD88+mutations+in+human+lymphoma&doi=10.1038%2Fnature09671"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Oncogenically active MYD88 mutations in human lymphoma</span></div><div class="casAuthors">Ngo, Vu N.; Young, Ryan M.; Schmitz, Roland; Jhavar, Sameer; Xiao, Wenming; Lim, Kian-Huat; Kohlhammer, Holger; Xu, Weihong; Yang, Yandan; Zhao, Hong; Shaffer, Arthur L.; Romesser, Paul; Wright, George; Powell, John; Rosenwald, Andreas; Muller-Hermelink, Hans Konrad; Ott, German; Gascoyne, Randy D.; Connors, Joseph M.; Rimsza, Lisa M.; Campo, Elias; Jaffe, Elaine S.; Delabie, Jan; Smeland, Erlend B.; Fisher, Richard I.; Braziel, Rita M.; Tubbs, Raymond R.; Cook, J. R.; Weisenburger, Denny D.; Chan, Wing C.; Staudt, Louis M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">470</span>
        (<span class="NLM_cas:issue">7332</span>),
    <span class="NLM_cas:pages">115-119</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The activated B-cell-like (ABC) subtype of diffuse large B-cell lymphoma (DLBCL) remains the least curable form of this malignancy despite recent advances in therapy.  Constitutive nuclear factor (NF)-κB and JAK kinase signaling promotes malignant cell survival in these lymphomas, but the genetic basis for this signaling is incompletely understood.  Here we describe the dependence of ABC DLBCLs on MYD88, an adaptor protein that mediates toll and interleukin (IL)-1 receptor signaling, and the discovery of highly recurrent oncogenic mutations affecting MYD88 in ABC DLBCL tumors.  RNA interference screening revealed that MYD88 and the assocd. kinases IRAK1 and IRAK4 are essential for ABC DLBCL survival.  High-throughput RNA resequencing uncovered MYD88 mutations in ABC DLBCL lines.  Notably, 29% of ABC DLBCL tumors harbored the same amino acid substitution, L265P, in the MYD88 Toll/IL-1 receptor (TIR) domain at an evolutionarily invariant residue in its hydrophobic core.  This mutation was rare or absent in other DLBCL subtypes and Burkitt's lymphoma, but was obsd. in 9% of mucosa-assocd. lymphoid tissue lymphomas.  At a lower frequency, addnl. mutations were obsd. in the MYD88 TIR domain, occurring in both the ABC and germinal center B-cell-like (GCB) DLBCL subtypes.  Survival of ABC DLBCL cells bearing the L265P mutation was sustained by the mutant but not the wild-type MYD88 isoform, demonstrating that L265P is a gain-of-function driver mutation.  The L265P mutant promoted cell survival by spontaneously assembling a protein complex contg. IRAK1 and IRAK4, leading to IRAK4 kinase activity, IRAK1 phosphorylation, NF-κB signaling, JAK kinase activation of STAT3, and secretion of IL-6, IL-10 and interferon-β.  Hence, the MYD88 signaling pathway is integral to the pathogenesis of ABC DLBCL, supporting the development of inhibitors of IRAK4 kinase and other components of this pathway for the treatment of tumors bearing oncogenic MYD88 mutations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq5pEPxh1G6J7Vg90H21EOLACvtfcHk0liOyTGsf4JvQA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtVCksQ%253D%253D&md5=3dff4d54af8f64bb9e57f04cf274fee8</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1038%2Fnature09671&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature09671%26sid%3Dliteratum%253Aachs%26aulast%3DNgo%26aufirst%3DV.%2BN.%26aulast%3DYoung%26aufirst%3DR.%2BM.%26aulast%3DSchmitz%26aufirst%3DR.%26aulast%3DJhavar%26aufirst%3DS.%26aulast%3DXiao%26aufirst%3DW.%26aulast%3DLim%26aufirst%3DK.%2BH.%26aulast%3DKohlhammer%26aufirst%3DH.%26aulast%3DXu%26aufirst%3DW.%26aulast%3DYang%26aufirst%3DY.%26aulast%3DZhao%26aufirst%3DH.%26aulast%3DShaffer%26aufirst%3DA.%2BL.%26aulast%3DRomesser%26aufirst%3DP.%26aulast%3DWright%26aufirst%3DG.%26aulast%3DPowell%26aufirst%3DJ.%26aulast%3DRosenwald%26aufirst%3DA.%26aulast%3DMuller-Hermelink%26aufirst%3DH.%2BK.%26aulast%3DOtt%26aufirst%3DG.%26aulast%3DGascoyne%26aufirst%3DR.%2BD.%26aulast%3DConnors%26aufirst%3DJ.%2BM.%26aulast%3DRimsza%26aufirst%3DL.%2BM.%26aulast%3DCampo%26aufirst%3DE.%26aulast%3DJaffe%26aufirst%3DE.%2BS.%26aulast%3DDelabie%26aufirst%3DJ.%26aulast%3DSmeland%26aufirst%3DE.%2BB.%26aulast%3DFisher%26aufirst%3DR.%2BI.%26aulast%3DBraziel%26aufirst%3DR.%2BM.%26aulast%3DTubbs%26aufirst%3DR.%2BR.%26aulast%3DCook%26aufirst%3DJ.%2BR.%26aulast%3DWeisenburger%26aufirst%3DD.%2BD.%26aulast%3DChan%26aufirst%3DW.%2BC.%26aulast%3DStaudt%26aufirst%3DL.%2BM.%26atitle%3DOncogenically%2520active%2520MYD88%2520mutations%2520in%2520human%2520lymphoma%26jtitle%3DNature%26date%3D2011%26volume%3D470%26spage%3D115%26epage%3D119%26doi%3D10.1038%2Fnature09671" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Davids, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, J. R.</span></span> <span> </span><span class="NLM_article-title">Ibrutinib: a first in class covalent inhibitor of Bruton’s Tyrosine Kinase</span>. <i>Future Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">957</span>– <span class="NLM_lpage">967</span>, <span class="refDoi"> DOI: 10.2217/fon.14.51</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01346&amp;key=10.2217%2Ffon.14.51" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01346&amp;key=24941982" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01346&amp;key=1%3ACAS%3A528%3ADC%252BC2cXpvFCrtbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2014&pages=957-967&author=M.+S.+Davidsauthor=J.+R.+Brown&title=Ibrutinib%3A+a+first+in+class+covalent+inhibitor+of+Bruton%E2%80%99s+Tyrosine+Kinase&doi=10.2217%2Ffon.14.51"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Ibrutinib: a first in class covalent inhibitor of Bruton's tyrosine kinase</span></div><div class="casAuthors">Davids, Matthew S.; Brown, Jennifer R.</div><div class="citationInfo"><span class="NLM_cas:title">Future Oncology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">957-967</span>CODEN:
                <span class="NLM_cas:coden">FOUNBN</span>;
        ISSN:<span class="NLM_cas:issn">1479-6694</span>.
    
            (<span class="NLM_cas:orgname">Future Medicine Ltd.</span>)
        </div><div class="casAbstract">A review.  Ibrutinib (formerly PCI-32765) is a potent, covalent inhibitor of Bruton's tyrosine kinase, a kinase downstream of the B-cell receptor that is crit. for B-cell survival and proliferation.  In preclin. studies, ibrutinib bound to Bruton's tyrosine kinase with high affinity, leading to inhibition of B-cell receptor signaling, decreased B-cell activation and induction of apoptosis.  In clin. studies, ibrutinib has been well-tolerated and has demonstrated profound anti-tumor activity in a variety of hematol. malignancies, most notably chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL), leading to US FDA approval for relapsed CLL and MCL.  Ongoing studies are evaluating ibrutinib in other types of non-Hodgkin's lymphoma, such as diffuse large B-cell lymphoma and Waldenstroem's macrogobulinemia, in larger Phase III studies in CLL and MCL, and in combination studies with monoclonal antibodies and chemotherapy.  Future studies will combine ibrutinib with other promising novel agents currently in development in hematol. malignancies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr3o_pMnFVskLVg90H21EOLACvtfcHk0liOyTGsf4JvQA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXpvFCrtbc%253D&md5=345b4e839a830be822d474f62755a022</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.2217%2Ffon.14.51&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2217%252Ffon.14.51%26sid%3Dliteratum%253Aachs%26aulast%3DDavids%26aufirst%3DM.%2BS.%26aulast%3DBrown%26aufirst%3DJ.%2BR.%26atitle%3DIbrutinib%253A%2520a%2520first%2520in%2520class%2520covalent%2520inhibitor%2520of%2520Bruton%25E2%2580%2599s%2520Tyrosine%2520Kinase%26jtitle%3DFuture%2520Oncol.%26date%3D2014%26volume%3D10%26spage%3D957%26epage%3D967%26doi%3D10.2217%2Ffon.14.51" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, W. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmitz, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pittaluga, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wright, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lih, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaffer, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerecitano, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Vos, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kenkre, V. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barr, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blum, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shustov, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Advani, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fowler, N. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vose, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elstrom, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Habermann, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrientos, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGreivy, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fardis, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, B. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clow, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Munneke, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moussa, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beaupre, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Staudt, L. M.</span></span> <span> </span><span class="NLM_article-title">Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma</span>. <i>Nat. Med.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">922</span>– <span class="NLM_lpage">926</span>, <span class="refDoi"> DOI: 10.1038/nm.3884</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01346&amp;key=10.1038%2Fnm.3884" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01346&amp;key=26193343" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01346&amp;key=1%3ACAS%3A528%3ADC%252BC2MXht1WltLjK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2015&pages=922-926&author=W.+H.+Wilsonauthor=R.+M.+Youngauthor=R.+Schmitzauthor=Y.+Yangauthor=S.+Pittalugaauthor=G.+Wrightauthor=C.+J.+Lihauthor=P.+M.+Williamsauthor=A.+L.+Shafferauthor=J.+Gerecitanoauthor=S.+de+Vosauthor=A.+Goyauthor=V.+P.+Kenkreauthor=P.+M.+Barrauthor=K.+A.+Blumauthor=A.+Shustovauthor=R.+Advaniauthor=N.+H.+Fowlerauthor=J.+M.+Voseauthor=R.+L.+Elstromauthor=T.+M.+Habermannauthor=J.+C.+Barrientosauthor=J.+McGreivyauthor=M.+Fardisauthor=B.+Y.+Changauthor=F.+Clowauthor=B.+Munnekeauthor=D.+Moussaauthor=D.+M.+Beaupreauthor=L.+M.+Staudt&title=Targeting+B+cell+receptor+signaling+with+ibrutinib+in+diffuse+large+B+cell+lymphoma&doi=10.1038%2Fnm.3884"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma</span></div><div class="casAuthors">Wilson, Wyndham H.; Young, Ryan M.; Schmitz, Roland; Yang, Yandan; Pittaluga, Stefania; Wright, George; Lih, Chih-Jian; Williams, P. Mickey; Shaffer, Arthur L.; Gerecitano, John; de Vos, Sven; Goy, Andre; Kenkre, Vaishalee P.; Barr, Paul M.; Blum, Kristie A.; Shustov, Andrei; Advani, Ranjana; Fowler, Nathan H.; Vose, Julie M.; Elstrom, Rebecca L.; Habermann, Thomas M.; Barrientos, Jacqueline C.; McGreivy, Jesse; Fardis, Maria; Chang, Betty Y.; Clow, Fong; Munneke, Brian; Moussa, Davina; Beaupre, Darrin M.; Staudt, Louis M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">922-926</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The two major subtypes of diffuse large B cell lymphoma (DLBCL)-activated B cell-like (ABC) and germinal center B cell-like (GCB)-arise by distinct mechanisms, with ABC selectively acquiring mutations that target the B cell receptor (BCR), fostering chronic active BCR signaling.  The ABC subtype has a ∼40% cure rate with currently available therapies, which is worse than the rate for GCB DLBCL, and highlights the need for ABC subtype-specific treatment strategies.  We hypothesized that ABC, but not GCB, DLBCL tumors would respond to ibrutinib, an inhibitor of BCR signaling.  In a phase 1/2 clin. trial that involved 80 subjects with relapsed or refractory DLBCL, ibrutinib produced complete or partial responses in 37% (14/38) of those with ABC DLBCL, but in only 5% (1/20) of subjects with GCB DLBCL (P = 0.0106).  ABC tumors with BCR mutations responded to ibrutinib frequently (5/9; 55.5%), esp. those with concomitant myeloid differentiation primary response 88 (MYD88) mutations (4/5; 80%), a result that is consistent with in vitro cooperation between the BCR and MYD88 pathways.  However, the highest no. of responses occurred in ABC tumors that lacked BCR mutations (9/29; 31%), suggesting that oncogenic BCR signaling in ABC does not require BCR mutations and might be initiated by non-genetic mechanisms.  These results support the selective development of ibrutinib for the treatment of ABC DLBCL.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpryc32RWzm77Vg90H21EOLACvtfcHk0liOyTGsf4JvQA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXht1WltLjK&md5=d3342e8baa16eb379eed112c21d0b4ba</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1038%2Fnm.3884&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm.3884%26sid%3Dliteratum%253Aachs%26aulast%3DWilson%26aufirst%3DW.%2BH.%26aulast%3DYoung%26aufirst%3DR.%2BM.%26aulast%3DSchmitz%26aufirst%3DR.%26aulast%3DYang%26aufirst%3DY.%26aulast%3DPittaluga%26aufirst%3DS.%26aulast%3DWright%26aufirst%3DG.%26aulast%3DLih%26aufirst%3DC.%2BJ.%26aulast%3DWilliams%26aufirst%3DP.%2BM.%26aulast%3DShaffer%26aufirst%3DA.%2BL.%26aulast%3DGerecitano%26aufirst%3DJ.%26aulast%3Dde%2BVos%26aufirst%3DS.%26aulast%3DGoy%26aufirst%3DA.%26aulast%3DKenkre%26aufirst%3DV.%2BP.%26aulast%3DBarr%26aufirst%3DP.%2BM.%26aulast%3DBlum%26aufirst%3DK.%2BA.%26aulast%3DShustov%26aufirst%3DA.%26aulast%3DAdvani%26aufirst%3DR.%26aulast%3DFowler%26aufirst%3DN.%2BH.%26aulast%3DVose%26aufirst%3DJ.%2BM.%26aulast%3DElstrom%26aufirst%3DR.%2BL.%26aulast%3DHabermann%26aufirst%3DT.%2BM.%26aulast%3DBarrientos%26aufirst%3DJ.%2BC.%26aulast%3DMcGreivy%26aufirst%3DJ.%26aulast%3DFardis%26aufirst%3DM.%26aulast%3DChang%26aufirst%3DB.%2BY.%26aulast%3DClow%26aufirst%3DF.%26aulast%3DMunneke%26aufirst%3DB.%26aulast%3DMoussa%26aufirst%3DD.%26aulast%3DBeaupre%26aufirst%3DD.%2BM.%26aulast%3DStaudt%26aufirst%3DL.%2BM.%26atitle%3DTargeting%2520B%2520cell%2520receptor%2520signaling%2520with%2520ibrutinib%2520in%2520diffuse%2520large%2520B%2520cell%2520lymphoma%26jtitle%3DNat.%2520Med.%26date%3D2015%26volume%3D21%26spage%3D922%26epage%3D926%26doi%3D10.1038%2Fnm.3884" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Barf, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Covey, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Izumi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van de Kar, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gulrajani, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Lith, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Hoek, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Zwart, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mittag, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Demont, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verkaik, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krantz, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pearson, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ulrich, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaptein, A.</span></span> <span> </span><span class="NLM_article-title">Acalabrutinib (ACP-196): A covalent Bruton Tyrosine Kinase inhibitor with a differentiated selectivity and in vivo potency profile</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>363</i></span>,  <span class="NLM_fpage">240</span>– <span class="NLM_lpage">252</span>, <span class="refDoi"> DOI: 10.1124/jpet.117.242909</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01346&amp;key=10.1124%2Fjpet.117.242909" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01346&amp;key=28882879" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01346&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtleltrnO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=363&publication_year=2017&pages=240-252&author=T.+Barfauthor=T.+Coveyauthor=R.+Izumiauthor=B.+van+de+Karauthor=M.+Gulrajaniauthor=B.+van+Lithauthor=M.+van+Hoekauthor=E.+de+Zwartauthor=D.+Mittagauthor=D.+Demontauthor=S.+Verkaikauthor=F.+Krantzauthor=P.+G.+Pearsonauthor=R.+Ulrichauthor=A.+Kaptein&title=Acalabrutinib+%28ACP-196%29%3A+A+covalent+Bruton+Tyrosine+Kinase+inhibitor+with+a+differentiated+selectivity+and+in+vivo+potency+profile&doi=10.1124%2Fjpet.117.242909"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Acalabrutinib (ACP-196): a covalent Bruton tyrosine kinase inhibitor with a differentiated selectivity and in vivo potency profile</span></div><div class="casAuthors">Barf, Tjeerd; Covey, Todd; Izumi, Raquel; van de Kar, Bas; Gulrajani, Michael; van Lith, Bart; van Hoek, Maaike; de Zwart, Edwin; Mittag, Diana; Demont, Dennis; Verkaik, Saskia; Krantz, Fanny; Pearson, Paul G.; Ulrich, Roger; Kaptein, Allard</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">363</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">240-252</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Several small-mol. Bruton tyrosine kinase (BTK) inhibitors are in development for B cell malignancies and autoimmune disorders, each characterized by distinct potency and selectivity patterns.  Herein we describe the pharmacol. characterization of BTK inhibitor acalabrutinib [compd. 1, ACP-196 (4-[8- amino-3-[(2S)-1-but-2-ynoylpyrrolidin-2-yl]imidazo[1,5-a]pyrazin1-yl]-N-(2-pyridyl)benzamide)].  Acalabrutinib possesses a reactive butynamide group that binds covalently to Cys481 in BTK.  Relative to the other BTK inhibitors described here, the reduced intrinsic reactivity of acalabrutinib helps to limit inhibition of off-target kinases having cysteine-mediated covalent binding potential.  Acalabrutinib demonstrated higher biochem. and cellular selectivity than ibrutinib and spebrutinib (compds. 2 and 3, resp.).  Importantly, off-target kinases, such as epidermal growth factor receptor (EGFR) and interleukin 2-inducible T cell kinase (ITK), were not inhibited.  Detn. of the inhibitory potential of anti-IgM-induced CD69 expression in human peripheral blood mononuclear cells and whole blood demonstrated that acalabrutinib is a potent functional BTK inhibitor.  In vivo evaluation in mice revealed that acalabrutinib is more potent than ibrutinib and spebrutinib.  Preclin. and clin. studies showed that the level and duration of BTK occupancy correlates with in vivo efficacy.  Evaluation of the pharmacokinetic properties of acalabrutinib in healthy adult volunteers demonstrated rapid absorption and fast elimination.  In these healthy individuals, a single oral dose of 100 mg showed approx. 99% median target coverage at 3 and 12 h and around 90% at 24 h in peripheral B cells.  In conclusion, acalabrutinib is a BTK inhibitor with key pharmacol. differentiators vs. ibrutinib and spebrutinib and is currently being evaluated in clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGol9xhDmwvup7Vg90H21EOLACvtfcHk0liXiWejfsrFEw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtleltrnO&md5=73cbd3a87396abbf8cb20e4361f96f64</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1124%2Fjpet.117.242909&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.117.242909%26sid%3Dliteratum%253Aachs%26aulast%3DBarf%26aufirst%3DT.%26aulast%3DCovey%26aufirst%3DT.%26aulast%3DIzumi%26aufirst%3DR.%26aulast%3Dvan%2Bde%2BKar%26aufirst%3DB.%26aulast%3DGulrajani%26aufirst%3DM.%26aulast%3Dvan%2BLith%26aufirst%3DB.%26aulast%3Dvan%2BHoek%26aufirst%3DM.%26aulast%3Dde%2BZwart%26aufirst%3DE.%26aulast%3DMittag%26aufirst%3DD.%26aulast%3DDemont%26aufirst%3DD.%26aulast%3DVerkaik%26aufirst%3DS.%26aulast%3DKrantz%26aufirst%3DF.%26aulast%3DPearson%26aufirst%3DP.%2BG.%26aulast%3DUlrich%26aufirst%3DR.%26aulast%3DKaptein%26aufirst%3DA.%26atitle%3DAcalabrutinib%2520%2528ACP-196%2529%253A%2520A%2520covalent%2520Bruton%2520Tyrosine%2520Kinase%2520inhibitor%2520with%2520a%2520differentiated%2520selectivity%2520and%2520in%2520vivo%2520potency%2520profile%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2017%26volume%3D363%26spage%3D240%26epage%3D252%26doi%3D10.1124%2Fjpet.117.242909" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lim, K.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romero, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chaudhary, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robinson, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Staudt, L. M.</span></span> <span> </span><span class="NLM_article-title">IRAK4 kinase as a novel therapeutic target in the ABC subtype of diffuse large B cell lymphoma</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>120</i></span>,  <span class="NLM_fpage">62</span>, <span class="refDoi"> DOI: 10.1182/blood.V120.21.62.62</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01346&amp;key=10.1182%2Fblood.V120.21.62.62" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=120&publication_year=2012&pages=62&author=K.-H.+Limauthor=D.+L.+Romeroauthor=D.+Chaudharyauthor=S.+D.+Robinsonauthor=L.+M.+Staudt&title=IRAK4+kinase+as+a+novel+therapeutic+target+in+the+ABC+subtype+of+diffuse+large+B+cell+lymphoma&doi=10.1182%2Fblood.V120.21.62.62"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1182%2Fblood.V120.21.62.62&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood.V120.21.62.62%26sid%3Dliteratum%253Aachs%26aulast%3DLim%26aufirst%3DK.-H.%26aulast%3DRomero%26aufirst%3DD.%2BL.%26aulast%3DChaudhary%26aufirst%3DD.%26aulast%3DRobinson%26aufirst%3DS.%2BD.%26aulast%3DStaudt%26aufirst%3DL.%2BM.%26atitle%3DIRAK4%2520kinase%2520as%2520a%2520novel%2520therapeutic%2520target%2520in%2520the%2520ABC%2520subtype%2520of%2520diffuse%2520large%2520B%2520cell%2520lymphoma%26jtitle%3DBlood%26date%3D2012%26volume%3D120%26spage%3D62%26doi%3D10.1182%2Fblood.V120.21.62.62" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Suzuki, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suzuki, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duncan, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Millar, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wada, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mirtsos, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takada, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wakeham, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Itie, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Penninger, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wesche, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohashi, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mak, T. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeh, W. C.</span></span> <span> </span><span class="NLM_article-title">Severe impairment of interleukin-1 and Toll-like receptor signalling in mice lacking IRAK-4</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>416</i></span>,  <span class="NLM_fpage">750</span>– <span class="NLM_lpage">756</span>, <span class="refDoi"> DOI: 10.1038/nature736</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01346&amp;key=10.1038%2Fnature736" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01346&amp;key=11923871" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01346&amp;key=1%3ACAS%3A528%3ADC%252BD38XjtVKksb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=416&publication_year=2002&pages=750-756&author=N.+Suzukiauthor=S.+Suzukiauthor=G.+S.+Duncanauthor=D.+G.+Millarauthor=T.+Wadaauthor=C.+Mirtsosauthor=H.+Takadaauthor=A.+Wakehamauthor=A.+Itieauthor=S.+Liauthor=J.+M.+Penningerauthor=H.+Wescheauthor=P.+S.+Ohashiauthor=T.+W.+Makauthor=W.+C.+Yeh&title=Severe+impairment+of+interleukin-1+and+Toll-like+receptor+signalling+in+mice+lacking+IRAK-4&doi=10.1038%2Fnature736"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Severe impairment of interleukin-1 and Toll-like receptor signaling in mice lacking IRAK-4</span></div><div class="casAuthors">Suzuki, N.; Suzuki, S.; Duncan, G. S.; Millar, D. G.; Wada, T.; Mirtsos, C.; Takada, H.; Wakeham, A.; Itie, A.; Li, S.; Penninger, J. M.; Wesche, H.; Ohashi, P. S.; Mak, T. W.; Yeh, W. C.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">416</span>
        (<span class="NLM_cas:issue">6882</span>),
    <span class="NLM_cas:pages">750-756</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Toll-like receptors (TLRs), which recognize pathogen-assocd. mol. patterns, and members of the pro-inflammatory interleukin-1 receptor (IL-1R) family, share homologies in their cytoplasmic domains called Toll/IL-1R/plant R gene homol. (TIR) domains.  Intracellular signaling mechanisms mediated by TLRs are similar, with MyD88 and TRAF6 having crit. roles.  Signal transduction between MyD88 and TRAF6 is known to involve the serine-threonine kinase IL-1 receptor-assocd. kinase 1 (IRAK-1) and two homologous proteins, IRAK-2 and IRAK-M.  However, the physiol. functions of the IRAK mols. remain unclear, and gene-targeting studies have shown that IRAK-1 is only partially required for IL-1R and TLR signaling.  Here we show by gene-targeting that IRAK-4, an IRAK mol. closely related to the Drosophila Pelle protein, is indispensable for the responses of animals and cultured cells to IL-1 and ligands that stimulate various TLRs.  IRAK-4-deficient animals are completely resistant to a LD of lipopolysaccharide (LPS).  In addn., animals lacking IRAK-4 are severely impaired in their responses to viral and bacterial challenges.  Our results indicate that IRAK-4 has an essential role in innate immunity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrtPWpLv8IBGbVg90H21EOLACvtfcHk0liXiWejfsrFEw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XjtVKksb4%253D&md5=3cab6526ac8aa58532f50c5bfb364e5c</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1038%2Fnature736&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature736%26sid%3Dliteratum%253Aachs%26aulast%3DSuzuki%26aufirst%3DN.%26aulast%3DSuzuki%26aufirst%3DS.%26aulast%3DDuncan%26aufirst%3DG.%2BS.%26aulast%3DMillar%26aufirst%3DD.%2BG.%26aulast%3DWada%26aufirst%3DT.%26aulast%3DMirtsos%26aufirst%3DC.%26aulast%3DTakada%26aufirst%3DH.%26aulast%3DWakeham%26aufirst%3DA.%26aulast%3DItie%26aufirst%3DA.%26aulast%3DLi%26aufirst%3DS.%26aulast%3DPenninger%26aufirst%3DJ.%2BM.%26aulast%3DWesche%26aufirst%3DH.%26aulast%3DOhashi%26aufirst%3DP.%2BS.%26aulast%3DMak%26aufirst%3DT.%2BW.%26aulast%3DYeh%26aufirst%3DW.%2BC.%26atitle%3DSevere%2520impairment%2520of%2520interleukin-1%2520and%2520Toll-like%2520receptor%2520signalling%2520in%2520mice%2520lacking%2520IRAK-4%26jtitle%3DNature%26date%3D2002%26volume%3D416%26spage%3D750%26epage%3D756%26doi%3D10.1038%2Fnature736" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Degorce, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anjum, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dillman, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drew, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Groombridge, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Halsall, C. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lenz, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindsay, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mayo, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pink, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robb, G. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scott, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stokes, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xue, Y.</span></span> <span> </span><span class="NLM_article-title">Optimization of permeability in a series of pyrrolotriazine inhibitors of IRAK4</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">913</span>– <span class="NLM_lpage">924</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2018.01.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01346&amp;key=10.1016%2Fj.bmc.2018.01.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01346&amp;key=29398441" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01346&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisVSitLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2018&pages=913-924&author=S.+L.+Degorceauthor=R.+Anjumauthor=K.+S.+Dillmanauthor=L.+Drewauthor=S.+D.+Groombridgeauthor=C.+T.+Halsallauthor=E.+M.+Lenzauthor=N.+A.+Lindsayauthor=M.+F.+Mayoauthor=J.+H.+Pinkauthor=G.+R.+Robbauthor=J.+S.+Scottauthor=S.+Stokesauthor=Y.+Xue&title=Optimization+of+permeability+in+a+series+of+pyrrolotriazine+inhibitors+of+IRAK4&doi=10.1016%2Fj.bmc.2018.01.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Optimization of permeability in a series of pyrrolotriazine inhibitors of IRAK4</span></div><div class="casAuthors">Degorce, Sebastien L.; Anjum, Rana; Dillman, Keith S.; Drew, Lisa; Groombridge, Sam D.; Halsall, Christopher T.; Lenz, Eva M.; Lindsay, Nicola A.; Mayo, Michele F.; Pink, Jennifer H.; Robb, Graeme R.; Scott, James S.; Stokes, Stephen; Xue, Yafeng</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">913-924</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The authors have developed a series of orally efficacious IRAK4 inhibitors, based on a scaffold hopping strategy and using rational structure based design.  Efforts to tackle low permeability and high efflux in the authors' previously reported pyrrolopyrimidine series (Scott et al., 2017) led to the identification of pyrrolotriazines which contained one less formal hydrogen bond donor and were intrinsically more lipophilic.  Further optimization of substituents on this pyrrolotriazine core culminated with the discovery of compd. 30 (trans-1-(4-(4-((5-isopropylpyrrolo[2,1-f]-[1,2,4]triazin-4-yl)amino)cyclohexyl)piperazin-1-yl)ethanone) as a promising in vivo probe to assess the potential of IRAK4 inhibition for the treatment of MyD88 mutant Diffuse Large B Cell Lymphoma (DLBCL) in combination with a BTK inhibitor.  When tested in an ABC-DLBCL model with a dual MyD88/CD79 mutation (OCI-LY10), 30 demonstrated tumor regressions in combination with ibrutinib.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrao5i7H0tVFrVg90H21EOLACvtfcHk0lg9g13fnwXLVA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisVSitLc%253D&md5=772fab4ca7c899bb85bcd9ea8a9d47f3</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2018.01.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2018.01.008%26sid%3Dliteratum%253Aachs%26aulast%3DDegorce%26aufirst%3DS.%2BL.%26aulast%3DAnjum%26aufirst%3DR.%26aulast%3DDillman%26aufirst%3DK.%2BS.%26aulast%3DDrew%26aufirst%3DL.%26aulast%3DGroombridge%26aufirst%3DS.%2BD.%26aulast%3DHalsall%26aufirst%3DC.%2BT.%26aulast%3DLenz%26aufirst%3DE.%2BM.%26aulast%3DLindsay%26aufirst%3DN.%2BA.%26aulast%3DMayo%26aufirst%3DM.%2BF.%26aulast%3DPink%26aufirst%3DJ.%2BH.%26aulast%3DRobb%26aufirst%3DG.%2BR.%26aulast%3DScott%26aufirst%3DJ.%2BS.%26aulast%3DStokes%26aufirst%3DS.%26aulast%3DXue%26aufirst%3DY.%26atitle%3DOptimization%2520of%2520permeability%2520in%2520a%2520series%2520of%2520pyrrolotriazine%2520inhibitors%2520of%2520IRAK4%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2018%26volume%3D26%26spage%3D913%26epage%3D924%26doi%3D10.1016%2Fj.bmc.2018.01.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kelly, P. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romero, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaffer, A. L.,  3rd</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chaudhary, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robinson, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miao, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rui, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Westlin, W. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kapeller, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Staudt, L. M.</span></span> <span> </span><span class="NLM_article-title">Selective Interleukin-1 Receptor-Associated Kinase 4 inhibitors for the treatment of autoimmune disorders and lymphoid malignancy</span>. <i>J. Exp. Med.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>212</i></span>,  <span class="NLM_fpage">2189</span>– <span class="NLM_lpage">2201</span>, <span class="refDoi"> DOI: 10.1084/jem.20151074</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01346&amp;key=10.1084%2Fjem.20151074" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01346&amp;key=26621451" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01346&amp;key=1%3ACAS%3A528%3ADC%252BC28XjtlSgu7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=212&publication_year=2015&pages=2189-2201&author=P.+N.+Kellyauthor=D.+L.+Romeroauthor=Y.+Yangauthor=A.+L.+Shafferauthor=D.+Chaudharyauthor=S.+Robinsonauthor=W.+Miaoauthor=L.+Ruiauthor=W.+F.+Westlinauthor=R.+Kapellerauthor=L.+M.+Staudt&title=Selective+Interleukin-1+Receptor-Associated+Kinase+4+inhibitors+for+the+treatment+of+autoimmune+disorders+and+lymphoid+malignancy&doi=10.1084%2Fjem.20151074"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Selective interleukin-1 receptor-associated kinase 4 inhibitors for the treatment of autoimmune disorders and lymphoid malignancy</span></div><div class="casAuthors">Kelly, Priscilla N.; Romero, Donna L.; Yang, Yibin; Shaffer, Arthur L., III; Chaudhary, Divya; Robinson, Shaughnessy; Miao, Wenyan; Rui, Lixin; Westlin, William F.; Kapeller, Rosana; Staudt, Louis M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Experimental Medicine</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">212</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">2189-2201</span>CODEN:
                <span class="NLM_cas:coden">JEMEAV</span>;
        ISSN:<span class="NLM_cas:issn">1540-9538</span>.
    
            (<span class="NLM_cas:orgname">Rockefeller University Press</span>)
        </div><div class="casAbstract">Pathol. activation of the Toll-like receptor signaling adaptor protein MYD88 underlies many autoimmune and inflammatory disease states.  In the activated B cell-like (ABC) subtype of diffuse large B cell lymphoma (DLB CL), the oncogenic MYD88 L265P mutation occurs in 29% of cases, making it the most prevalent activating mutation in this malignancy.  IRAK4 kinase accounts for almost all of the biol. functions of MYD88, highlighting IRAK4 as a therapeutic target for diseases driven by aberrant MYD88 signaling.  Using innovative structure-based drug design methodologies, we report the development of highly selective and bioavailable small mol. IRAK4 inhibitors, ND-2158 and ND-2110.  These small mols. suppressed LPS-induced TNF prodn., alleviated collagen-induced arthritis, and blocked gout formation in mouse models.  IRAK4 inhibition promoted killing of ABC DLB CL lines harboring MYD88 L265P, by down-modulating survival signals, including NF-κB and autocrine IL-6/IL-10 engagement of the JAK-STAT3 pathway.  In ABC DLB CL xenograft models, IRAK4 inhibition suppressed tumor growth as a single agent, and in combination with the Bruton's tyrosine kinase (BTK) inhibitor ibrutinib or the Bcl-2 inhibitor ABT-199.  Our findings support pharmacol. inhibition of IRAK4 as a therapeutic strategy in autoimmune disorders, in a genetically defined population of ABC DLB CL, and possibly other malignancies dependent on aberrant MYD88 signaling.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoJuS2v8AyXXrVg90H21EOLACvtfcHk0lg9g13fnwXLVA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XjtlSgu7s%253D&md5=cf477aff5f649644017cbe5330995a70</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1084%2Fjem.20151074&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1084%252Fjem.20151074%26sid%3Dliteratum%253Aachs%26aulast%3DKelly%26aufirst%3DP.%2BN.%26aulast%3DRomero%26aufirst%3DD.%2BL.%26aulast%3DYang%26aufirst%3DY.%26aulast%3DShaffer%26aufirst%3DA.%2BL.%26aulast%3DChaudhary%26aufirst%3DD.%26aulast%3DRobinson%26aufirst%3DS.%26aulast%3DMiao%26aufirst%3DW.%26aulast%3DRui%26aufirst%3DL.%26aulast%3DWestlin%26aufirst%3DW.%2BF.%26aulast%3DKapeller%26aufirst%3DR.%26aulast%3DStaudt%26aufirst%3DL.%2BM.%26atitle%3DSelective%2520Interleukin-1%2520Receptor-Associated%2520Kinase%25204%2520inhibitors%2520for%2520the%2520treatment%2520of%2520autoimmune%2520disorders%2520and%2520lymphoid%2520malignancy%26jtitle%3DJ.%2520Exp.%2520Med.%26date%3D2015%26volume%3D212%26spage%3D2189%26epage%3D2201%26doi%3D10.1084%2Fjem.20151074" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Scott, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Degorce, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anjum, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Culshaw, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davies, R. M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davies, N. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dillman, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dowling, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drew, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferguson, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Groombridge, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Halsall, C. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hudson, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamont, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindsay, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marden, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mayo, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pease, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perkins, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pink, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robb, G. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McWhirter, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, D.</span></span> <span> </span><span class="NLM_article-title">Discovery and optimisation of pyrrolopyrimidine inhibitors of Interleukin-1 Receptor Associated Kinase 4 (IRAK4) for the treatment of mutant MYD88L265P diffuse large B-cell lymphoma</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">10071</span>– <span class="NLM_lpage">10091</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b01290</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b01290" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01346&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvVOitrjO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=10071-10091&author=J.+S.+Scottauthor=S.+L.+Degorceauthor=R.+Anjumauthor=J.+Culshawauthor=R.+M.+D.+Daviesauthor=N.+L.+Daviesauthor=K.+S.+Dillmanauthor=J.+E.+Dowlingauthor=L.+Drewauthor=A.+D.+Fergusonauthor=S.+D.+Groombridgeauthor=C.+T.+Halsallauthor=J.+A.+Hudsonauthor=S.+Lamontauthor=N.+A.+Lindsayauthor=S.+K.+Mardenauthor=M.+F.+Mayoauthor=J.+E.+Peaseauthor=D.+R.+Perkinsauthor=J.+H.+Pinkauthor=G.+R.+Robbauthor=A.+Rosenauthor=M.+Shenauthor=C.+McWhirterauthor=D.+Wu&title=Discovery+and+optimisation+of+pyrrolopyrimidine+inhibitors+of+Interleukin-1+Receptor+Associated+Kinase+4+%28IRAK4%29+for+the+treatment+of+mutant+MYD88L265P+diffuse+large+B-cell+lymphoma&doi=10.1021%2Facs.jmedchem.7b01290"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and Optimization of Pyrrolopyrimidine Inhibitors of Interleukin-1 Receptor Associated Kinase 4 (IRAK4) for the Treatment of Mutant MYD88L265P Diffuse Large B-Cell Lymphoma</span></div><div class="casAuthors">Scott, James S.; Degorce, Sebastien L.; Anjum, Rana; Culshaw, Janet; Davies, Robert D. M.; Davies, Nichola L.; Dillman, Keith S.; Dowling, James E.; Drew, Lisa; Ferguson, Andrew D.; Groombridge, Sam D.; Halsall, Christopher T.; Hudson, Julian A.; Lamont, Scott; Lindsay, Nicola A.; Marden, Stacey K.; Mayo, Michele F.; Pease, J. Elizabeth; Perkins, David R.; Pink, Jennifer H.; Robb, Graeme R.; Rosen, Alan; Shen, Minhui; McWhirter, Claire; Wu, Dedong</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">10071-10091</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Herein we report the optimization of a series of pyrrolopyrimidine inhibitors of interleukin-1 receptor assocd. kinase 4 (IRAK4) using x-ray crystal structures and structure based design to identify and optimize our scaffold.  Compd. 28 demonstrated a favorable physicochem. and kinase selectivity profile and was identified as a promising in vivo tool with which to explore the role of IRAK4 inhibition in the treatment of mutant MYD88L265P diffuse large B-cell lymphoma (DLBCL).  Compd. 28 was shown to be capable of demonstrating inhibition of NF-κB activation and growth of the ABC subtype of DLBCL cell lines in vitro at high concns. but showed greater effects in combination with a BTK inhibitor at lower concns.  In vivo, the combination of compd. 28 and ibrutinib led to tumor regression in an ABC-DLBCL mouse model.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrBCn7WCzPrrrVg90H21EOLACvtfcHk0lg9g13fnwXLVA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvVOitrjO&md5=9760f425ec33b238a43e1de0ec6d24f1</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b01290&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b01290%26sid%3Dliteratum%253Aachs%26aulast%3DScott%26aufirst%3DJ.%2BS.%26aulast%3DDegorce%26aufirst%3DS.%2BL.%26aulast%3DAnjum%26aufirst%3DR.%26aulast%3DCulshaw%26aufirst%3DJ.%26aulast%3DDavies%26aufirst%3DR.%2BM.%2BD.%26aulast%3DDavies%26aufirst%3DN.%2BL.%26aulast%3DDillman%26aufirst%3DK.%2BS.%26aulast%3DDowling%26aufirst%3DJ.%2BE.%26aulast%3DDrew%26aufirst%3DL.%26aulast%3DFerguson%26aufirst%3DA.%2BD.%26aulast%3DGroombridge%26aufirst%3DS.%2BD.%26aulast%3DHalsall%26aufirst%3DC.%2BT.%26aulast%3DHudson%26aufirst%3DJ.%2BA.%26aulast%3DLamont%26aufirst%3DS.%26aulast%3DLindsay%26aufirst%3DN.%2BA.%26aulast%3DMarden%26aufirst%3DS.%2BK.%26aulast%3DMayo%26aufirst%3DM.%2BF.%26aulast%3DPease%26aufirst%3DJ.%2BE.%26aulast%3DPerkins%26aufirst%3DD.%2BR.%26aulast%3DPink%26aufirst%3DJ.%2BH.%26aulast%3DRobb%26aufirst%3DG.%2BR.%26aulast%3DRosen%26aufirst%3DA.%26aulast%3DShen%26aufirst%3DM.%26aulast%3DMcWhirter%26aufirst%3DC.%26aulast%3DWu%26aufirst%3DD.%26atitle%3DDiscovery%2520and%2520optimisation%2520of%2520pyrrolopyrimidine%2520inhibitors%2520of%2520Interleukin-1%2520Receptor%2520Associated%2520Kinase%25204%2520%2528IRAK4%2529%2520for%2520the%2520treatment%2520of%2520mutant%2520MYD88L265P%2520diffuse%2520large%2520B-cell%2520lymphoma%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D10071%26epage%3D10091%26doi%3D10.1021%2Facs.jmedchem.7b01290" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Genung, N. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guckian, K. M.</span></span> <span> </span><span class="NLM_article-title">Small molecule inhibition of Interleukin-1 Receptor-Associated Kinase 4 (IRAK4)</span>. <i>Prog. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">117</span>– <span class="NLM_lpage">163</span>, <span class="refDoi"> DOI: 10.1016/bs.pmch.2016.11.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01346&amp;key=10.1016%2Fbs.pmch.2016.11.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01346&amp;key=28314411" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01346&amp;key=1%3ACAS%3A280%3ADC%252BC1czot12hsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2017&pages=117-163&author=N.+E.+Genungauthor=K.+M.+Guckian&title=Small+molecule+inhibition+of+Interleukin-1+Receptor-Associated+Kinase+4+%28IRAK4%29&doi=10.1016%2Fbs.pmch.2016.11.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Small Molecule Inhibition of Interleukin-1 Receptor-Associated Kinase 4 (IRAK4)</span></div><div class="casAuthors">Genung N E; Guckian K M</div><div class="citationInfo"><span class="NLM_cas:title">Progress in medicinal chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">117-163</span>
        ISSN:<span class="NLM_cas:issn">0079-6468</span>.
    </div><div class="casAbstract">In recent years, interleukin-1 receptor-associated kinase 4, IRAK4, has become an attractive target for many medicinal chemistry programmes.  Target inhibition is of potential therapeutic value in areas including autoimmune disorders, cancer, inflammatory diseases, and possibly neurodegenerative diseases.  Results from high-throughput screening efforts have led, in conjunction with structure-based drug design, to the identification of highly potent and selective small molecule IRAK4 inhibitors from many diverse chemical series.  In vitro and in vivo studies with entities from distinct structural classes have helped elucidate the downstream pharmacological responses associated with IRAK4 inhibition as a proof of concept in disease models, leading to the recent initiation of human clinical trials.  Within this review, we will highlight the considerable effort by numerous groups dedicated to the development of small molecule IRAK4 inhibitors for the treatment of human disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRZNiMykZj_Wv6xYuD7tu2XfW6udTcc2eb24QmladXFmbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1czot12hsg%253D%253D&md5=30805b2fb55ac3e6be120a7557c0f24c</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1016%2Fbs.pmch.2016.11.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fbs.pmch.2016.11.004%26sid%3Dliteratum%253Aachs%26aulast%3DGenung%26aufirst%3DN.%2BE.%26aulast%3DGuckian%26aufirst%3DK.%2BM.%26atitle%3DSmall%2520molecule%2520inhibition%2520of%2520Interleukin-1%2520Receptor-Associated%2520Kinase%25204%2520%2528IRAK4%2529%26jtitle%3DProg.%2520Med.%2520Chem.%26date%3D2017%26volume%3D56%26spage%3D117%26epage%3D163%26doi%3D10.1016%2Fbs.pmch.2016.11.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McElroy, W. T.</span></span> <span> </span><span class="NLM_article-title">Interleukin-1 Receptor-Associated Kinase 4 (IRAK4) inhibitors: an updated patent review (2016-2018)</span>. <i>Expert Opin. Ther. Pat.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">243</span>– <span class="NLM_lpage">259</span>, <span class="refDoi"> DOI: 10.1080/13543776.2019.1597850</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01346&amp;key=10.1080%2F13543776.2019.1597850" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01346&amp;key=30916602" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01346&amp;key=1%3ACAS%3A528%3ADC%252BC1MXmtFKntrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2019&pages=243-259&author=W.+T.+McElroy&title=Interleukin-1+Receptor-Associated+Kinase+4+%28IRAK4%29+inhibitors%3A+an+updated+patent+review+%282016-2018%29&doi=10.1080%2F13543776.2019.1597850"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitors: an updated patent review (2016-2018)</span></div><div class="casAuthors">McElroy, William T.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Patents</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">243-259</span>CODEN:
                <span class="NLM_cas:coden">EOTPEG</span>;
        ISSN:<span class="NLM_cas:issn">1354-3776</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">A review.  : Interleukin-1 receptor-assocd. kinase 4 (IRAK4) is the most upstream kinase in Toll/Interleukin-1 receptor (TIR) signaling.  Human and rodent genetics support the role of IRAK4 in immune function and the involvement of IRAK4-dependent signaling in certain cancers is hypothesized.  The accumulating evidence has motivated the discovery of IRAK4 inhibitors that could be used therapeutically.: This review summarizes patents published in 2016-2018 claiming IRAK4 inhibitors.  Representative analogs from each patent are presented with a focus on compds. that have been profiled in cellular and in vivo assays.: The last three years have seen an increased no. of IRAK4 inhibitors with which to assess the therapeutic potential of the target.  At least 5 companies are believed to have advanced to the clinic.  Pfizer is in phase II for rheumatoid arthritis (RA).  The outcomes of these studies should inform on the therapeutic potential in autoimmune disease and cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqsRn4myhM3hrVg90H21EOLACvtfcHk0ljWWwTIsKTV7Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXmtFKntrs%253D&md5=0da99e75950dba1d5f0c1ecc1dea0b47</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1080%2F13543776.2019.1597850&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F13543776.2019.1597850%26sid%3Dliteratum%253Aachs%26aulast%3DMcElroy%26aufirst%3DW.%2BT.%26atitle%3DInterleukin-1%2520Receptor-Associated%2520Kinase%25204%2520%2528IRAK4%2529%2520inhibitors%253A%2520an%2520updated%2520patent%2520review%2520%25282016-2018%2529%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Pat.%26date%3D2019%26volume%3D29%26spage%3D243%26epage%3D259%26doi%3D10.1080%2F13543776.2019.1597850" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ambler, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boscoe, B. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bree, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brodfuehrer, J. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chung, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Curran, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Day, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dehnhardt, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dower, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drozda, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frisbie, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gavrin, L. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldberg, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hegen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hepworth, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hope, H. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kamtekar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kilty, I. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, L. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lovering, F. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lowe, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathias, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morgan, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murphy, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Papaioannou, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patny, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pierce, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rao, V. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saiah, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Samardjiev, I. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Samas, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, M. W. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shin, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soutter, H. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strohbach, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Symanowicz, P. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomason, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trzupek, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vargas, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vincent, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zapf, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wright, S. W.</span></span> <span> </span><span class="NLM_article-title">Discovery of clinical candidate 1-{[(2S,3S,4S)-3-ethyl-4-fluoro-5-oxopyrrolidin-2-yl]methoxy}-7-methoxyisoquinoline-6-carboxamide (PF-06650833), a potent, selective inhibitor of Interleukin-1 Receptor Associated Kinase 4 (IRAK4), by fragment-based drug design</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">5521</span>– <span class="NLM_lpage">5542</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b00231</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b00231" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01346&amp;key=1%3ACAS%3A528%3ADC%252BC2sXnslGqu7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=5521-5542&author=K.+L.+Leeauthor=C.+M.+Amblerauthor=D.+R.+Andersonauthor=B.+P.+Boscoeauthor=A.+G.+Breeauthor=J.+I.+Brodfuehrerauthor=J.+S.+Changauthor=C.+Choiauthor=S.+Chungauthor=K.+J.+Curranauthor=J.+E.+Dayauthor=C.+M.+Dehnhardtauthor=K.+Dowerauthor=S.+E.+Drozdaauthor=R.+K.+Frisbieauthor=L.+K.+Gavrinauthor=J.+A.+Goldbergauthor=S.+Hanauthor=M.+Hegenauthor=D.+Hepworthauthor=H.+R.+Hopeauthor=S.+Kamtekarauthor=I.+C.+Kiltyauthor=A.+Leeauthor=L.+L.+Linauthor=F.+E.+Loveringauthor=M.+D.+Loweauthor=J.+P.+Mathiasauthor=H.+M.+Morganauthor=E.+A.+Murphyauthor=N.+Papaioannouauthor=A.+Patnyauthor=B.+S.+Pierceauthor=V.+R.+Raoauthor=E.+Saiahauthor=I.+J.+Samardjievauthor=B.+M.+Samasauthor=M.+W.+H.+Shenauthor=J.+H.+Shinauthor=H.+H.+Soutterauthor=J.+W.+Strohbachauthor=P.+T.+Symanowiczauthor=J.+R.+Thomasonauthor=J.+D.+Trzupekauthor=R.+Vargasauthor=F.+Vincentauthor=J.+Yanauthor=C.+W.+Zapfauthor=S.+W.+Wright&title=Discovery+of+clinical+candidate+1-%7B%5B%282S%2C3S%2C4S%29-3-ethyl-4-fluoro-5-oxopyrrolidin-2-yl%5Dmethoxy%7D-7-methoxyisoquinoline-6-carboxamide+%28PF-06650833%29%2C+a+potent%2C+selective+inhibitor+of+Interleukin-1+Receptor+Associated+Kinase+4+%28IRAK4%29%2C+by+fragment-based+drug+design&doi=10.1021%2Facs.jmedchem.7b00231"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Clinical Candidate 1-{[(2S,3S,4S)-3-Ethyl-4-fluoro-5-oxopyrrolidin-2-yl]methoxy}-7-methoxyisoquinoline-6-carboxamide (PF-06650833), a Potent, Selective Inhibitor of Interleukin-1 Receptor Associated Kinase 4 (IRAK4), by Fragment-Based Drug Design</span></div><div class="casAuthors">Lee, Katherine L.; Ambler, Catherine M.; Anderson, David R.; Boscoe, Brian P.; Bree, Andrea G.; Brodfuehrer, Joanne I.; Chang, Jeanne S.; Choi, Chulho; Chung, Seungwon; Curran, Kevin J.; Day, Jacqueline E.; Dehnhardt, Christoph M.; Dower, Ken; Drozda, Susan E.; Frisbie, Richard K.; Gavrin, Lori K.; Goldberg, Joel A.; Han, Seungil; Hegen, Martin; Hepworth, David; Hope, Heidi R.; Kamtekar, Satwik; Kilty, Iain C.; Lee, Arthur; Lin, Lih-Ling; Lovering, Frank E.; Lowe, Michael D.; Mathias, John P.; Morgan, Heidi M.; Murphy, Elizabeth A.; Papaioannou, Nikolaos; Patny, Akshay; Pierce, Betsy S.; Rao, Vikram R.; Saiah, Eddine; Samardjiev, Ivan J.; Samas, Brian M.; Shen, Marina W. H.; Shin, Julia H.; Soutter, Holly H.; Strohbach, Joseph W.; Symanowicz, Peter T.; Thomason, Jennifer R.; Trzupek, John D.; Vargas, Richard; Vincent, Fabien; Yan, Jiangli; Zapf, Christoph W.; Wright, Stephen W.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">5521-5542</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Through fragment-based drug design focused on engaging the active site of IRAK4 and leveraging three-dimensional topol. in a ligand-efficient manner, a micromolar hit identified from a screen of a Pfizer fragment library was optimized to afford IRAK4 inhibitors with nanomolar potency in cellular assays.  The medicinal chem. effort featured the judicious placement of lipophilicity, informed by cocrystal structures with IRAK4 and optimization of ADME properties to deliver clin. candidate I.  This compd. benefitted from a 5-unit increase in lipophilic efficiency from the fragment hit, excellent kinase selectivity, and pharmacokinetic properties suitable for oral administration.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpYrCep64bhMbVg90H21EOLACvtfcHk0ljuQ6irZm7kQA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXnslGqu7c%253D&md5=9771ad2d33089f6ef3dba3556536ff1a</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b00231&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b00231%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DK.%2BL.%26aulast%3DAmbler%26aufirst%3DC.%2BM.%26aulast%3DAnderson%26aufirst%3DD.%2BR.%26aulast%3DBoscoe%26aufirst%3DB.%2BP.%26aulast%3DBree%26aufirst%3DA.%2BG.%26aulast%3DBrodfuehrer%26aufirst%3DJ.%2BI.%26aulast%3DChang%26aufirst%3DJ.%2BS.%26aulast%3DChoi%26aufirst%3DC.%26aulast%3DChung%26aufirst%3DS.%26aulast%3DCurran%26aufirst%3DK.%2BJ.%26aulast%3DDay%26aufirst%3DJ.%2BE.%26aulast%3DDehnhardt%26aufirst%3DC.%2BM.%26aulast%3DDower%26aufirst%3DK.%26aulast%3DDrozda%26aufirst%3DS.%2BE.%26aulast%3DFrisbie%26aufirst%3DR.%2BK.%26aulast%3DGavrin%26aufirst%3DL.%2BK.%26aulast%3DGoldberg%26aufirst%3DJ.%2BA.%26aulast%3DHan%26aufirst%3DS.%26aulast%3DHegen%26aufirst%3DM.%26aulast%3DHepworth%26aufirst%3DD.%26aulast%3DHope%26aufirst%3DH.%2BR.%26aulast%3DKamtekar%26aufirst%3DS.%26aulast%3DKilty%26aufirst%3DI.%2BC.%26aulast%3DLee%26aufirst%3DA.%26aulast%3DLin%26aufirst%3DL.%2BL.%26aulast%3DLovering%26aufirst%3DF.%2BE.%26aulast%3DLowe%26aufirst%3DM.%2BD.%26aulast%3DMathias%26aufirst%3DJ.%2BP.%26aulast%3DMorgan%26aufirst%3DH.%2BM.%26aulast%3DMurphy%26aufirst%3DE.%2BA.%26aulast%3DPapaioannou%26aufirst%3DN.%26aulast%3DPatny%26aufirst%3DA.%26aulast%3DPierce%26aufirst%3DB.%2BS.%26aulast%3DRao%26aufirst%3DV.%2BR.%26aulast%3DSaiah%26aufirst%3DE.%26aulast%3DSamardjiev%26aufirst%3DI.%2BJ.%26aulast%3DSamas%26aufirst%3DB.%2BM.%26aulast%3DShen%26aufirst%3DM.%2BW.%2BH.%26aulast%3DShin%26aufirst%3DJ.%2BH.%26aulast%3DSoutter%26aufirst%3DH.%2BH.%26aulast%3DStrohbach%26aufirst%3DJ.%2BW.%26aulast%3DSymanowicz%26aufirst%3DP.%2BT.%26aulast%3DThomason%26aufirst%3DJ.%2BR.%26aulast%3DTrzupek%26aufirst%3DJ.%2BD.%26aulast%3DVargas%26aufirst%3DR.%26aulast%3DVincent%26aufirst%3DF.%26aulast%3DYan%26aufirst%3DJ.%26aulast%3DZapf%26aufirst%3DC.%2BW.%26aulast%3DWright%26aufirst%3DS.%2BW.%26atitle%3DDiscovery%2520of%2520clinical%2520candidate%25201-%257B%255B%25282S%252C3S%252C4S%2529-3-ethyl-4-fluoro-5-oxopyrrolidin-2-yl%255Dmethoxy%257D-7-methoxyisoquinoline-6-carboxamide%2520%2528PF-06650833%2529%252C%2520a%2520potent%252C%2520selective%2520inhibitor%2520of%2520Interleukin-1%2520Receptor%2520Associated%2520Kinase%25204%2520%2528IRAK4%2529%252C%2520by%2520fragment-based%2520drug%2520design%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D5521%26epage%3D5542%26doi%3D10.1021%2Facs.jmedchem.7b00231" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><a href="https://clinicaltrials.gov/ct2/show/NCT02996500?term=PF-06650833" class="extLink">https://clinicaltrials.gov/ct2/show/NCT02996500?term=PF-06650833</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT02996500%3Fterm%3DPF-06650833."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lindsay-Scott, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clarke, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richardson, J.</span></span> <span> </span><span class="NLM_article-title">Two-step cyanomethylation protocol: convenient access to functionalized aryl- and heteroarylacetonitriles</span>. <i>Org. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">476</span>– <span class="NLM_lpage">479</span>, <span class="refDoi"> DOI: 10.1021/ol503479g</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ol503479g" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01346&amp;key=1%3ACAS%3A528%3ADC%252BC2MXosVOqtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2015&pages=476-479&author=P.+J.+Lindsay-Scottauthor=A.+Clarkeauthor=J.+Richardson&title=Two-step+cyanomethylation+protocol%3A+convenient+access+to+functionalized+aryl-+and+heteroarylacetonitriles&doi=10.1021%2Fol503479g"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Two-Step Cyanomethylation Protocol: Convenient Access to Functionalized Aryl- and Heteroarylacetonitriles</span></div><div class="casAuthors">Lindsay-Scott, Peter J.; Clarke, Aimee; Richardson, Jeffery</div><div class="citationInfo"><span class="NLM_cas:title">Organic Letters</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">476-479</span>CODEN:
                <span class="NLM_cas:coden">ORLEF7</span>;
        ISSN:<span class="NLM_cas:issn">1523-7052</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A two-step protocol has been developed for the introduction of cyanomethylene groups to metalated aroms. through the intermediacy of substituted isoxazoles.  A palladium-mediated cross-coupling reaction was used to introduce the isoxazole unit, followed by release of the cyanomethylene function under thermal or microwave-assisted conditions.  The intermediate isoxazoles were shown to be amenable to further functionalization prior to deprotection of the sensitive cyanomethylene motif, allowing access to a wide range of aryl- and heteroaryl-substituted acetonitrile building blocks.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrLVGuIHMHQvrVg90H21EOLACvtfcHk0ljuQ6irZm7kQA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXosVOqtA%253D%253D&md5=e2dedd972367ccaa673fc2423e786830</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1021%2Fol503479g&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fol503479g%26sid%3Dliteratum%253Aachs%26aulast%3DLindsay-Scott%26aufirst%3DP.%2BJ.%26aulast%3DClarke%26aufirst%3DA.%26aulast%3DRichardson%26aufirst%3DJ.%26atitle%3DTwo-step%2520cyanomethylation%2520protocol%253A%2520convenient%2520access%2520to%2520functionalized%2520aryl-%2520and%2520heteroarylacetonitriles%26jtitle%3DOrg.%2520Lett.%26date%3D2015%26volume%3D17%26spage%3D476%26epage%3D479%26doi%3D10.1021%2Fol503479g" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Romero, D. L.</span>; <span class="NLM_string-name">Robinson, S.</span>; <span class="NLM_string-name">Greenwood, J. R.</span>; <span class="NLM_string-name">Shelley, M.</span>; <span class="NLM_string-name">Masse, C.
E.</span>; <span class="NLM_string-name">Harriman, G. C.</span></span> <span> </span><span class="NLM_article-title">Preparation of Quinazoline and Quinoline Derivatives as Interleukin-1 Receptor-Associated Kinases (IRAK) inhibitors</span>. U.S. Patent <span class="NLM_patent">WO2015164374A1</span>, <span class="NLM_year">2015</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&author=D.+L.+Romero&author=S.+Robinson&author=J.+R.+Greenwood&author=M.+Shelley&author=C.%0AE.+Masse&author=G.+C.+Harriman&title=Preparation+of+Quinazoline+and+Quinoline+Derivatives+as+Interleukin-1+Receptor-Associated+Kinases+%28IRAK%29+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DRomero%26aufirst%3DD.%2BL.%26atitle%3DPreparation%2520of%2520Quinazoline%2520and%2520Quinoline%2520Derivatives%2520as%2520Interleukin-1%2520Receptor-Associated%2520Kinases%2520%2528IRAK%2529%2520inhibitors%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Smith, G. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Altman, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andresen, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baker, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brubaker, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Childers, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donofrio, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferguson, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischer, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischmann, T. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gibeau, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hicks, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kattar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kleinschek, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leccese, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lesburg, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lim, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maclean, J. K. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mansoor, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moy, L. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mulrooney, E. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Necheva, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Presland, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rakhilina, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Torres, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang-Hoover, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Northrup, A.</span></span> <span> </span><span class="NLM_article-title">Identification of quinazoline based inhibitors of IRAK4 for the treatment of inflammation</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">2721</span>– <span class="NLM_lpage">2726</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2017.04.050</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01346&amp;key=10.1016%2Fj.bmcl.2017.04.050" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01346&amp;key=28501511" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01346&amp;key=1%3ACAS%3A528%3ADC%252BC2sXnslKhtrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2017&pages=2721-2726&author=G.+F.+Smithauthor=M.+D.+Altmanauthor=B.+Andresenauthor=J.+Bakerauthor=J.+D.+Brubakerauthor=H.+Chenauthor=Y.+Chenauthor=M.+Childersauthor=A.+Donofrioauthor=H.+Fergusonauthor=C.+Fischerauthor=T.+O.+Fischmannauthor=C.+Gibeauauthor=A.+Hicksauthor=S.+Jinauthor=S.+Kattarauthor=M.+A.+Kleinschekauthor=E.+Lecceseauthor=C.+Lesburgauthor=C.+Liauthor=J.+Limauthor=D.+Liuauthor=J.+K.+F.+Macleanauthor=F.+Mansoorauthor=L.+Y.+Moyauthor=E.+F.+Mulrooneyauthor=A.+S.+Nechevaauthor=J.+Preslandauthor=L.+Rakhilinaauthor=R.+Yangauthor=L.+Torresauthor=J.+Zhang-Hooverauthor=A.+Northrup&title=Identification+of+quinazoline+based+inhibitors+of+IRAK4+for+the+treatment+of+inflammation&doi=10.1016%2Fj.bmcl.2017.04.050"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of quinazoline based inhibitors of IRAK4 for the treatment of inflammation</span></div><div class="casAuthors">Smith, Graham F.; Altman, Michael D.; Andresen, Brian; Baker, James; Brubaker, Jason D.; Chen, Hongmin; Chen, Yiping; Childers, Matthew; Donofrio, Anthony; Ferguson, Heidi; Fischer, Christian; Fischmann, Thierry O.; Gibeau, Craig; Hicks, Alexander; Jin, Sue; Kattar, Sam; Kleinschek, Melanie A.; Leccese, Erica; Lesburg, Charles; Li, Chaomin; Lim, Jongwon; Liu, Duan; MacLean, John K. F.; Mansoor, Faruk; Moy, Lilly Y.; Mulrooney, Erin F.; Necheva, Antoaneta S.; Presland, Jeremy; Rakhilina, Larissa; Yang, Ruojing; Torres, Luis; Zhang-Hoover, Jie; Northrup, Alan</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2721-2726</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Interleukin-1 receptor assocd. kinase 4 (IRAK4) has been implicated in IL-1R and TLR based signaling.  Therefore selective inhibition of the kinase activity of this protein represents an attractive target for the treatment of inflammatory diseases.  Medicinal chem. optimization of high throughput screening (HTS) hits with the help of structure based drug design led to the identification of orally-bioavailable quinazoline based IRAK4 inhibitors with excellent pharmacokinetic profile and kinase selectivity.  These highly selective IRAK4 compds. show activity in vivo via oral dosing in a TLR7 driven model of inflammation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpQgzgP8TjUWbVg90H21EOLACvtfcHk0liLelZlTxmdPQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXnslKhtrk%253D&md5=9a60520e66940d9d96859c6b77cb97a5</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2017.04.050&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2017.04.050%26sid%3Dliteratum%253Aachs%26aulast%3DSmith%26aufirst%3DG.%2BF.%26aulast%3DAltman%26aufirst%3DM.%2BD.%26aulast%3DAndresen%26aufirst%3DB.%26aulast%3DBaker%26aufirst%3DJ.%26aulast%3DBrubaker%26aufirst%3DJ.%2BD.%26aulast%3DChen%26aufirst%3DH.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DChilders%26aufirst%3DM.%26aulast%3DDonofrio%26aufirst%3DA.%26aulast%3DFerguson%26aufirst%3DH.%26aulast%3DFischer%26aufirst%3DC.%26aulast%3DFischmann%26aufirst%3DT.%2BO.%26aulast%3DGibeau%26aufirst%3DC.%26aulast%3DHicks%26aufirst%3DA.%26aulast%3DJin%26aufirst%3DS.%26aulast%3DKattar%26aufirst%3DS.%26aulast%3DKleinschek%26aufirst%3DM.%2BA.%26aulast%3DLeccese%26aufirst%3DE.%26aulast%3DLesburg%26aufirst%3DC.%26aulast%3DLi%26aufirst%3DC.%26aulast%3DLim%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DD.%26aulast%3DMaclean%26aufirst%3DJ.%2BK.%2BF.%26aulast%3DMansoor%26aufirst%3DF.%26aulast%3DMoy%26aufirst%3DL.%2BY.%26aulast%3DMulrooney%26aufirst%3DE.%2BF.%26aulast%3DNecheva%26aufirst%3DA.%2BS.%26aulast%3DPresland%26aufirst%3DJ.%26aulast%3DRakhilina%26aufirst%3DL.%26aulast%3DYang%26aufirst%3DR.%26aulast%3DTorres%26aufirst%3DL.%26aulast%3DZhang-Hoover%26aufirst%3DJ.%26aulast%3DNorthrup%26aufirst%3DA.%26atitle%3DIdentification%2520of%2520quinazoline%2520based%2520inhibitors%2520of%2520IRAK4%2520for%2520the%2520treatment%2520of%2520inflammation%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2017%26volume%3D27%26spage%3D2721%26epage%3D2726%26doi%3D10.1016%2Fj.bmcl.2017.04.050" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fensome, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ambler, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arnold, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banker, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chrencik, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clark, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dowty, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Efremov, I. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flick, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerstenberger, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gopalsamy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hayward, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hegen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hollingshead, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jussif, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knafels, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Limburg, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pierce, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saiah, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Symanowicz, P. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Telliez, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trujillo, J. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vajdos, F. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vincent, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wan, Z. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xing, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span> <span> </span><span class="NLM_article-title">Dual inhibition of TYK2 and JAK1 for the treatment of autoimmune diseases: discovery of ((S)-2,2-difluorocyclopropyl)((1R,5S)-3-(2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octan-8-yl)methanone (PF-06700841)</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">8597</span>– <span class="NLM_lpage">8612</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00917</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00917" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01346&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsFWgtLfI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=8597-8612&author=A.+Fensomeauthor=C.+M.+Amblerauthor=E.+Arnoldauthor=M.+E.+Bankerauthor=M.+F.+Brownauthor=J.+Chrencikauthor=J.+D.+Clarkauthor=M.+E.+Dowtyauthor=I.+V.+Efremovauthor=A.+Flickauthor=B.+S.+Gerstenbergerauthor=A.+Gopalsamyauthor=M.+M.+Haywardauthor=M.+Hegenauthor=B.+D.+Hollingsheadauthor=J.+Jussifauthor=J.+D.+Knafelsauthor=D.+C.+Limburgauthor=D.+Linauthor=T.+H.+Linauthor=B.+S.+Pierceauthor=E.+Saiahauthor=R.+Sharmaauthor=P.+T.+Symanowiczauthor=J.+B.+Telliezauthor=J.+I.+Trujilloauthor=F.+F.+Vajdosauthor=F.+Vincentauthor=Z.+K.+Wanauthor=L.+Xingauthor=X.+Yangauthor=X.+Yangauthor=L.+Zhang&title=Dual+inhibition+of+TYK2+and+JAK1+for+the+treatment+of+autoimmune+diseases%3A+discovery+of+%28%28S%29-2%2C2-difluorocyclopropyl%29%28%281R%2C5S%29-3-%282-%28%281-methyl-1H-pyrazol-4-yl%29amino%29pyrimidin-4-yl%29-3%2C8-diazabicyclo%5B3.2.1%5Doctan-8-yl%29methanone+%28PF-06700841%29&doi=10.1021%2Facs.jmedchem.8b00917"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Dual Inhibition of TYK2 and JAK1 for the Treatment of Autoimmune Diseases: Discovery of ((S)-2,2-Difluorocyclopropyl)((1R,5S)-3-(2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octan-8-yl)methanone (PF-06700841)</span></div><div class="casAuthors">Fensome, Andrew; Ambler, Catherine M.; Arnold, Eric; Banker, Mary Ellen; Brown, Matthew F.; Chrencik, Jill; Clark, James D.; Dowty, Martin E.; Efremov, Ivan V.; Flick, Andrew; Gerstenberger, Brian S.; Gopalsamy, Ariamala; Hayward, Matthew M.; Hegen, Martin; Hollingshead, Brett D.; Jussif, Jason; Knafels, John D.; Limburg, David C.; Lin, David; Lin, Tsung H.; Pierce, Betsy S.; Saiah, Eddine; Sharma, Raman; Symanowicz, Peter T.; Telliez, Jean-Baptiste; Trujillo, John I.; Vajdos, Felix F.; Vincent, Fabien; Wan, Zhao-Kui; Xing, Li; Yang, Xiaojing; Yang, Xin; Zhang, Liying</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">8597-8612</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Cytokine signaling is an important characteristic of autoimmune diseases.  Many pro-inflammatory cytokines signal through the Janus kinase (JAK)/Signal transducer and activator of transcription (STAT) pathway.  JAK1 is important for the γ-common chain cytokines, interleukin (IL)-6 and type-I interferon (IFN) family, while TYK2 in addn. to type-I IFN signaling also plays a role in IL-23 and IL-12 signaling.  Intervention with monoclonal antibodies (mAbs) or JAK1 inhibitors has demonstrated efficacy in Phase III psoriasis, psoriatic arthritis, inflammatory bowel disease and rheumatoid arthritis studies, leading to multiple drug approvals.  It is hypothesized that a dual JAK1/TYK2 inhibitor will provide addnl. efficacy, while managing risk by optimizing selectivity against JAK2 driven hematopoietic changes.  Our program began with a conformationally constrained piperazinyl-pyrimidine Type 1 ATP site inhibitor, subsequent work led to the discovery of PF-06700841 (compd. 23), which is in Phase II clin. development (NCT02969018, NCT02958865, NCT03395184, and NCT02974868).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqWNhVkNWDMq7Vg90H21EOLACvtfcHk0liLelZlTxmdPQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsFWgtLfI&md5=c321512f524560cba445d070b9639e55</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00917&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00917%26sid%3Dliteratum%253Aachs%26aulast%3DFensome%26aufirst%3DA.%26aulast%3DAmbler%26aufirst%3DC.%2BM.%26aulast%3DArnold%26aufirst%3DE.%26aulast%3DBanker%26aufirst%3DM.%2BE.%26aulast%3DBrown%26aufirst%3DM.%2BF.%26aulast%3DChrencik%26aufirst%3DJ.%26aulast%3DClark%26aufirst%3DJ.%2BD.%26aulast%3DDowty%26aufirst%3DM.%2BE.%26aulast%3DEfremov%26aufirst%3DI.%2BV.%26aulast%3DFlick%26aufirst%3DA.%26aulast%3DGerstenberger%26aufirst%3DB.%2BS.%26aulast%3DGopalsamy%26aufirst%3DA.%26aulast%3DHayward%26aufirst%3DM.%2BM.%26aulast%3DHegen%26aufirst%3DM.%26aulast%3DHollingshead%26aufirst%3DB.%2BD.%26aulast%3DJussif%26aufirst%3DJ.%26aulast%3DKnafels%26aufirst%3DJ.%2BD.%26aulast%3DLimburg%26aufirst%3DD.%2BC.%26aulast%3DLin%26aufirst%3DD.%26aulast%3DLin%26aufirst%3DT.%2BH.%26aulast%3DPierce%26aufirst%3DB.%2BS.%26aulast%3DSaiah%26aufirst%3DE.%26aulast%3DSharma%26aufirst%3DR.%26aulast%3DSymanowicz%26aufirst%3DP.%2BT.%26aulast%3DTelliez%26aufirst%3DJ.%2BB.%26aulast%3DTrujillo%26aufirst%3DJ.%2BI.%26aulast%3DVajdos%26aufirst%3DF.%2BF.%26aulast%3DVincent%26aufirst%3DF.%26aulast%3DWan%26aufirst%3DZ.%2BK.%26aulast%3DXing%26aufirst%3DL.%26aulast%3DYang%26aufirst%3DX.%26aulast%3DYang%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DL.%26atitle%3DDual%2520inhibition%2520of%2520TYK2%2520and%2520JAK1%2520for%2520the%2520treatment%2520of%2520autoimmune%2520diseases%253A%2520discovery%2520of%2520%2528%2528S%2529-2%252C2-difluorocyclopropyl%2529%2528%25281R%252C5S%2529-3-%25282-%2528%25281-methyl-1H-pyrazol-4-yl%2529amino%2529pyrimidin-4-yl%2529-3%252C8-diazabicyclo%255B3.2.1%255Doctan-8-yl%2529methanone%2520%2528PF-06700841%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D8597%26epage%3D8612%26doi%3D10.1021%2Facs.jmedchem.8b00917" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kettle, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grimster, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawatkar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Throner, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woessner, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bebernitz, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bell, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruston, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winter-Holt, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lyne, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vasbinder, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chuaqui, C.</span></span> <span> </span><span class="NLM_article-title">Abstract 979: Discovery of the JAK1 selective kinase inhibitor AZD4205</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>77</i></span>,  <span class="NLM_fpage">979</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=77&publication_year=2017&pages=979&author=J.+G.+Kettleauthor=Q.+Suauthor=N.+Grimsterauthor=S.+Kawatkarauthor=S.+Thronerauthor=R.+Woessnerauthor=H.+Chenauthor=G.+Bebernitzauthor=K.+Bellauthor=E.+Andersonauthor=L.+Rustonauthor=J.+Winter-Holtauthor=P.+Lyneauthor=M.+Vasbinderauthor=C.+Chuaqui&title=Abstract+979%3A+Discovery+of+the+JAK1+selective+kinase+inhibitor+AZD4205"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKettle%26aufirst%3DJ.%2BG.%26aulast%3DSu%26aufirst%3DQ.%26aulast%3DGrimster%26aufirst%3DN.%26aulast%3DKawatkar%26aufirst%3DS.%26aulast%3DThroner%26aufirst%3DS.%26aulast%3DWoessner%26aufirst%3DR.%26aulast%3DChen%26aufirst%3DH.%26aulast%3DBebernitz%26aufirst%3DG.%26aulast%3DBell%26aufirst%3DK.%26aulast%3DAnderson%26aufirst%3DE.%26aulast%3DRuston%26aufirst%3DL.%26aulast%3DWinter-Holt%26aufirst%3DJ.%26aulast%3DLyne%26aufirst%3DP.%26aulast%3DVasbinder%26aufirst%3DM.%26aulast%3DChuaqui%26aufirst%3DC.%26atitle%3DAbstract%2520979%253A%2520Discovery%2520of%2520the%2520JAK1%2520selective%2520kinase%2520inhibitor%2520AZD4205%26jtitle%3DCancer%2520Res.%26date%3D2017%26volume%3D77%26spage%3D979" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Soars, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grime, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sproston, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Webborn, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riley, R. J.</span></span> <span> </span><span class="NLM_article-title">Use of hepatocytes to assess the contribution of hepatic uptake to clearance in vivo</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>35</i></span>,  <span class="NLM_fpage">859</span>– <span class="NLM_lpage">865</span>, <span class="refDoi"> DOI: 10.1124/dmd.106.014464</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01346&amp;key=10.1124%2Fdmd.106.014464" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01346&amp;key=17344337" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01346&amp;key=1%3ACAS%3A528%3ADC%252BD2sXmt1ait7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2007&pages=859-865&author=M.+G.+Soarsauthor=K.+Grimeauthor=J.+L.+Sprostonauthor=P.+J.+Webbornauthor=R.+J.+Riley&title=Use+of+hepatocytes+to+assess+the+contribution+of+hepatic+uptake+to+clearance+in+vivo&doi=10.1124%2Fdmd.106.014464"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Use of hepatocytes to assess the contribution of hepatic uptake to clearance in vivo</span></div><div class="casAuthors">Soars, Matthew G.; Grime, Ken; Sproston, Joanne L.; Webborn, Peter J. H.; Riley, Robert J.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism and Disposition</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">859-865</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">0090-9556</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">The wealth of information that has emerged in recent years detailing the substrate specificity of hepatic transporters necessitates an investigation into their potential role in drug elimination.  Therefore, an assay in which the loss of parent compd. from the incubation medium into hepatocytes ("media loss" assay) was developed to assess the impact of hepatic uptake on unbound drug intrinsic clearance in vivo (CLint ub in vivo).  Studies using conventional hepatocyte incubations for a subset of 36 AstraZeneca new chem. entities (NCEs) resulted in a poor projection of CLint ub in vivo (r2 = 0.25, p = 0.002, av. fold error = 57).  This significant underestimation of CLint ub in vivo suggested that metab. was not the dominant clearance mechanism for the majority of compds. examd.  However, CLint ub in vivo was described well for this dataset using an initial compd. "disappearance" CLint obtained from media loss assays (r2 = 0.72, p = 6.3 × 10-11, av. fold error = 3).  Subsequent studies, using this method for the same 36 NCEs, suggested that the active uptake into human hepatocytes was generally slower (3-fold on av.) than that obsd. with rat hepatocytes.  The accurate prediction of human CLint ub in vivo (within 4-fold) for the marketed drug transporter substrates montelukast, bosentan, atorvastatin, and pravastatin confirmed further the utility of this assay.  This work has described a simple method, amenable for use within a drug discovery setting, for predicting the in vivo clearance of drugs with significant hepatic uptake.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo_EFTWIivbs7Vg90H21EOLACvtfcHk0lhT-8eO0UXImQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXmt1ait7Y%253D&md5=3298ecc4f3a3e3109162c5ebbf89fda4</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1124%2Fdmd.106.014464&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.106.014464%26sid%3Dliteratum%253Aachs%26aulast%3DSoars%26aufirst%3DM.%2BG.%26aulast%3DGrime%26aufirst%3DK.%26aulast%3DSproston%26aufirst%3DJ.%2BL.%26aulast%3DWebborn%26aufirst%3DP.%2BJ.%26aulast%3DRiley%26aufirst%3DR.%2BJ.%26atitle%3DUse%2520of%2520hepatocytes%2520to%2520assess%2520the%2520contribution%2520of%2520hepatic%2520uptake%2520to%2520clearance%2520in%2520vivo%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2007%26volume%3D35%26spage%3D859%26epage%3D865%26doi%3D10.1124%2Fdmd.106.014464" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Camenisch, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alsenz, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van de Waterbeemd, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Folkers, G.</span></span> <span> </span><span class="NLM_article-title">Estimation of permeability by passive diffusion through Caco-2 cell monolayers using the drugs’ lipophilicity and molecular weight</span>. <i>Eur. J. Pharm. Sci.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">313</span>– <span class="NLM_lpage">319</span>, <span class="refDoi"> DOI: 10.1016/S0928-0987(97)10019-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01346&amp;key=10.1016%2FS0928-0987%2897%2910019-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01346&amp;key=1%3ACAS%3A528%3ADyaK1cXmtl2nsr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=1998&pages=313-319&author=G.+Camenischauthor=J.+Alsenzauthor=H.+van+de+Waterbeemdauthor=G.+Folkers&title=Estimation+of+permeability+by+passive+diffusion+through+Caco-2+cell+monolayers+using+the+drugs%E2%80%99+lipophilicity+and+molecular+weight&doi=10.1016%2FS0928-0987%2897%2910019-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Estimation of permeability by passive diffusion through Caco-2 cell monolayers using the drugs' lipophilicity and molecular weight</span></div><div class="casAuthors">Camenisch, Gian; Alsenz, Jochem; van de Waterbeemd, Han; Folkers, Gerd</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmaceutical Sciences</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">313-319</span>CODEN:
                <span class="NLM_cas:coden">EPSCED</span>;
        ISSN:<span class="NLM_cas:issn">0928-0987</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ireland Ltd.</span>)
        </div><div class="casAbstract">A recently developed, new theor. absorption model for passive diffusion through biol. membranes describing the dependency of membrane permeability on lipophilicity and mol. size, predicts different sigmoid-hyperbolic permeability-lipophilicity relationships for different mol. wt. ranges.  This model has been tested with exptl. in vitro cultured epithelial cell (Caco-2) permeability data for structurally diverse drugs differing in lipophilicity, ionization state and mol. size.  These data were pooled with literature values.  Using this simple physicochem. approach, the permeability of a compd. through Caco-2 cells by passive diffusion can be predicted from the compds.' distribution coeff. in 1-octanol/water (log Doct) and its mol. wt. (MW).  Deviations from this expected behavior may point to the involvement of biol. components in the transport process, which may require further investigations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrPZi9YD6wRi7Vg90H21EOLACvtfcHk0lhT-8eO0UXImQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXmtl2nsr0%253D&md5=034f5764416eb407cc22d2119c1dce3c</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1016%2FS0928-0987%2897%2910019-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0928-0987%252897%252910019-7%26sid%3Dliteratum%253Aachs%26aulast%3DCamenisch%26aufirst%3DG.%26aulast%3DAlsenz%26aufirst%3DJ.%26aulast%3Dvan%2Bde%2BWaterbeemd%26aufirst%3DH.%26aulast%3DFolkers%26aufirst%3DG.%26atitle%3DEstimation%2520of%2520permeability%2520by%2520passive%2520diffusion%2520through%2520Caco-2%2520cell%2520monolayers%2520using%2520the%2520drugs%25E2%2580%2599%2520lipophilicity%2520and%2520molecular%2520weight%26jtitle%3DEur.%2520J.%2520Pharm.%2520Sci.%26date%3D1998%26volume%3D6%26spage%3D313%26epage%3D319%26doi%3D10.1016%2FS0928-0987%2897%2910019-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Abraham, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abraham, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Acree, W. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aliev, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leo, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whaley, W. L.</span></span> <span> </span><span class="NLM_article-title">An NMR method for the quantitative assessment of intramolecular hydrogen bonding; application to physicochemical, environmental, and biochemical properties</span>. <i>J. Org. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>79</i></span>,  <span class="NLM_fpage">11075</span>– <span class="NLM_lpage">11083</span>, <span class="refDoi"> DOI: 10.1021/jo502080p</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jo502080p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01346&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvVensLrM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=79&publication_year=2014&pages=11075-11083&author=M.+H.+Abrahamauthor=R.+J.+Abrahamauthor=W.+E.+Acreeauthor=A.+E.+Alievauthor=A.+J.+Leoauthor=W.+L.+Whaley&title=An+NMR+method+for+the+quantitative+assessment+of+intramolecular+hydrogen+bonding%3B+application+to+physicochemical%2C+environmental%2C+and+biochemical+properties&doi=10.1021%2Fjo502080p"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">An NMR Method for the Quantitative Assessment of Intramolecular Hydrogen Bonding; Application to Physicochemical, Environmental, and Biochemical Properties</span></div><div class="casAuthors">Abraham, Michael H.; Abraham, Raymond J.; Acree, William E.; Aliev, Abil E.; Leo, Al J.; Whaley, William L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Organic Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">79</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">11075-11083</span>CODEN:
                <span class="NLM_cas:coden">JOCEAH</span>;
        ISSN:<span class="NLM_cas:issn">0022-3263</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">1H NMR chem. shifts have been obtained in the solvents deuterochloroform and DMSO.  The difference in the chem. shifts of an OH or NH group in these two solvents, Δδ = δ(DMSO) - δ(CDCl3), can be converted into the hydrogen bond acidity, A, of the group using the equation A = 0.0065 + 0.133Δδ.  The NMR A value, ANMR, can be used as a quant. assessment of intramol. hydrogen bonding.  We list values of Δδ and ANMR for 55 compds. contg. an OH group and 60 compds. with an NH group.  For the hydroxy compds., if A > 0.5 then the OH group is not part of an intramol. hydrogen bond, but if A < 0.1 then the OH group forms part of an intramol. hydrogen bond.  For NH compds., if A > 0.16 the NH group is not part of an intramol. hydrogen bond, and if A < 0.05 the NH group is part of an intramol. hydrogen bond.  No comparison compds. are needed, and the method is extremely simple.  We further show how it is possible to relate intramol. hydrogen bonding to the actual effect on values of a no. of physicochem., environmental, and biochem. properties.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpS3GZXQi7robVg90H21EOLACvtfcHk0lg1wYxaY7GpoQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvVensLrM&md5=b5e9948a04237fadb3b4fc3237bde8b1</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1021%2Fjo502080p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo502080p%26sid%3Dliteratum%253Aachs%26aulast%3DAbraham%26aufirst%3DM.%2BH.%26aulast%3DAbraham%26aufirst%3DR.%2BJ.%26aulast%3DAcree%26aufirst%3DW.%2BE.%26aulast%3DAliev%26aufirst%3DA.%2BE.%26aulast%3DLeo%26aufirst%3DA.%2BJ.%26aulast%3DWhaley%26aufirst%3DW.%2BL.%26atitle%3DAn%2520NMR%2520method%2520for%2520the%2520quantitative%2520assessment%2520of%2520intramolecular%2520hydrogen%2520bonding%253B%2520application%2520to%2520physicochemical%252C%2520environmental%252C%2520and%2520biochemical%2520properties%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D2014%26volume%3D79%26spage%3D11075%26epage%3D11083%26doi%3D10.1021%2Fjo502080p" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lenz, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morin, P. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weston, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bayrakdarian, M.</span></span> <span> </span><span class="NLM_article-title">Reactive metabolite trapping screens and potential pitfalls: bioactivation of a homomorpholine and formation of an unstable thiazolidine adduct</span>. <i>Chem. Res. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">968</span>– <span class="NLM_lpage">980</span>, <span class="refDoi"> DOI: 10.1021/tx5000409</span> </span><div class="citationLinks">[<a href="/doi/10.1021/tx5000409" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01346&amp;key=1%3ACAS%3A528%3ADC%252BC2cXosFaisbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2014&pages=968-980&author=E.+M.+Lenzauthor=S.+Martinauthor=R.+Schmidtauthor=P.+E.+Morinauthor=R.+Smithauthor=D.+J.+Westonauthor=M.+Bayrakdarian&title=Reactive+metabolite+trapping+screens+and+potential+pitfalls%3A+bioactivation+of+a+homomorpholine+and+formation+of+an+unstable+thiazolidine+adduct&doi=10.1021%2Ftx5000409"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Reactive Metabolite Trapping Screens and Potential Pitfalls: Bioactivation of a Homomorpholine and Formation of an Unstable Thiazolidine Adduct</span></div><div class="casAuthors">Lenz, Eva. M.; Martin, Scott; Schmidt, Ralf; Morin, Pierre-Emmanuel; Smith, Robin; Weston, Daniel J.; Bayrakdarian, Malken</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Research in Toxicology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">968-980</span>CODEN:
                <span class="NLM_cas:coden">CRTOEC</span>;
        ISSN:<span class="NLM_cas:issn">0893-228X</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Successful early attrition of potential problematic compds. is of great importance in the pharmaceutical industry.  The lead compd. in a recent project targeting neuropathic pain was susceptible to metabolic bioactivation, which produced reactive metabolites and showed covalent binding to protein.  Therefore, as a part of the backup series for this compd. several structural modifications were explored to mediate the reactive metabolite and covalent binding risk.  A homomorpholine contg. series of compds. was identified without compromising potency.  However, when these compds. were incubated with human liver microsomes in the presence of GSH, Cys-Gly adducts were identified, instead of intact GSH conjugates.  This article examines the formation of the Cys-Gly adduct with AZX ([M+H]+ 486) as a representative compd. for this series.  The AZX-Cys-Gly-adduct ([M+H]+ 662) showed evidence of ring contraction by formation of a thiazolidine-glycine and was addnl. shown to be unstable.  During its isolation for structural characterization by 1H NMR spectroscopy, it was found to have decompd. to a product with [M+H]+ 446.  The characterization and identification of this labile GSH-derived adduct using LC-MS/MS and 1H NMR are described, along with observations around stability.  In addn., various structurally related trapping reagents were employed in an attempt to further investigate the reaction mechanism along with a methoxylamine trapping expt. to confirm the structure of the postulated reactive intermediate.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpPS272xX7pjbVg90H21EOLACvtfcHk0lg1wYxaY7GpoQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXosFaisbY%253D&md5=df277154a86526015e0cb770b75bf756</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1021%2Ftx5000409&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Ftx5000409%26sid%3Dliteratum%253Aachs%26aulast%3DLenz%26aufirst%3DE.%2BM.%26aulast%3DMartin%26aufirst%3DS.%26aulast%3DSchmidt%26aufirst%3DR.%26aulast%3DMorin%26aufirst%3DP.%2BE.%26aulast%3DSmith%26aufirst%3DR.%26aulast%3DWeston%26aufirst%3DD.%2BJ.%26aulast%3DBayrakdarian%26aufirst%3DM.%26atitle%3DReactive%2520metabolite%2520trapping%2520screens%2520and%2520potential%2520pitfalls%253A%2520bioactivation%2520of%2520a%2520homomorpholine%2520and%2520formation%2520of%2520an%2520unstable%2520thiazolidine%2520adduct%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D2014%26volume%3D27%26spage%3D968%26epage%3D980%26doi%3D10.1021%2Ftx5000409" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 7 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Zhouling Xie, Xiaoxiao Yang, Yajun Duan, Jihong Han, <span class="NLM_string-name hlFld-ContribAuthor">Chenzhong Liao</span>. </span><span class="cited-content_cbyCitation_article-title">Small-Molecule Kinase Inhibitors for the Treatment of Nononcologic Diseases. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (3)
                                     , 1283-1345. <a href="https://doi.org/10.1021/acs.jmedchem.0c01511" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c01511</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c01511&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c01511%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DSmall-Molecule%252BKinase%252BInhibitors%252Bfor%252Bthe%252BTreatment%252Bof%252BNononcologic%252BDiseases%26aulast%3DXie%26aufirst%3DZhouling%26date%3D2021%26date%3D2021%26date%3D2020%26date%3D29082020%26date%3D22012021%26volume%3D64%26issue%3D3%26spage%3D1283%26epage%3D1345" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Yun Chen, Yi Ning, Gang Bai, Linjiang Tong, Tao Zhang, Jinpei Zhou, Huibin Zhang, Hua Xie, Jian Ding, <span class="NLM_string-name hlFld-ContribAuthor">Wenhu Duan</span>. </span><span class="cited-content_cbyCitation_article-title">Design, Synthesis, and Biological Evaluation of IRAK4-Targeting PROTACs. </span><span class="cited-content_cbyCitation_journal-name">ACS Medicinal Chemistry Letters</span><span> <strong>2021,</strong> <em>12 </em>
                                    (1)
                                     , 82-87. <a href="https://doi.org/10.1021/acsmedchemlett.0c00474" title="DOI URL">https://doi.org/10.1021/acsmedchemlett.0c00474</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsmedchemlett.0c00474&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsmedchemlett.0c00474%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DDesign%25252C%252BSynthesis%25252C%252Band%252BBiological%252BEvaluation%252Bof%252BIRAK4-Targeting%252BPROTACs%26aulast%3DChen%26aufirst%3DYun%26date%3D2021%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D28082020%26date%3D08122020%26date%3D10122020%26volume%3D12%26issue%3D1%26spage%3D82%26epage%3D87" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Sheng-Ge Li, Yue-Tong Wang, Qin Zhang, Kai-Bo Wang, Jing-Jing Xue, Da-Hong Li, Yong-Kui Jing, Bin Lin, <span class="NLM_string-name hlFld-ContribAuthor">Hui-Ming Hua</span>. </span><span class="cited-content_cbyCitation_article-title">Pegaharmols A–B, Axially Chiral β-Carboline-quinazoline Dimers from the Roots of Peganum harmala. </span><span class="cited-content_cbyCitation_journal-name">Organic Letters</span><span> <strong>2020,</strong> <em>22 </em>
                                    (19)
                                     , 7522-7525. <a href="https://doi.org/10.1021/acs.orglett.0c02709" title="DOI URL">https://doi.org/10.1021/acs.orglett.0c02709</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.orglett.0c02709&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.orglett.0c02709%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Letters%26atitle%3DPegaharmols%252BA%2525E2%252580%252593B%25252C%252BAxially%252BChiral%252B%2525CE%2525B2-Carboline-quinazoline%252BDimers%252Bfrom%252Bthe%252BRoots%252Bof%252BPeganum%252Bharmala%26aulast%3DLi%26aufirst%3DSheng-Ge%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D14082020%26date%3D16092020%26volume%3D22%26issue%3D19%26spage%3D7522%26epage%3D7525" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Sébastien L. Degorce, Omid Tavana, Erica Banks, Claire Crafter, Lakshmaiah Gingipalli, David Kouvchinov, Yumeng Mao, Fiona Pachl, Anisha Solanki, Viia Valge-Archer, Bin Yang, <span class="NLM_string-name hlFld-ContribAuthor">Scott D. Edmondson</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of Proteolysis-Targeting Chimera Molecules that Selectively Degrade the IRAK3 Pseudokinase. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (18)
                                     , 10460-10473. <a href="https://doi.org/10.1021/acs.jmedchem.0c01125" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c01125</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c01125&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c01125%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252BProteolysis-Targeting%252BChimera%252BMolecules%252Bthat%252BSelectively%252BDegrade%252Bthe%252BIRAK3%252BPseudokinase%26aulast%3DDegorce%26aufirst%3DS%25C3%25A9bastien%2BL.%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D30062020%26date%3D14092020%26date%3D17082020%26volume%3D63%26issue%3D18%26spage%3D10460%26epage%3D10473" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Geetha  Nalairndran</span>, <span class="hlFld-ContribAuthor ">Ivy  Chung</span>, <span class="hlFld-ContribAuthor ">Azad Hassan  Abdul Razack</span>, <span class="hlFld-ContribAuthor ">Felicia Fei‐Lei  Chung</span>, <span class="hlFld-ContribAuthor ">Ling‐Wei  Hii</span>, <span class="hlFld-ContribAuthor ">Wei‐Meng  Lim</span>, <span class="hlFld-ContribAuthor ">Chin King  Looi</span>, <span class="hlFld-ContribAuthor ">Chun‐Wai  Mai</span>, <span class="hlFld-ContribAuthor ">Chee‐Onn  Leong</span>. </span><span class="cited-content_cbyCitation_article-title">Inhibition of Janus Kinase 1 synergizes docetaxel sensitivity in prostate cancer cells. </span><span class="cited-content_cbyCitation_journal-name">Journal of Cellular and Molecular Medicine</span><span> <strong>2021,</strong> <em>5 </em><a href="https://doi.org/10.1111/jcmm.16684" title="DOI URL">https://doi.org/10.1111/jcmm.16684</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1111/jcmm.16684&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1111%2Fjcmm.16684%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Cellular%2520and%2520Molecular%2520Medicine%26atitle%3DInhibition%252Bof%252BJanus%252BKinase%252B1%252Bsynergizes%252Bdocetaxel%252Bsensitivity%252Bin%252Bprostate%252Bcancer%252Bcells%26aulast%3DNalairndran%26aufirst%3DGeetha%26date%3D2021%26date%3D2021%26volume%3D5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Sébastien L.  Degorce</span>, <span class="hlFld-ContribAuthor ">Anna  Aagaard</span>, <span class="hlFld-ContribAuthor ">Rana  Anjum</span>, <span class="hlFld-ContribAuthor ">Iain A.  Cumming</span>, <span class="hlFld-ContribAuthor ">Coura R.  Diène</span>, <span class="hlFld-ContribAuthor ">Charlene  Fallan</span>, <span class="hlFld-ContribAuthor ">Tony  Johnson</span>, <span class="hlFld-ContribAuthor ">Karl-Johan  Leuchowius</span>, <span class="hlFld-ContribAuthor ">Alexandra L.  Orton</span>, <span class="hlFld-ContribAuthor ">Stuart  Pearson</span>, <span class="hlFld-ContribAuthor ">Graeme R.  Robb</span>, <span class="hlFld-ContribAuthor ">Alan  Rosen</span>, <span class="hlFld-ContribAuthor ">Graeme B.  Scarfe</span>, <span class="hlFld-ContribAuthor ">James S.  Scott</span>, <span class="hlFld-ContribAuthor ">James M.  Smith</span>, <span class="hlFld-ContribAuthor ">Oliver R.  Steward</span>, <span class="hlFld-ContribAuthor ">Ina  Terstiege</span>, <span class="hlFld-ContribAuthor ">Michael J.  Tucker</span>, <span class="hlFld-ContribAuthor ">Paul  Turner</span>, <span class="hlFld-ContribAuthor ">Stephen D.  Wilkinson</span>, <span class="hlFld-ContribAuthor ">Gail L.  Wrigley</span>, <span class="hlFld-ContribAuthor ">Yafeng  Xue</span>. </span><span class="cited-content_cbyCitation_article-title">Improving metabolic stability and removing aldehyde oxidase liability in a 5-azaquinazoline series of IRAK4 inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2020,</strong> <em>28 </em>
                                    (23)
                                     , 115815. <a href="https://doi.org/10.1016/j.bmc.2020.115815" title="DOI URL">https://doi.org/10.1016/j.bmc.2020.115815</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2020.115815&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2020.115815%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3DImproving%252Bmetabolic%252Bstability%252Band%252Bremoving%252Baldehyde%252Boxidase%252Bliability%252Bin%252Ba%252B5-azaquinazoline%252Bseries%252Bof%252BIRAK4%252Binhibitors%26aulast%3DDegorce%26aufirst%3DS%25C3%25A9bastien%2BL.%26date%3D2020%26volume%3D28%26issue%3D23%26spage%3D115815" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Bhawana  George</span>, <span class="hlFld-ContribAuthor ">Sayan  Mullick Chowdhury</span>, <span class="hlFld-ContribAuthor ">Amber  Hart</span>, <span class="hlFld-ContribAuthor ">Anuvrat  Sircar</span>, <span class="hlFld-ContribAuthor ">Satish Kumar  Singh</span>, <span class="hlFld-ContribAuthor ">Uttam Kumar  Nath</span>, <span class="hlFld-ContribAuthor ">Mukesh  Mamgain</span>, <span class="hlFld-ContribAuthor ">Naveen Kumar  Singhal</span>, <span class="hlFld-ContribAuthor ">Lalit  Sehgal</span>, <span class="hlFld-ContribAuthor ">Neeraj  Jain</span>. </span><span class="cited-content_cbyCitation_article-title">Ibrutinib Resistance Mechanisms and Treatment Strategies for B-Cell Lymphomas. </span><span class="cited-content_cbyCitation_journal-name">Cancers</span><span> <strong>2020,</strong> <em>12 </em>
                                    (5)
                                     , 1328. <a href="https://doi.org/10.3390/cancers12051328" title="DOI URL">https://doi.org/10.3390/cancers12051328</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/cancers12051328&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fcancers12051328%26sid%3Dliteratum%253Aachs%26jtitle%3DCancers%26atitle%3DIbrutinib%252BResistance%252BMechanisms%252Band%252BTreatment%252BStrategies%252Bfor%252BB-Cell%252BLymphomas%26aulast%3DGeorge%26aufirst%3DBhawana%26date%3D2020%26date%3D2020%26volume%3D12%26issue%3D5%26spage%3D1328" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-21/acs.jmedchem.9b01346/20191108/images/medium/jm9b01346_0005.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-21/acs.jmedchem.9b01346/20191108/images/large/jm9b01346_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01346&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-21/acs.jmedchem.9b01346/20191108/images/medium/jm9b01346_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-21/acs.jmedchem.9b01346/20191108/images/large/jm9b01346_0008.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of Quinazolines <b>4</b>, <b>6</b>, <b>7</b>, and <b>9</b> and 5-Azaquinazolines <b>10</b> and <b>12</b>–<b>13</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-21/acs.jmedchem.9b01346/20191108/images/large/jm9b01346_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01346&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) methyl 4-(<i>trans</i>-4-aminocyclohexyl)piperazine-1-carboxylate or 1-(4-(<i>trans</i>-4-aminocyclohexyl)piperazin-1-yl)ethanone, DIPEA, <i>n</i>-BuOH or <i>i</i>-PrOH or NMP, 60–150 °C, 3 h (37–84%); (b) 1-methyl-4-aminopyrazole, RuPhos-Pd-G3, Cs<sub>2</sub>CO<sub>3</sub>, 1,4-dioxane, 100 °C, 16 h (<b>6</b>, 49%); (c) 1-methyl-4-aminopyrazole, TsOH, EtOH, 90 °C, 3 h (32–97%); (d) Pd/C, H<sub>2</sub>, dimethylformamide (DMF)/EtOH, room temperature (RT), 18 h (28%); (e) XPhos-Pd-G2, 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)isoxazole, KF, dimethyl sulfoxide (DMSO), 100 °C, 2 h (94%); and (f) KF, MeOH, 100 °C, 2 h (51%).</p></p></figure><figure data-id="sch2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-21/acs.jmedchem.9b01346/20191108/images/medium/jm9b01346_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-21/acs.jmedchem.9b01346/20191108/images/large/jm9b01346_0015.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of 5-Azaquinazolines <b>11</b> and <b>14</b>–<b>16</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-21/acs.jmedchem.9b01346/20191108/images/large/jm9b01346_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01346&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) ethyl 2-cyanopropanoate, <i>t</i>-BuONa, DMF, 80 °C, 48 h (61%); (b) methyl 4-(<i>trans</i>-4-aminocyclohexyl)piperazine-1-carboxylate, DIPEA, PyBOP, DMF, RT, 16 h (19%); (c) 1-methyl-4-aminopyrazole, HCl, EtOH, 60 °C, 30 min (72%); (d) Br<sub>2</sub>, NaOAc, AcOH, RT, 30 min (86–90%); (e) Zn(CN)<sub>2</sub>, Pd(PPh<sub>3</sub>)<sub>4</sub>, DMF, 100 °C, 21 h (94–95%); (f) H<sub>2</sub>O<sub>2</sub>, K<sub>2</sub>CO<sub>3</sub>, DMSO, 0–20 °C, 2–3 h (94–95%); (g) (i) triphosgene, 1,4-dioxane, 100 °C, 3 h; (ii) POCl<sub>3</sub>, DIPEA, toluene, 100 °C, 16 h (<b>11</b>, 49% over two steps); (h) thiophosgene, 1,4-dioxane, RT-reflux, 2 h (<b>15</b>–<b>16</b>, 78–83%); (j) (i) methyl 4-(<i>trans</i>-4-aminocyclohexyl)piperazine-1-carboxylate, DIPEA, <i>i</i>-PrOH, 100 °C, 1 h; (ii) 1-methyl-4-aminopyrazole, TsOH, EtOH, 80 °C, 2 h (<b>11</b>, 11% over two steps); and (k) (i) 1-methyl-4-aminopyrazole, HCl, EtOH, 70–80 °C, 1 h; (ii) methyl 4-(<i>trans</i>-4-aminocyclohexyl)piperazine-1-carboxylate, DIPEA, PyBOP, DMF, RT, 16 h (<b>15</b>–<b>16</b>, 8–35%, over two steps).</p></p></figure><figure data-id="fig1" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-21/acs.jmedchem.9b01346/20191108/images/medium/jm9b01346_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-21/acs.jmedchem.9b01346/20191108/images/large/jm9b01346_0003.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. X-ray crystallographic structures of quinazoline <b>4</b> (orange, PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6RFI">6RFI</a>) relative to <b>8</b> (cyan, PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5T1T">5T1T</a>). Solvent molecules are only shown for 6RFI.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-21/acs.jmedchem.9b01346/20191108/images/large/jm9b01346_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01346&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-21/acs.jmedchem.9b01346/20191108/images/medium/jm9b01346_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-21/acs.jmedchem.9b01346/20191108/images/large/jm9b01346_0014.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Predicted solution conformations of quinazoline <b>9</b> and 5-azaquinazoline <b>10</b> based on experimental NMR data and computational models.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-21/acs.jmedchem.9b01346/20191108/images/large/jm9b01346_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01346&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-21/acs.jmedchem.9b01346/20191108/images/medium/jm9b01346_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-21/acs.jmedchem.9b01346/20191108/images/large/jm9b01346_0001.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Predicted torsion profiles for indicated C–N bond of quinazoline <b>9</b> and 5-azaquinazoline <b>10</b> based on QM calculations, representing molecules (A) solvated in water and (B) in nonaqueous environment (e.g., cell membrane).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-21/acs.jmedchem.9b01346/20191108/images/large/jm9b01346_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01346&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-21/acs.jmedchem.9b01346/20191108/images/medium/jm9b01346_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-21/acs.jmedchem.9b01346/20191108/images/large/jm9b01346_0012.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. X-ray crystallographic structures of 5-azaquinazoline <b>13</b> (green, PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6RFJ">6RFJ</a>) relative to <b>4</b> (orange).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-21/acs.jmedchem.9b01346/20191108/images/large/jm9b01346_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01346&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-21/acs.jmedchem.9b01346/20191108/images/medium/jm9b01346_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-21/acs.jmedchem.9b01346/20191108/images/large/jm9b01346_0009.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Kinome selectivity of <b>4</b> (A, 1 μM) and <b>13</b> (B, 0.1 μM).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-21/acs.jmedchem.9b01346/20191108/images/large/jm9b01346_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01346&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-21/acs.jmedchem.9b01346/20191108/images/medium/jm9b01346_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-21/acs.jmedchem.9b01346/20191108/images/large/jm9b01346_0010.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Mouse exposure following a 50 mg/kg oral dose, normalized as a free cover over the pIRAK4 cell IC<sub>50</sub> for <b>4</b> (blue) and <b>13</b> (green).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-21/acs.jmedchem.9b01346/20191108/images/large/jm9b01346_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01346&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-21/acs.jmedchem.9b01346/20191108/images/medium/jm9b01346_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-21/acs.jmedchem.9b01346/20191108/images/large/jm9b01346_0011.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. In vitro synergistic suppression of IκBα phosphorylation: OCI-LY10 cells were treated with increasing concentrations of compound <b>4</b> (A) or compound <b>13</b> (B) and ibrutinib for 14 h. Vinculin served as a loading control.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-21/acs.jmedchem.9b01346/20191108/images/large/jm9b01346_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01346&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig8" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-21/acs.jmedchem.9b01346/20191108/images/medium/jm9b01346_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-21/acs.jmedchem.9b01346/20191108/images/large/jm9b01346_0002.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. (A) combination of <b>13</b> and ibrutinib leads to synergistic growth inhibition in OCI-LY10 cells (ABC-DLBCL double CD79<sup>MUT</sup>/MYD88<sup>L265P</sup> cell line). (B) Lack of combination benefit in OCI-LY19 cells (GCB-DLBCL double CD79<sup>WT</sup>/MYD88<sup>WT</sup> cell line). Numbers represent the percent growth inhibition in a 6 × 6 dose matrix in a 3 day growth assay, where 0–100 signifies increasing cell growth inhibition and >100 signifies increasing cell death.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-21/acs.jmedchem.9b01346/20191108/images/large/jm9b01346_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01346&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig9" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-21/acs.jmedchem.9b01346/20191108/images/medium/jm9b01346_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-21/acs.jmedchem.9b01346/20191108/images/large/jm9b01346_0004.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Efficacy of quinazoline <b>4</b> (A) and 5-azaquinazoline <b>13</b> (B) in combination with ibrutinib in OCI-LY10 xenografts.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-21/acs.jmedchem.9b01346/20191108/images/large/jm9b01346_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01346&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i47">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_74523" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_74523" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 23 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Camicia, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winkler, H. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hassa, P. O.</span></span> <span> </span><span class="NLM_article-title">Novel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive review</span>. <i>Mol. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">207</span>, <span class="refDoi"> DOI: 10.1186/s12943-015-0474-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01346&amp;key=10.1186%2Fs12943-015-0474-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01346&amp;key=26654227" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01346&amp;key=1%3ACAS%3A528%3ADC%252BC28Xpt1Olurk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2015&pages=207&author=R.+Camiciaauthor=H.+C.+Winklerauthor=P.+O.+Hassa&title=Novel+drug+targets+for+personalized+precision+medicine+in+relapsed%2Frefractory+diffuse+large+B-cell+lymphoma%3A+a+comprehensive+review&doi=10.1186%2Fs12943-015-0474-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Novel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive review</span></div><div class="casAuthors">Camicia, Rosalba; Winkler, Hans C.; Hassa, Paul O.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">207/1-207/62</span>CODEN:
                <span class="NLM_cas:coden">MCOACG</span>;
        ISSN:<span class="NLM_cas:issn">1476-4598</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Diffuse large B-cell lymphoma (DLBCL) is a clin. heterogeneous lymphoid malignancy and the most common subtype of non-Hodgkin's lymphoma in adults, with one of the highest mortality rates in most developed areas of the world.  More than half of DLBLC patients can be cured with std. R-CHOP regimens, however approx. 30 to 40 % of patients will develop relapsed/refractory disease that remains a major cause of morbidity and mortality due to the limited therapeutic options.  Recent advances in gene expression profiling have led to the identification of at least three distinct mol. subtypes of DLBCL: a germinal center B cell-like subtype, an activated B cell-like subtype, and a primary mediastinal B-cell lymphoma subtype.  Moreover, recent findings have not only increased our understanding of the mol. basis of chemotherapy resistance but have also helped identify mol. subsets of DLBCL and rational targets for drug interventions that may allow for subtype/subset-specific molecularly targeted precision medicine and personalized combinations to both prevent and treat relapsed/refractory DLBCL.  Novel agents such as lenalidomide, ibrutinib, bortezomib, CC-122, epratuzumab or pidilizumab used as single-agent or in combination with (rituximab-based) chemotherapy have already demonstrated promising activity in patients with relapsed/ refractory DLBCL.  Several novel potential drug targets have been recently identified such as the BET bromodomain protein (BRD)-4, phosphoribosyl-pyrophosphate synthetase (PRPS)-2, macrodomain-contg. mono-ADP-ribosyltransferase (ARTD)-9 (also known as PARP9), deltex-3-like E3 ubiquitin ligase (DTX3L) (also known as BBAP), NF-kappaB inducing kinase (NIK) and transforming growth factor beta receptor (TGFssR).  This review highlights the new insights into the mol. basis of relapsed/refractory DLBCL and summarizes the most promising drug targets and exptl. treatments for relapsed/refractory DLBCL, including the use of novel agents such as lenalidomide, ibrutinib, bortezomib, pidilizumab, epratuzumab, brentuximab-vedotin or CAR T cells, dual inhibitors, as well as mechanism-based combinatorial exptl. therapies.  We also provide a comprehensive and updated list of current drugs, drug targets and preclin. and clin. exptl. studies in DLBCL.  A special focus is given on STAT1, ARTD9, DTX3L and ARTD8 (also known as PARP14) as novel potential drug targets in distinct mol. subsets of DLBCL.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpJp4JiT_yM07Vg90H21EOLACvtfcHk0lh86Lxm8TB3KQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xpt1Olurk%253D&md5=c4365573bf9b7d942ecdefadf08c7741</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1186%2Fs12943-015-0474-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs12943-015-0474-2%26sid%3Dliteratum%253Aachs%26aulast%3DCamicia%26aufirst%3DR.%26aulast%3DWinkler%26aufirst%3DH.%2BC.%26aulast%3DHassa%26aufirst%3DP.%2BO.%26atitle%3DNovel%2520drug%2520targets%2520for%2520personalized%2520precision%2520medicine%2520in%2520relapsed%252Frefractory%2520diffuse%2520large%2520B-cell%2520lymphoma%253A%2520a%2520comprehensive%2520review%26jtitle%3DMol.%2520Cancer%26date%3D2015%26volume%3D14%26spage%3D207%26doi%3D10.1186%2Fs12943-015-0474-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ngo, V. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmitz, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jhavar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lim, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kohlhammer, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaffer, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romesser, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wright, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Powell, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosenwald, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muller-Hermelink, H. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ott, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gascoyne, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Connors, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rimsza, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campo, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jaffe, E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delabie, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smeland, E. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fisher, R. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Braziel, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tubbs, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cook, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weisenburger, D. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Staudt, L. M.</span></span> <span> </span><span class="NLM_article-title">Oncogenically active MYD88 mutations in human lymphoma</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>470</i></span>,  <span class="NLM_fpage">115</span>– <span class="NLM_lpage">119</span>, <span class="refDoi"> DOI: 10.1038/nature09671</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01346&amp;key=10.1038%2Fnature09671" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01346&amp;key=21179087" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01346&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtVCksQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=470&publication_year=2011&pages=115-119&author=V.+N.+Ngoauthor=R.+M.+Youngauthor=R.+Schmitzauthor=S.+Jhavarauthor=W.+Xiaoauthor=K.+H.+Limauthor=H.+Kohlhammerauthor=W.+Xuauthor=Y.+Yangauthor=H.+Zhaoauthor=A.+L.+Shafferauthor=P.+Romesserauthor=G.+Wrightauthor=J.+Powellauthor=A.+Rosenwaldauthor=H.+K.+Muller-Hermelinkauthor=G.+Ottauthor=R.+D.+Gascoyneauthor=J.+M.+Connorsauthor=L.+M.+Rimszaauthor=E.+Campoauthor=E.+S.+Jaffeauthor=J.+Delabieauthor=E.+B.+Smelandauthor=R.+I.+Fisherauthor=R.+M.+Brazielauthor=R.+R.+Tubbsauthor=J.+R.+Cookauthor=D.+D.+Weisenburgerauthor=W.+C.+Chanauthor=L.+M.+Staudt&title=Oncogenically+active+MYD88+mutations+in+human+lymphoma&doi=10.1038%2Fnature09671"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Oncogenically active MYD88 mutations in human lymphoma</span></div><div class="casAuthors">Ngo, Vu N.; Young, Ryan M.; Schmitz, Roland; Jhavar, Sameer; Xiao, Wenming; Lim, Kian-Huat; Kohlhammer, Holger; Xu, Weihong; Yang, Yandan; Zhao, Hong; Shaffer, Arthur L.; Romesser, Paul; Wright, George; Powell, John; Rosenwald, Andreas; Muller-Hermelink, Hans Konrad; Ott, German; Gascoyne, Randy D.; Connors, Joseph M.; Rimsza, Lisa M.; Campo, Elias; Jaffe, Elaine S.; Delabie, Jan; Smeland, Erlend B.; Fisher, Richard I.; Braziel, Rita M.; Tubbs, Raymond R.; Cook, J. R.; Weisenburger, Denny D.; Chan, Wing C.; Staudt, Louis M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">470</span>
        (<span class="NLM_cas:issue">7332</span>),
    <span class="NLM_cas:pages">115-119</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The activated B-cell-like (ABC) subtype of diffuse large B-cell lymphoma (DLBCL) remains the least curable form of this malignancy despite recent advances in therapy.  Constitutive nuclear factor (NF)-κB and JAK kinase signaling promotes malignant cell survival in these lymphomas, but the genetic basis for this signaling is incompletely understood.  Here we describe the dependence of ABC DLBCLs on MYD88, an adaptor protein that mediates toll and interleukin (IL)-1 receptor signaling, and the discovery of highly recurrent oncogenic mutations affecting MYD88 in ABC DLBCL tumors.  RNA interference screening revealed that MYD88 and the assocd. kinases IRAK1 and IRAK4 are essential for ABC DLBCL survival.  High-throughput RNA resequencing uncovered MYD88 mutations in ABC DLBCL lines.  Notably, 29% of ABC DLBCL tumors harbored the same amino acid substitution, L265P, in the MYD88 Toll/IL-1 receptor (TIR) domain at an evolutionarily invariant residue in its hydrophobic core.  This mutation was rare or absent in other DLBCL subtypes and Burkitt's lymphoma, but was obsd. in 9% of mucosa-assocd. lymphoid tissue lymphomas.  At a lower frequency, addnl. mutations were obsd. in the MYD88 TIR domain, occurring in both the ABC and germinal center B-cell-like (GCB) DLBCL subtypes.  Survival of ABC DLBCL cells bearing the L265P mutation was sustained by the mutant but not the wild-type MYD88 isoform, demonstrating that L265P is a gain-of-function driver mutation.  The L265P mutant promoted cell survival by spontaneously assembling a protein complex contg. IRAK1 and IRAK4, leading to IRAK4 kinase activity, IRAK1 phosphorylation, NF-κB signaling, JAK kinase activation of STAT3, and secretion of IL-6, IL-10 and interferon-β.  Hence, the MYD88 signaling pathway is integral to the pathogenesis of ABC DLBCL, supporting the development of inhibitors of IRAK4 kinase and other components of this pathway for the treatment of tumors bearing oncogenic MYD88 mutations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq5pEPxh1G6J7Vg90H21EOLACvtfcHk0ljiMMIMPhQjNQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtVCksQ%253D%253D&md5=3dff4d54af8f64bb9e57f04cf274fee8</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1038%2Fnature09671&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature09671%26sid%3Dliteratum%253Aachs%26aulast%3DNgo%26aufirst%3DV.%2BN.%26aulast%3DYoung%26aufirst%3DR.%2BM.%26aulast%3DSchmitz%26aufirst%3DR.%26aulast%3DJhavar%26aufirst%3DS.%26aulast%3DXiao%26aufirst%3DW.%26aulast%3DLim%26aufirst%3DK.%2BH.%26aulast%3DKohlhammer%26aufirst%3DH.%26aulast%3DXu%26aufirst%3DW.%26aulast%3DYang%26aufirst%3DY.%26aulast%3DZhao%26aufirst%3DH.%26aulast%3DShaffer%26aufirst%3DA.%2BL.%26aulast%3DRomesser%26aufirst%3DP.%26aulast%3DWright%26aufirst%3DG.%26aulast%3DPowell%26aufirst%3DJ.%26aulast%3DRosenwald%26aufirst%3DA.%26aulast%3DMuller-Hermelink%26aufirst%3DH.%2BK.%26aulast%3DOtt%26aufirst%3DG.%26aulast%3DGascoyne%26aufirst%3DR.%2BD.%26aulast%3DConnors%26aufirst%3DJ.%2BM.%26aulast%3DRimsza%26aufirst%3DL.%2BM.%26aulast%3DCampo%26aufirst%3DE.%26aulast%3DJaffe%26aufirst%3DE.%2BS.%26aulast%3DDelabie%26aufirst%3DJ.%26aulast%3DSmeland%26aufirst%3DE.%2BB.%26aulast%3DFisher%26aufirst%3DR.%2BI.%26aulast%3DBraziel%26aufirst%3DR.%2BM.%26aulast%3DTubbs%26aufirst%3DR.%2BR.%26aulast%3DCook%26aufirst%3DJ.%2BR.%26aulast%3DWeisenburger%26aufirst%3DD.%2BD.%26aulast%3DChan%26aufirst%3DW.%2BC.%26aulast%3DStaudt%26aufirst%3DL.%2BM.%26atitle%3DOncogenically%2520active%2520MYD88%2520mutations%2520in%2520human%2520lymphoma%26jtitle%3DNature%26date%3D2011%26volume%3D470%26spage%3D115%26epage%3D119%26doi%3D10.1038%2Fnature09671" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Davids, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, J. R.</span></span> <span> </span><span class="NLM_article-title">Ibrutinib: a first in class covalent inhibitor of Bruton’s Tyrosine Kinase</span>. <i>Future Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">957</span>– <span class="NLM_lpage">967</span>, <span class="refDoi"> DOI: 10.2217/fon.14.51</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01346&amp;key=10.2217%2Ffon.14.51" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01346&amp;key=24941982" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01346&amp;key=1%3ACAS%3A528%3ADC%252BC2cXpvFCrtbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2014&pages=957-967&author=M.+S.+Davidsauthor=J.+R.+Brown&title=Ibrutinib%3A+a+first+in+class+covalent+inhibitor+of+Bruton%E2%80%99s+Tyrosine+Kinase&doi=10.2217%2Ffon.14.51"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Ibrutinib: a first in class covalent inhibitor of Bruton's tyrosine kinase</span></div><div class="casAuthors">Davids, Matthew S.; Brown, Jennifer R.</div><div class="citationInfo"><span class="NLM_cas:title">Future Oncology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">957-967</span>CODEN:
                <span class="NLM_cas:coden">FOUNBN</span>;
        ISSN:<span class="NLM_cas:issn">1479-6694</span>.
    
            (<span class="NLM_cas:orgname">Future Medicine Ltd.</span>)
        </div><div class="casAbstract">A review.  Ibrutinib (formerly PCI-32765) is a potent, covalent inhibitor of Bruton's tyrosine kinase, a kinase downstream of the B-cell receptor that is crit. for B-cell survival and proliferation.  In preclin. studies, ibrutinib bound to Bruton's tyrosine kinase with high affinity, leading to inhibition of B-cell receptor signaling, decreased B-cell activation and induction of apoptosis.  In clin. studies, ibrutinib has been well-tolerated and has demonstrated profound anti-tumor activity in a variety of hematol. malignancies, most notably chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL), leading to US FDA approval for relapsed CLL and MCL.  Ongoing studies are evaluating ibrutinib in other types of non-Hodgkin's lymphoma, such as diffuse large B-cell lymphoma and Waldenstroem's macrogobulinemia, in larger Phase III studies in CLL and MCL, and in combination studies with monoclonal antibodies and chemotherapy.  Future studies will combine ibrutinib with other promising novel agents currently in development in hematol. malignancies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr3o_pMnFVskLVg90H21EOLACvtfcHk0ljiMMIMPhQjNQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXpvFCrtbc%253D&md5=345b4e839a830be822d474f62755a022</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.2217%2Ffon.14.51&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2217%252Ffon.14.51%26sid%3Dliteratum%253Aachs%26aulast%3DDavids%26aufirst%3DM.%2BS.%26aulast%3DBrown%26aufirst%3DJ.%2BR.%26atitle%3DIbrutinib%253A%2520a%2520first%2520in%2520class%2520covalent%2520inhibitor%2520of%2520Bruton%25E2%2580%2599s%2520Tyrosine%2520Kinase%26jtitle%3DFuture%2520Oncol.%26date%3D2014%26volume%3D10%26spage%3D957%26epage%3D967%26doi%3D10.2217%2Ffon.14.51" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, W. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmitz, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pittaluga, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wright, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lih, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaffer, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerecitano, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Vos, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kenkre, V. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barr, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blum, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shustov, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Advani, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fowler, N. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vose, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elstrom, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Habermann, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrientos, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGreivy, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fardis, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, B. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clow, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Munneke, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moussa, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beaupre, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Staudt, L. M.</span></span> <span> </span><span class="NLM_article-title">Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma</span>. <i>Nat. Med.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">922</span>– <span class="NLM_lpage">926</span>, <span class="refDoi"> DOI: 10.1038/nm.3884</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01346&amp;key=10.1038%2Fnm.3884" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01346&amp;key=26193343" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01346&amp;key=1%3ACAS%3A528%3ADC%252BC2MXht1WltLjK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2015&pages=922-926&author=W.+H.+Wilsonauthor=R.+M.+Youngauthor=R.+Schmitzauthor=Y.+Yangauthor=S.+Pittalugaauthor=G.+Wrightauthor=C.+J.+Lihauthor=P.+M.+Williamsauthor=A.+L.+Shafferauthor=J.+Gerecitanoauthor=S.+de+Vosauthor=A.+Goyauthor=V.+P.+Kenkreauthor=P.+M.+Barrauthor=K.+A.+Blumauthor=A.+Shustovauthor=R.+Advaniauthor=N.+H.+Fowlerauthor=J.+M.+Voseauthor=R.+L.+Elstromauthor=T.+M.+Habermannauthor=J.+C.+Barrientosauthor=J.+McGreivyauthor=M.+Fardisauthor=B.+Y.+Changauthor=F.+Clowauthor=B.+Munnekeauthor=D.+Moussaauthor=D.+M.+Beaupreauthor=L.+M.+Staudt&title=Targeting+B+cell+receptor+signaling+with+ibrutinib+in+diffuse+large+B+cell+lymphoma&doi=10.1038%2Fnm.3884"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma</span></div><div class="casAuthors">Wilson, Wyndham H.; Young, Ryan M.; Schmitz, Roland; Yang, Yandan; Pittaluga, Stefania; Wright, George; Lih, Chih-Jian; Williams, P. Mickey; Shaffer, Arthur L.; Gerecitano, John; de Vos, Sven; Goy, Andre; Kenkre, Vaishalee P.; Barr, Paul M.; Blum, Kristie A.; Shustov, Andrei; Advani, Ranjana; Fowler, Nathan H.; Vose, Julie M.; Elstrom, Rebecca L.; Habermann, Thomas M.; Barrientos, Jacqueline C.; McGreivy, Jesse; Fardis, Maria; Chang, Betty Y.; Clow, Fong; Munneke, Brian; Moussa, Davina; Beaupre, Darrin M.; Staudt, Louis M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">922-926</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The two major subtypes of diffuse large B cell lymphoma (DLBCL)-activated B cell-like (ABC) and germinal center B cell-like (GCB)-arise by distinct mechanisms, with ABC selectively acquiring mutations that target the B cell receptor (BCR), fostering chronic active BCR signaling.  The ABC subtype has a ∼40% cure rate with currently available therapies, which is worse than the rate for GCB DLBCL, and highlights the need for ABC subtype-specific treatment strategies.  We hypothesized that ABC, but not GCB, DLBCL tumors would respond to ibrutinib, an inhibitor of BCR signaling.  In a phase 1/2 clin. trial that involved 80 subjects with relapsed or refractory DLBCL, ibrutinib produced complete or partial responses in 37% (14/38) of those with ABC DLBCL, but in only 5% (1/20) of subjects with GCB DLBCL (P = 0.0106).  ABC tumors with BCR mutations responded to ibrutinib frequently (5/9; 55.5%), esp. those with concomitant myeloid differentiation primary response 88 (MYD88) mutations (4/5; 80%), a result that is consistent with in vitro cooperation between the BCR and MYD88 pathways.  However, the highest no. of responses occurred in ABC tumors that lacked BCR mutations (9/29; 31%), suggesting that oncogenic BCR signaling in ABC does not require BCR mutations and might be initiated by non-genetic mechanisms.  These results support the selective development of ibrutinib for the treatment of ABC DLBCL.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpryc32RWzm77Vg90H21EOLACvtfcHk0ljiMMIMPhQjNQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXht1WltLjK&md5=d3342e8baa16eb379eed112c21d0b4ba</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1038%2Fnm.3884&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm.3884%26sid%3Dliteratum%253Aachs%26aulast%3DWilson%26aufirst%3DW.%2BH.%26aulast%3DYoung%26aufirst%3DR.%2BM.%26aulast%3DSchmitz%26aufirst%3DR.%26aulast%3DYang%26aufirst%3DY.%26aulast%3DPittaluga%26aufirst%3DS.%26aulast%3DWright%26aufirst%3DG.%26aulast%3DLih%26aufirst%3DC.%2BJ.%26aulast%3DWilliams%26aufirst%3DP.%2BM.%26aulast%3DShaffer%26aufirst%3DA.%2BL.%26aulast%3DGerecitano%26aufirst%3DJ.%26aulast%3Dde%2BVos%26aufirst%3DS.%26aulast%3DGoy%26aufirst%3DA.%26aulast%3DKenkre%26aufirst%3DV.%2BP.%26aulast%3DBarr%26aufirst%3DP.%2BM.%26aulast%3DBlum%26aufirst%3DK.%2BA.%26aulast%3DShustov%26aufirst%3DA.%26aulast%3DAdvani%26aufirst%3DR.%26aulast%3DFowler%26aufirst%3DN.%2BH.%26aulast%3DVose%26aufirst%3DJ.%2BM.%26aulast%3DElstrom%26aufirst%3DR.%2BL.%26aulast%3DHabermann%26aufirst%3DT.%2BM.%26aulast%3DBarrientos%26aufirst%3DJ.%2BC.%26aulast%3DMcGreivy%26aufirst%3DJ.%26aulast%3DFardis%26aufirst%3DM.%26aulast%3DChang%26aufirst%3DB.%2BY.%26aulast%3DClow%26aufirst%3DF.%26aulast%3DMunneke%26aufirst%3DB.%26aulast%3DMoussa%26aufirst%3DD.%26aulast%3DBeaupre%26aufirst%3DD.%2BM.%26aulast%3DStaudt%26aufirst%3DL.%2BM.%26atitle%3DTargeting%2520B%2520cell%2520receptor%2520signaling%2520with%2520ibrutinib%2520in%2520diffuse%2520large%2520B%2520cell%2520lymphoma%26jtitle%3DNat.%2520Med.%26date%3D2015%26volume%3D21%26spage%3D922%26epage%3D926%26doi%3D10.1038%2Fnm.3884" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Barf, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Covey, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Izumi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van de Kar, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gulrajani, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Lith, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Hoek, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Zwart, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mittag, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Demont, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verkaik, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krantz, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pearson, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ulrich, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaptein, A.</span></span> <span> </span><span class="NLM_article-title">Acalabrutinib (ACP-196): A covalent Bruton Tyrosine Kinase inhibitor with a differentiated selectivity and in vivo potency profile</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>363</i></span>,  <span class="NLM_fpage">240</span>– <span class="NLM_lpage">252</span>, <span class="refDoi"> DOI: 10.1124/jpet.117.242909</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01346&amp;key=10.1124%2Fjpet.117.242909" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01346&amp;key=28882879" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01346&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtleltrnO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=363&publication_year=2017&pages=240-252&author=T.+Barfauthor=T.+Coveyauthor=R.+Izumiauthor=B.+van+de+Karauthor=M.+Gulrajaniauthor=B.+van+Lithauthor=M.+van+Hoekauthor=E.+de+Zwartauthor=D.+Mittagauthor=D.+Demontauthor=S.+Verkaikauthor=F.+Krantzauthor=P.+G.+Pearsonauthor=R.+Ulrichauthor=A.+Kaptein&title=Acalabrutinib+%28ACP-196%29%3A+A+covalent+Bruton+Tyrosine+Kinase+inhibitor+with+a+differentiated+selectivity+and+in+vivo+potency+profile&doi=10.1124%2Fjpet.117.242909"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Acalabrutinib (ACP-196): a covalent Bruton tyrosine kinase inhibitor with a differentiated selectivity and in vivo potency profile</span></div><div class="casAuthors">Barf, Tjeerd; Covey, Todd; Izumi, Raquel; van de Kar, Bas; Gulrajani, Michael; van Lith, Bart; van Hoek, Maaike; de Zwart, Edwin; Mittag, Diana; Demont, Dennis; Verkaik, Saskia; Krantz, Fanny; Pearson, Paul G.; Ulrich, Roger; Kaptein, Allard</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">363</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">240-252</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Several small-mol. Bruton tyrosine kinase (BTK) inhibitors are in development for B cell malignancies and autoimmune disorders, each characterized by distinct potency and selectivity patterns.  Herein we describe the pharmacol. characterization of BTK inhibitor acalabrutinib [compd. 1, ACP-196 (4-[8- amino-3-[(2S)-1-but-2-ynoylpyrrolidin-2-yl]imidazo[1,5-a]pyrazin1-yl]-N-(2-pyridyl)benzamide)].  Acalabrutinib possesses a reactive butynamide group that binds covalently to Cys481 in BTK.  Relative to the other BTK inhibitors described here, the reduced intrinsic reactivity of acalabrutinib helps to limit inhibition of off-target kinases having cysteine-mediated covalent binding potential.  Acalabrutinib demonstrated higher biochem. and cellular selectivity than ibrutinib and spebrutinib (compds. 2 and 3, resp.).  Importantly, off-target kinases, such as epidermal growth factor receptor (EGFR) and interleukin 2-inducible T cell kinase (ITK), were not inhibited.  Detn. of the inhibitory potential of anti-IgM-induced CD69 expression in human peripheral blood mononuclear cells and whole blood demonstrated that acalabrutinib is a potent functional BTK inhibitor.  In vivo evaluation in mice revealed that acalabrutinib is more potent than ibrutinib and spebrutinib.  Preclin. and clin. studies showed that the level and duration of BTK occupancy correlates with in vivo efficacy.  Evaluation of the pharmacokinetic properties of acalabrutinib in healthy adult volunteers demonstrated rapid absorption and fast elimination.  In these healthy individuals, a single oral dose of 100 mg showed approx. 99% median target coverage at 3 and 12 h and around 90% at 24 h in peripheral B cells.  In conclusion, acalabrutinib is a BTK inhibitor with key pharmacol. differentiators vs. ibrutinib and spebrutinib and is currently being evaluated in clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGol9xhDmwvup7Vg90H21EOLACvtfcHk0ljt6cpBXVlahA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtleltrnO&md5=73cbd3a87396abbf8cb20e4361f96f64</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1124%2Fjpet.117.242909&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.117.242909%26sid%3Dliteratum%253Aachs%26aulast%3DBarf%26aufirst%3DT.%26aulast%3DCovey%26aufirst%3DT.%26aulast%3DIzumi%26aufirst%3DR.%26aulast%3Dvan%2Bde%2BKar%26aufirst%3DB.%26aulast%3DGulrajani%26aufirst%3DM.%26aulast%3Dvan%2BLith%26aufirst%3DB.%26aulast%3Dvan%2BHoek%26aufirst%3DM.%26aulast%3Dde%2BZwart%26aufirst%3DE.%26aulast%3DMittag%26aufirst%3DD.%26aulast%3DDemont%26aufirst%3DD.%26aulast%3DVerkaik%26aufirst%3DS.%26aulast%3DKrantz%26aufirst%3DF.%26aulast%3DPearson%26aufirst%3DP.%2BG.%26aulast%3DUlrich%26aufirst%3DR.%26aulast%3DKaptein%26aufirst%3DA.%26atitle%3DAcalabrutinib%2520%2528ACP-196%2529%253A%2520A%2520covalent%2520Bruton%2520Tyrosine%2520Kinase%2520inhibitor%2520with%2520a%2520differentiated%2520selectivity%2520and%2520in%2520vivo%2520potency%2520profile%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2017%26volume%3D363%26spage%3D240%26epage%3D252%26doi%3D10.1124%2Fjpet.117.242909" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lim, K.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romero, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chaudhary, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robinson, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Staudt, L. M.</span></span> <span> </span><span class="NLM_article-title">IRAK4 kinase as a novel therapeutic target in the ABC subtype of diffuse large B cell lymphoma</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>120</i></span>,  <span class="NLM_fpage">62</span>, <span class="refDoi"> DOI: 10.1182/blood.V120.21.62.62</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01346&amp;key=10.1182%2Fblood.V120.21.62.62" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=120&publication_year=2012&pages=62&author=K.-H.+Limauthor=D.+L.+Romeroauthor=D.+Chaudharyauthor=S.+D.+Robinsonauthor=L.+M.+Staudt&title=IRAK4+kinase+as+a+novel+therapeutic+target+in+the+ABC+subtype+of+diffuse+large+B+cell+lymphoma&doi=10.1182%2Fblood.V120.21.62.62"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1182%2Fblood.V120.21.62.62&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood.V120.21.62.62%26sid%3Dliteratum%253Aachs%26aulast%3DLim%26aufirst%3DK.-H.%26aulast%3DRomero%26aufirst%3DD.%2BL.%26aulast%3DChaudhary%26aufirst%3DD.%26aulast%3DRobinson%26aufirst%3DS.%2BD.%26aulast%3DStaudt%26aufirst%3DL.%2BM.%26atitle%3DIRAK4%2520kinase%2520as%2520a%2520novel%2520therapeutic%2520target%2520in%2520the%2520ABC%2520subtype%2520of%2520diffuse%2520large%2520B%2520cell%2520lymphoma%26jtitle%3DBlood%26date%3D2012%26volume%3D120%26spage%3D62%26doi%3D10.1182%2Fblood.V120.21.62.62" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Suzuki, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suzuki, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duncan, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Millar, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wada, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mirtsos, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takada, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wakeham, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Itie, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Penninger, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wesche, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohashi, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mak, T. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeh, W. C.</span></span> <span> </span><span class="NLM_article-title">Severe impairment of interleukin-1 and Toll-like receptor signalling in mice lacking IRAK-4</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>416</i></span>,  <span class="NLM_fpage">750</span>– <span class="NLM_lpage">756</span>, <span class="refDoi"> DOI: 10.1038/nature736</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01346&amp;key=10.1038%2Fnature736" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01346&amp;key=11923871" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01346&amp;key=1%3ACAS%3A528%3ADC%252BD38XjtVKksb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=416&publication_year=2002&pages=750-756&author=N.+Suzukiauthor=S.+Suzukiauthor=G.+S.+Duncanauthor=D.+G.+Millarauthor=T.+Wadaauthor=C.+Mirtsosauthor=H.+Takadaauthor=A.+Wakehamauthor=A.+Itieauthor=S.+Liauthor=J.+M.+Penningerauthor=H.+Wescheauthor=P.+S.+Ohashiauthor=T.+W.+Makauthor=W.+C.+Yeh&title=Severe+impairment+of+interleukin-1+and+Toll-like+receptor+signalling+in+mice+lacking+IRAK-4&doi=10.1038%2Fnature736"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Severe impairment of interleukin-1 and Toll-like receptor signaling in mice lacking IRAK-4</span></div><div class="casAuthors">Suzuki, N.; Suzuki, S.; Duncan, G. S.; Millar, D. G.; Wada, T.; Mirtsos, C.; Takada, H.; Wakeham, A.; Itie, A.; Li, S.; Penninger, J. M.; Wesche, H.; Ohashi, P. S.; Mak, T. W.; Yeh, W. C.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">416</span>
        (<span class="NLM_cas:issue">6882</span>),
    <span class="NLM_cas:pages">750-756</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Toll-like receptors (TLRs), which recognize pathogen-assocd. mol. patterns, and members of the pro-inflammatory interleukin-1 receptor (IL-1R) family, share homologies in their cytoplasmic domains called Toll/IL-1R/plant R gene homol. (TIR) domains.  Intracellular signaling mechanisms mediated by TLRs are similar, with MyD88 and TRAF6 having crit. roles.  Signal transduction between MyD88 and TRAF6 is known to involve the serine-threonine kinase IL-1 receptor-assocd. kinase 1 (IRAK-1) and two homologous proteins, IRAK-2 and IRAK-M.  However, the physiol. functions of the IRAK mols. remain unclear, and gene-targeting studies have shown that IRAK-1 is only partially required for IL-1R and TLR signaling.  Here we show by gene-targeting that IRAK-4, an IRAK mol. closely related to the Drosophila Pelle protein, is indispensable for the responses of animals and cultured cells to IL-1 and ligands that stimulate various TLRs.  IRAK-4-deficient animals are completely resistant to a LD of lipopolysaccharide (LPS).  In addn., animals lacking IRAK-4 are severely impaired in their responses to viral and bacterial challenges.  Our results indicate that IRAK-4 has an essential role in innate immunity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrtPWpLv8IBGbVg90H21EOLACvtfcHk0ljt6cpBXVlahA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XjtVKksb4%253D&md5=3cab6526ac8aa58532f50c5bfb364e5c</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1038%2Fnature736&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature736%26sid%3Dliteratum%253Aachs%26aulast%3DSuzuki%26aufirst%3DN.%26aulast%3DSuzuki%26aufirst%3DS.%26aulast%3DDuncan%26aufirst%3DG.%2BS.%26aulast%3DMillar%26aufirst%3DD.%2BG.%26aulast%3DWada%26aufirst%3DT.%26aulast%3DMirtsos%26aufirst%3DC.%26aulast%3DTakada%26aufirst%3DH.%26aulast%3DWakeham%26aufirst%3DA.%26aulast%3DItie%26aufirst%3DA.%26aulast%3DLi%26aufirst%3DS.%26aulast%3DPenninger%26aufirst%3DJ.%2BM.%26aulast%3DWesche%26aufirst%3DH.%26aulast%3DOhashi%26aufirst%3DP.%2BS.%26aulast%3DMak%26aufirst%3DT.%2BW.%26aulast%3DYeh%26aufirst%3DW.%2BC.%26atitle%3DSevere%2520impairment%2520of%2520interleukin-1%2520and%2520Toll-like%2520receptor%2520signalling%2520in%2520mice%2520lacking%2520IRAK-4%26jtitle%3DNature%26date%3D2002%26volume%3D416%26spage%3D750%26epage%3D756%26doi%3D10.1038%2Fnature736" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Degorce, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anjum, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dillman, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drew, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Groombridge, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Halsall, C. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lenz, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindsay, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mayo, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pink, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robb, G. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scott, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stokes, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xue, Y.</span></span> <span> </span><span class="NLM_article-title">Optimization of permeability in a series of pyrrolotriazine inhibitors of IRAK4</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">913</span>– <span class="NLM_lpage">924</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2018.01.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01346&amp;key=10.1016%2Fj.bmc.2018.01.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01346&amp;key=29398441" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01346&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisVSitLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2018&pages=913-924&author=S.+L.+Degorceauthor=R.+Anjumauthor=K.+S.+Dillmanauthor=L.+Drewauthor=S.+D.+Groombridgeauthor=C.+T.+Halsallauthor=E.+M.+Lenzauthor=N.+A.+Lindsayauthor=M.+F.+Mayoauthor=J.+H.+Pinkauthor=G.+R.+Robbauthor=J.+S.+Scottauthor=S.+Stokesauthor=Y.+Xue&title=Optimization+of+permeability+in+a+series+of+pyrrolotriazine+inhibitors+of+IRAK4&doi=10.1016%2Fj.bmc.2018.01.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Optimization of permeability in a series of pyrrolotriazine inhibitors of IRAK4</span></div><div class="casAuthors">Degorce, Sebastien L.; Anjum, Rana; Dillman, Keith S.; Drew, Lisa; Groombridge, Sam D.; Halsall, Christopher T.; Lenz, Eva M.; Lindsay, Nicola A.; Mayo, Michele F.; Pink, Jennifer H.; Robb, Graeme R.; Scott, James S.; Stokes, Stephen; Xue, Yafeng</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">913-924</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The authors have developed a series of orally efficacious IRAK4 inhibitors, based on a scaffold hopping strategy and using rational structure based design.  Efforts to tackle low permeability and high efflux in the authors' previously reported pyrrolopyrimidine series (Scott et al., 2017) led to the identification of pyrrolotriazines which contained one less formal hydrogen bond donor and were intrinsically more lipophilic.  Further optimization of substituents on this pyrrolotriazine core culminated with the discovery of compd. 30 (trans-1-(4-(4-((5-isopropylpyrrolo[2,1-f]-[1,2,4]triazin-4-yl)amino)cyclohexyl)piperazin-1-yl)ethanone) as a promising in vivo probe to assess the potential of IRAK4 inhibition for the treatment of MyD88 mutant Diffuse Large B Cell Lymphoma (DLBCL) in combination with a BTK inhibitor.  When tested in an ABC-DLBCL model with a dual MyD88/CD79 mutation (OCI-LY10), 30 demonstrated tumor regressions in combination with ibrutinib.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrao5i7H0tVFrVg90H21EOLACvtfcHk0ljt6cpBXVlahA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisVSitLc%253D&md5=772fab4ca7c899bb85bcd9ea8a9d47f3</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2018.01.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2018.01.008%26sid%3Dliteratum%253Aachs%26aulast%3DDegorce%26aufirst%3DS.%2BL.%26aulast%3DAnjum%26aufirst%3DR.%26aulast%3DDillman%26aufirst%3DK.%2BS.%26aulast%3DDrew%26aufirst%3DL.%26aulast%3DGroombridge%26aufirst%3DS.%2BD.%26aulast%3DHalsall%26aufirst%3DC.%2BT.%26aulast%3DLenz%26aufirst%3DE.%2BM.%26aulast%3DLindsay%26aufirst%3DN.%2BA.%26aulast%3DMayo%26aufirst%3DM.%2BF.%26aulast%3DPink%26aufirst%3DJ.%2BH.%26aulast%3DRobb%26aufirst%3DG.%2BR.%26aulast%3DScott%26aufirst%3DJ.%2BS.%26aulast%3DStokes%26aufirst%3DS.%26aulast%3DXue%26aufirst%3DY.%26atitle%3DOptimization%2520of%2520permeability%2520in%2520a%2520series%2520of%2520pyrrolotriazine%2520inhibitors%2520of%2520IRAK4%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2018%26volume%3D26%26spage%3D913%26epage%3D924%26doi%3D10.1016%2Fj.bmc.2018.01.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kelly, P. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romero, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaffer, A. L.,  3rd</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chaudhary, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robinson, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miao, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rui, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Westlin, W. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kapeller, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Staudt, L. M.</span></span> <span> </span><span class="NLM_article-title">Selective Interleukin-1 Receptor-Associated Kinase 4 inhibitors for the treatment of autoimmune disorders and lymphoid malignancy</span>. <i>J. Exp. Med.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>212</i></span>,  <span class="NLM_fpage">2189</span>– <span class="NLM_lpage">2201</span>, <span class="refDoi"> DOI: 10.1084/jem.20151074</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01346&amp;key=10.1084%2Fjem.20151074" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01346&amp;key=26621451" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01346&amp;key=1%3ACAS%3A528%3ADC%252BC28XjtlSgu7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=212&publication_year=2015&pages=2189-2201&author=P.+N.+Kellyauthor=D.+L.+Romeroauthor=Y.+Yangauthor=A.+L.+Shafferauthor=D.+Chaudharyauthor=S.+Robinsonauthor=W.+Miaoauthor=L.+Ruiauthor=W.+F.+Westlinauthor=R.+Kapellerauthor=L.+M.+Staudt&title=Selective+Interleukin-1+Receptor-Associated+Kinase+4+inhibitors+for+the+treatment+of+autoimmune+disorders+and+lymphoid+malignancy&doi=10.1084%2Fjem.20151074"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Selective interleukin-1 receptor-associated kinase 4 inhibitors for the treatment of autoimmune disorders and lymphoid malignancy</span></div><div class="casAuthors">Kelly, Priscilla N.; Romero, Donna L.; Yang, Yibin; Shaffer, Arthur L., III; Chaudhary, Divya; Robinson, Shaughnessy; Miao, Wenyan; Rui, Lixin; Westlin, William F.; Kapeller, Rosana; Staudt, Louis M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Experimental Medicine</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">212</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">2189-2201</span>CODEN:
                <span class="NLM_cas:coden">JEMEAV</span>;
        ISSN:<span class="NLM_cas:issn">1540-9538</span>.
    
            (<span class="NLM_cas:orgname">Rockefeller University Press</span>)
        </div><div class="casAbstract">Pathol. activation of the Toll-like receptor signaling adaptor protein MYD88 underlies many autoimmune and inflammatory disease states.  In the activated B cell-like (ABC) subtype of diffuse large B cell lymphoma (DLB CL), the oncogenic MYD88 L265P mutation occurs in 29% of cases, making it the most prevalent activating mutation in this malignancy.  IRAK4 kinase accounts for almost all of the biol. functions of MYD88, highlighting IRAK4 as a therapeutic target for diseases driven by aberrant MYD88 signaling.  Using innovative structure-based drug design methodologies, we report the development of highly selective and bioavailable small mol. IRAK4 inhibitors, ND-2158 and ND-2110.  These small mols. suppressed LPS-induced TNF prodn., alleviated collagen-induced arthritis, and blocked gout formation in mouse models.  IRAK4 inhibition promoted killing of ABC DLB CL lines harboring MYD88 L265P, by down-modulating survival signals, including NF-κB and autocrine IL-6/IL-10 engagement of the JAK-STAT3 pathway.  In ABC DLB CL xenograft models, IRAK4 inhibition suppressed tumor growth as a single agent, and in combination with the Bruton's tyrosine kinase (BTK) inhibitor ibrutinib or the Bcl-2 inhibitor ABT-199.  Our findings support pharmacol. inhibition of IRAK4 as a therapeutic strategy in autoimmune disorders, in a genetically defined population of ABC DLB CL, and possibly other malignancies dependent on aberrant MYD88 signaling.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoJuS2v8AyXXrVg90H21EOLACvtfcHk0lh7lhZ7LZuv_g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XjtlSgu7s%253D&md5=cf477aff5f649644017cbe5330995a70</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1084%2Fjem.20151074&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1084%252Fjem.20151074%26sid%3Dliteratum%253Aachs%26aulast%3DKelly%26aufirst%3DP.%2BN.%26aulast%3DRomero%26aufirst%3DD.%2BL.%26aulast%3DYang%26aufirst%3DY.%26aulast%3DShaffer%26aufirst%3DA.%2BL.%26aulast%3DChaudhary%26aufirst%3DD.%26aulast%3DRobinson%26aufirst%3DS.%26aulast%3DMiao%26aufirst%3DW.%26aulast%3DRui%26aufirst%3DL.%26aulast%3DWestlin%26aufirst%3DW.%2BF.%26aulast%3DKapeller%26aufirst%3DR.%26aulast%3DStaudt%26aufirst%3DL.%2BM.%26atitle%3DSelective%2520Interleukin-1%2520Receptor-Associated%2520Kinase%25204%2520inhibitors%2520for%2520the%2520treatment%2520of%2520autoimmune%2520disorders%2520and%2520lymphoid%2520malignancy%26jtitle%3DJ.%2520Exp.%2520Med.%26date%3D2015%26volume%3D212%26spage%3D2189%26epage%3D2201%26doi%3D10.1084%2Fjem.20151074" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Scott, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Degorce, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anjum, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Culshaw, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davies, R. M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davies, N. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dillman, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dowling, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drew, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferguson, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Groombridge, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Halsall, C. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hudson, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamont, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindsay, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marden, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mayo, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pease, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perkins, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pink, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robb, G. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McWhirter, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, D.</span></span> <span> </span><span class="NLM_article-title">Discovery and optimisation of pyrrolopyrimidine inhibitors of Interleukin-1 Receptor Associated Kinase 4 (IRAK4) for the treatment of mutant MYD88L265P diffuse large B-cell lymphoma</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">10071</span>– <span class="NLM_lpage">10091</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b01290</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b01290" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01346&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvVOitrjO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=10071-10091&author=J.+S.+Scottauthor=S.+L.+Degorceauthor=R.+Anjumauthor=J.+Culshawauthor=R.+M.+D.+Daviesauthor=N.+L.+Daviesauthor=K.+S.+Dillmanauthor=J.+E.+Dowlingauthor=L.+Drewauthor=A.+D.+Fergusonauthor=S.+D.+Groombridgeauthor=C.+T.+Halsallauthor=J.+A.+Hudsonauthor=S.+Lamontauthor=N.+A.+Lindsayauthor=S.+K.+Mardenauthor=M.+F.+Mayoauthor=J.+E.+Peaseauthor=D.+R.+Perkinsauthor=J.+H.+Pinkauthor=G.+R.+Robbauthor=A.+Rosenauthor=M.+Shenauthor=C.+McWhirterauthor=D.+Wu&title=Discovery+and+optimisation+of+pyrrolopyrimidine+inhibitors+of+Interleukin-1+Receptor+Associated+Kinase+4+%28IRAK4%29+for+the+treatment+of+mutant+MYD88L265P+diffuse+large+B-cell+lymphoma&doi=10.1021%2Facs.jmedchem.7b01290"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and Optimization of Pyrrolopyrimidine Inhibitors of Interleukin-1 Receptor Associated Kinase 4 (IRAK4) for the Treatment of Mutant MYD88L265P Diffuse Large B-Cell Lymphoma</span></div><div class="casAuthors">Scott, James S.; Degorce, Sebastien L.; Anjum, Rana; Culshaw, Janet; Davies, Robert D. M.; Davies, Nichola L.; Dillman, Keith S.; Dowling, James E.; Drew, Lisa; Ferguson, Andrew D.; Groombridge, Sam D.; Halsall, Christopher T.; Hudson, Julian A.; Lamont, Scott; Lindsay, Nicola A.; Marden, Stacey K.; Mayo, Michele F.; Pease, J. Elizabeth; Perkins, David R.; Pink, Jennifer H.; Robb, Graeme R.; Rosen, Alan; Shen, Minhui; McWhirter, Claire; Wu, Dedong</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">10071-10091</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Herein we report the optimization of a series of pyrrolopyrimidine inhibitors of interleukin-1 receptor assocd. kinase 4 (IRAK4) using x-ray crystal structures and structure based design to identify and optimize our scaffold.  Compd. 28 demonstrated a favorable physicochem. and kinase selectivity profile and was identified as a promising in vivo tool with which to explore the role of IRAK4 inhibition in the treatment of mutant MYD88L265P diffuse large B-cell lymphoma (DLBCL).  Compd. 28 was shown to be capable of demonstrating inhibition of NF-κB activation and growth of the ABC subtype of DLBCL cell lines in vitro at high concns. but showed greater effects in combination with a BTK inhibitor at lower concns.  In vivo, the combination of compd. 28 and ibrutinib led to tumor regression in an ABC-DLBCL mouse model.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrBCn7WCzPrrrVg90H21EOLACvtfcHk0lh7lhZ7LZuv_g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvVOitrjO&md5=9760f425ec33b238a43e1de0ec6d24f1</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b01290&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b01290%26sid%3Dliteratum%253Aachs%26aulast%3DScott%26aufirst%3DJ.%2BS.%26aulast%3DDegorce%26aufirst%3DS.%2BL.%26aulast%3DAnjum%26aufirst%3DR.%26aulast%3DCulshaw%26aufirst%3DJ.%26aulast%3DDavies%26aufirst%3DR.%2BM.%2BD.%26aulast%3DDavies%26aufirst%3DN.%2BL.%26aulast%3DDillman%26aufirst%3DK.%2BS.%26aulast%3DDowling%26aufirst%3DJ.%2BE.%26aulast%3DDrew%26aufirst%3DL.%26aulast%3DFerguson%26aufirst%3DA.%2BD.%26aulast%3DGroombridge%26aufirst%3DS.%2BD.%26aulast%3DHalsall%26aufirst%3DC.%2BT.%26aulast%3DHudson%26aufirst%3DJ.%2BA.%26aulast%3DLamont%26aufirst%3DS.%26aulast%3DLindsay%26aufirst%3DN.%2BA.%26aulast%3DMarden%26aufirst%3DS.%2BK.%26aulast%3DMayo%26aufirst%3DM.%2BF.%26aulast%3DPease%26aufirst%3DJ.%2BE.%26aulast%3DPerkins%26aufirst%3DD.%2BR.%26aulast%3DPink%26aufirst%3DJ.%2BH.%26aulast%3DRobb%26aufirst%3DG.%2BR.%26aulast%3DRosen%26aufirst%3DA.%26aulast%3DShen%26aufirst%3DM.%26aulast%3DMcWhirter%26aufirst%3DC.%26aulast%3DWu%26aufirst%3DD.%26atitle%3DDiscovery%2520and%2520optimisation%2520of%2520pyrrolopyrimidine%2520inhibitors%2520of%2520Interleukin-1%2520Receptor%2520Associated%2520Kinase%25204%2520%2528IRAK4%2529%2520for%2520the%2520treatment%2520of%2520mutant%2520MYD88L265P%2520diffuse%2520large%2520B-cell%2520lymphoma%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D10071%26epage%3D10091%26doi%3D10.1021%2Facs.jmedchem.7b01290" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Genung, N. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guckian, K. M.</span></span> <span> </span><span class="NLM_article-title">Small molecule inhibition of Interleukin-1 Receptor-Associated Kinase 4 (IRAK4)</span>. <i>Prog. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">117</span>– <span class="NLM_lpage">163</span>, <span class="refDoi"> DOI: 10.1016/bs.pmch.2016.11.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01346&amp;key=10.1016%2Fbs.pmch.2016.11.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01346&amp;key=28314411" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01346&amp;key=1%3ACAS%3A280%3ADC%252BC1czot12hsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2017&pages=117-163&author=N.+E.+Genungauthor=K.+M.+Guckian&title=Small+molecule+inhibition+of+Interleukin-1+Receptor-Associated+Kinase+4+%28IRAK4%29&doi=10.1016%2Fbs.pmch.2016.11.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Small Molecule Inhibition of Interleukin-1 Receptor-Associated Kinase 4 (IRAK4)</span></div><div class="casAuthors">Genung N E; Guckian K M</div><div class="citationInfo"><span class="NLM_cas:title">Progress in medicinal chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">117-163</span>
        ISSN:<span class="NLM_cas:issn">0079-6468</span>.
    </div><div class="casAbstract">In recent years, interleukin-1 receptor-associated kinase 4, IRAK4, has become an attractive target for many medicinal chemistry programmes.  Target inhibition is of potential therapeutic value in areas including autoimmune disorders, cancer, inflammatory diseases, and possibly neurodegenerative diseases.  Results from high-throughput screening efforts have led, in conjunction with structure-based drug design, to the identification of highly potent and selective small molecule IRAK4 inhibitors from many diverse chemical series.  In vitro and in vivo studies with entities from distinct structural classes have helped elucidate the downstream pharmacological responses associated with IRAK4 inhibition as a proof of concept in disease models, leading to the recent initiation of human clinical trials.  Within this review, we will highlight the considerable effort by numerous groups dedicated to the development of small molecule IRAK4 inhibitors for the treatment of human disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRZNiMykZj_Wv6xYuD7tu2XfW6udTcc2ebYjFe_fFQgBLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1czot12hsg%253D%253D&md5=30805b2fb55ac3e6be120a7557c0f24c</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1016%2Fbs.pmch.2016.11.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fbs.pmch.2016.11.004%26sid%3Dliteratum%253Aachs%26aulast%3DGenung%26aufirst%3DN.%2BE.%26aulast%3DGuckian%26aufirst%3DK.%2BM.%26atitle%3DSmall%2520molecule%2520inhibition%2520of%2520Interleukin-1%2520Receptor-Associated%2520Kinase%25204%2520%2528IRAK4%2529%26jtitle%3DProg.%2520Med.%2520Chem.%26date%3D2017%26volume%3D56%26spage%3D117%26epage%3D163%26doi%3D10.1016%2Fbs.pmch.2016.11.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McElroy, W. T.</span></span> <span> </span><span class="NLM_article-title">Interleukin-1 Receptor-Associated Kinase 4 (IRAK4) inhibitors: an updated patent review (2016-2018)</span>. <i>Expert Opin. Ther. Pat.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">243</span>– <span class="NLM_lpage">259</span>, <span class="refDoi"> DOI: 10.1080/13543776.2019.1597850</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01346&amp;key=10.1080%2F13543776.2019.1597850" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01346&amp;key=30916602" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01346&amp;key=1%3ACAS%3A528%3ADC%252BC1MXmtFKntrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2019&pages=243-259&author=W.+T.+McElroy&title=Interleukin-1+Receptor-Associated+Kinase+4+%28IRAK4%29+inhibitors%3A+an+updated+patent+review+%282016-2018%29&doi=10.1080%2F13543776.2019.1597850"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitors: an updated patent review (2016-2018)</span></div><div class="casAuthors">McElroy, William T.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Patents</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">243-259</span>CODEN:
                <span class="NLM_cas:coden">EOTPEG</span>;
        ISSN:<span class="NLM_cas:issn">1354-3776</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">A review.  : Interleukin-1 receptor-assocd. kinase 4 (IRAK4) is the most upstream kinase in Toll/Interleukin-1 receptor (TIR) signaling.  Human and rodent genetics support the role of IRAK4 in immune function and the involvement of IRAK4-dependent signaling in certain cancers is hypothesized.  The accumulating evidence has motivated the discovery of IRAK4 inhibitors that could be used therapeutically.: This review summarizes patents published in 2016-2018 claiming IRAK4 inhibitors.  Representative analogs from each patent are presented with a focus on compds. that have been profiled in cellular and in vivo assays.: The last three years have seen an increased no. of IRAK4 inhibitors with which to assess the therapeutic potential of the target.  At least 5 companies are believed to have advanced to the clinic.  Pfizer is in phase II for rheumatoid arthritis (RA).  The outcomes of these studies should inform on the therapeutic potential in autoimmune disease and cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqsRn4myhM3hrVg90H21EOLACvtfcHk0lhGvPRUS3SQ3g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXmtFKntrs%253D&md5=0da99e75950dba1d5f0c1ecc1dea0b47</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1080%2F13543776.2019.1597850&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F13543776.2019.1597850%26sid%3Dliteratum%253Aachs%26aulast%3DMcElroy%26aufirst%3DW.%2BT.%26atitle%3DInterleukin-1%2520Receptor-Associated%2520Kinase%25204%2520%2528IRAK4%2529%2520inhibitors%253A%2520an%2520updated%2520patent%2520review%2520%25282016-2018%2529%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Pat.%26date%3D2019%26volume%3D29%26spage%3D243%26epage%3D259%26doi%3D10.1080%2F13543776.2019.1597850" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ambler, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boscoe, B. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bree, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brodfuehrer, J. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chung, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Curran, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Day, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dehnhardt, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dower, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drozda, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frisbie, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gavrin, L. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldberg, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hegen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hepworth, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hope, H. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kamtekar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kilty, I. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, L. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lovering, F. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lowe, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathias, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morgan, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murphy, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Papaioannou, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patny, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pierce, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rao, V. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saiah, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Samardjiev, I. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Samas, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, M. W. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shin, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soutter, H. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strohbach, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Symanowicz, P. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomason, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trzupek, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vargas, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vincent, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zapf, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wright, S. W.</span></span> <span> </span><span class="NLM_article-title">Discovery of clinical candidate 1-{[(2S,3S,4S)-3-ethyl-4-fluoro-5-oxopyrrolidin-2-yl]methoxy}-7-methoxyisoquinoline-6-carboxamide (PF-06650833), a potent, selective inhibitor of Interleukin-1 Receptor Associated Kinase 4 (IRAK4), by fragment-based drug design</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">5521</span>– <span class="NLM_lpage">5542</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b00231</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b00231" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01346&amp;key=1%3ACAS%3A528%3ADC%252BC2sXnslGqu7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=5521-5542&author=K.+L.+Leeauthor=C.+M.+Amblerauthor=D.+R.+Andersonauthor=B.+P.+Boscoeauthor=A.+G.+Breeauthor=J.+I.+Brodfuehrerauthor=J.+S.+Changauthor=C.+Choiauthor=S.+Chungauthor=K.+J.+Curranauthor=J.+E.+Dayauthor=C.+M.+Dehnhardtauthor=K.+Dowerauthor=S.+E.+Drozdaauthor=R.+K.+Frisbieauthor=L.+K.+Gavrinauthor=J.+A.+Goldbergauthor=S.+Hanauthor=M.+Hegenauthor=D.+Hepworthauthor=H.+R.+Hopeauthor=S.+Kamtekarauthor=I.+C.+Kiltyauthor=A.+Leeauthor=L.+L.+Linauthor=F.+E.+Loveringauthor=M.+D.+Loweauthor=J.+P.+Mathiasauthor=H.+M.+Morganauthor=E.+A.+Murphyauthor=N.+Papaioannouauthor=A.+Patnyauthor=B.+S.+Pierceauthor=V.+R.+Raoauthor=E.+Saiahauthor=I.+J.+Samardjievauthor=B.+M.+Samasauthor=M.+W.+H.+Shenauthor=J.+H.+Shinauthor=H.+H.+Soutterauthor=J.+W.+Strohbachauthor=P.+T.+Symanowiczauthor=J.+R.+Thomasonauthor=J.+D.+Trzupekauthor=R.+Vargasauthor=F.+Vincentauthor=J.+Yanauthor=C.+W.+Zapfauthor=S.+W.+Wright&title=Discovery+of+clinical+candidate+1-%7B%5B%282S%2C3S%2C4S%29-3-ethyl-4-fluoro-5-oxopyrrolidin-2-yl%5Dmethoxy%7D-7-methoxyisoquinoline-6-carboxamide+%28PF-06650833%29%2C+a+potent%2C+selective+inhibitor+of+Interleukin-1+Receptor+Associated+Kinase+4+%28IRAK4%29%2C+by+fragment-based+drug+design&doi=10.1021%2Facs.jmedchem.7b00231"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Clinical Candidate 1-{[(2S,3S,4S)-3-Ethyl-4-fluoro-5-oxopyrrolidin-2-yl]methoxy}-7-methoxyisoquinoline-6-carboxamide (PF-06650833), a Potent, Selective Inhibitor of Interleukin-1 Receptor Associated Kinase 4 (IRAK4), by Fragment-Based Drug Design</span></div><div class="casAuthors">Lee, Katherine L.; Ambler, Catherine M.; Anderson, David R.; Boscoe, Brian P.; Bree, Andrea G.; Brodfuehrer, Joanne I.; Chang, Jeanne S.; Choi, Chulho; Chung, Seungwon; Curran, Kevin J.; Day, Jacqueline E.; Dehnhardt, Christoph M.; Dower, Ken; Drozda, Susan E.; Frisbie, Richard K.; Gavrin, Lori K.; Goldberg, Joel A.; Han, Seungil; Hegen, Martin; Hepworth, David; Hope, Heidi R.; Kamtekar, Satwik; Kilty, Iain C.; Lee, Arthur; Lin, Lih-Ling; Lovering, Frank E.; Lowe, Michael D.; Mathias, John P.; Morgan, Heidi M.; Murphy, Elizabeth A.; Papaioannou, Nikolaos; Patny, Akshay; Pierce, Betsy S.; Rao, Vikram R.; Saiah, Eddine; Samardjiev, Ivan J.; Samas, Brian M.; Shen, Marina W. H.; Shin, Julia H.; Soutter, Holly H.; Strohbach, Joseph W.; Symanowicz, Peter T.; Thomason, Jennifer R.; Trzupek, John D.; Vargas, Richard; Vincent, Fabien; Yan, Jiangli; Zapf, Christoph W.; Wright, Stephen W.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">5521-5542</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Through fragment-based drug design focused on engaging the active site of IRAK4 and leveraging three-dimensional topol. in a ligand-efficient manner, a micromolar hit identified from a screen of a Pfizer fragment library was optimized to afford IRAK4 inhibitors with nanomolar potency in cellular assays.  The medicinal chem. effort featured the judicious placement of lipophilicity, informed by cocrystal structures with IRAK4 and optimization of ADME properties to deliver clin. candidate I.  This compd. benefitted from a 5-unit increase in lipophilic efficiency from the fragment hit, excellent kinase selectivity, and pharmacokinetic properties suitable for oral administration.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpYrCep64bhMbVg90H21EOLACvtfcHk0lhGvPRUS3SQ3g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXnslGqu7c%253D&md5=9771ad2d33089f6ef3dba3556536ff1a</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b00231&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b00231%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DK.%2BL.%26aulast%3DAmbler%26aufirst%3DC.%2BM.%26aulast%3DAnderson%26aufirst%3DD.%2BR.%26aulast%3DBoscoe%26aufirst%3DB.%2BP.%26aulast%3DBree%26aufirst%3DA.%2BG.%26aulast%3DBrodfuehrer%26aufirst%3DJ.%2BI.%26aulast%3DChang%26aufirst%3DJ.%2BS.%26aulast%3DChoi%26aufirst%3DC.%26aulast%3DChung%26aufirst%3DS.%26aulast%3DCurran%26aufirst%3DK.%2BJ.%26aulast%3DDay%26aufirst%3DJ.%2BE.%26aulast%3DDehnhardt%26aufirst%3DC.%2BM.%26aulast%3DDower%26aufirst%3DK.%26aulast%3DDrozda%26aufirst%3DS.%2BE.%26aulast%3DFrisbie%26aufirst%3DR.%2BK.%26aulast%3DGavrin%26aufirst%3DL.%2BK.%26aulast%3DGoldberg%26aufirst%3DJ.%2BA.%26aulast%3DHan%26aufirst%3DS.%26aulast%3DHegen%26aufirst%3DM.%26aulast%3DHepworth%26aufirst%3DD.%26aulast%3DHope%26aufirst%3DH.%2BR.%26aulast%3DKamtekar%26aufirst%3DS.%26aulast%3DKilty%26aufirst%3DI.%2BC.%26aulast%3DLee%26aufirst%3DA.%26aulast%3DLin%26aufirst%3DL.%2BL.%26aulast%3DLovering%26aufirst%3DF.%2BE.%26aulast%3DLowe%26aufirst%3DM.%2BD.%26aulast%3DMathias%26aufirst%3DJ.%2BP.%26aulast%3DMorgan%26aufirst%3DH.%2BM.%26aulast%3DMurphy%26aufirst%3DE.%2BA.%26aulast%3DPapaioannou%26aufirst%3DN.%26aulast%3DPatny%26aufirst%3DA.%26aulast%3DPierce%26aufirst%3DB.%2BS.%26aulast%3DRao%26aufirst%3DV.%2BR.%26aulast%3DSaiah%26aufirst%3DE.%26aulast%3DSamardjiev%26aufirst%3DI.%2BJ.%26aulast%3DSamas%26aufirst%3DB.%2BM.%26aulast%3DShen%26aufirst%3DM.%2BW.%2BH.%26aulast%3DShin%26aufirst%3DJ.%2BH.%26aulast%3DSoutter%26aufirst%3DH.%2BH.%26aulast%3DStrohbach%26aufirst%3DJ.%2BW.%26aulast%3DSymanowicz%26aufirst%3DP.%2BT.%26aulast%3DThomason%26aufirst%3DJ.%2BR.%26aulast%3DTrzupek%26aufirst%3DJ.%2BD.%26aulast%3DVargas%26aufirst%3DR.%26aulast%3DVincent%26aufirst%3DF.%26aulast%3DYan%26aufirst%3DJ.%26aulast%3DZapf%26aufirst%3DC.%2BW.%26aulast%3DWright%26aufirst%3DS.%2BW.%26atitle%3DDiscovery%2520of%2520clinical%2520candidate%25201-%257B%255B%25282S%252C3S%252C4S%2529-3-ethyl-4-fluoro-5-oxopyrrolidin-2-yl%255Dmethoxy%257D-7-methoxyisoquinoline-6-carboxamide%2520%2528PF-06650833%2529%252C%2520a%2520potent%252C%2520selective%2520inhibitor%2520of%2520Interleukin-1%2520Receptor%2520Associated%2520Kinase%25204%2520%2528IRAK4%2529%252C%2520by%2520fragment-based%2520drug%2520design%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D5521%26epage%3D5542%26doi%3D10.1021%2Facs.jmedchem.7b00231" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><a href="https://clinicaltrials.gov/ct2/show/NCT02996500?term=PF-06650833" class="extLink">https://clinicaltrials.gov/ct2/show/NCT02996500?term=PF-06650833</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT02996500%3Fterm%3DPF-06650833."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lindsay-Scott, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clarke, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richardson, J.</span></span> <span> </span><span class="NLM_article-title">Two-step cyanomethylation protocol: convenient access to functionalized aryl- and heteroarylacetonitriles</span>. <i>Org. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">476</span>– <span class="NLM_lpage">479</span>, <span class="refDoi"> DOI: 10.1021/ol503479g</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ol503479g" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01346&amp;key=1%3ACAS%3A528%3ADC%252BC2MXosVOqtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2015&pages=476-479&author=P.+J.+Lindsay-Scottauthor=A.+Clarkeauthor=J.+Richardson&title=Two-step+cyanomethylation+protocol%3A+convenient+access+to+functionalized+aryl-+and+heteroarylacetonitriles&doi=10.1021%2Fol503479g"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Two-Step Cyanomethylation Protocol: Convenient Access to Functionalized Aryl- and Heteroarylacetonitriles</span></div><div class="casAuthors">Lindsay-Scott, Peter J.; Clarke, Aimee; Richardson, Jeffery</div><div class="citationInfo"><span class="NLM_cas:title">Organic Letters</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">476-479</span>CODEN:
                <span class="NLM_cas:coden">ORLEF7</span>;
        ISSN:<span class="NLM_cas:issn">1523-7052</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A two-step protocol has been developed for the introduction of cyanomethylene groups to metalated aroms. through the intermediacy of substituted isoxazoles.  A palladium-mediated cross-coupling reaction was used to introduce the isoxazole unit, followed by release of the cyanomethylene function under thermal or microwave-assisted conditions.  The intermediate isoxazoles were shown to be amenable to further functionalization prior to deprotection of the sensitive cyanomethylene motif, allowing access to a wide range of aryl- and heteroaryl-substituted acetonitrile building blocks.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrLVGuIHMHQvrVg90H21EOLACvtfcHk0lilANl7Z-3cIQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXosVOqtA%253D%253D&md5=e2dedd972367ccaa673fc2423e786830</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1021%2Fol503479g&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fol503479g%26sid%3Dliteratum%253Aachs%26aulast%3DLindsay-Scott%26aufirst%3DP.%2BJ.%26aulast%3DClarke%26aufirst%3DA.%26aulast%3DRichardson%26aufirst%3DJ.%26atitle%3DTwo-step%2520cyanomethylation%2520protocol%253A%2520convenient%2520access%2520to%2520functionalized%2520aryl-%2520and%2520heteroarylacetonitriles%26jtitle%3DOrg.%2520Lett.%26date%3D2015%26volume%3D17%26spage%3D476%26epage%3D479%26doi%3D10.1021%2Fol503479g" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Romero, D. L.</span>; <span class="NLM_string-name">Robinson, S.</span>; <span class="NLM_string-name">Greenwood, J. R.</span>; <span class="NLM_string-name">Shelley, M.</span>; <span class="NLM_string-name">Masse, C.
E.</span>; <span class="NLM_string-name">Harriman, G. C.</span></span> <span> </span><span class="NLM_article-title">Preparation of Quinazoline and Quinoline Derivatives as Interleukin-1 Receptor-Associated Kinases (IRAK) inhibitors</span>. U.S. Patent <span class="NLM_patent">WO2015164374A1</span>, <span class="NLM_year">2015</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&author=D.+L.+Romero&author=S.+Robinson&author=J.+R.+Greenwood&author=M.+Shelley&author=C.%0AE.+Masse&author=G.+C.+Harriman&title=Preparation+of+Quinazoline+and+Quinoline+Derivatives+as+Interleukin-1+Receptor-Associated+Kinases+%28IRAK%29+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DRomero%26aufirst%3DD.%2BL.%26atitle%3DPreparation%2520of%2520Quinazoline%2520and%2520Quinoline%2520Derivatives%2520as%2520Interleukin-1%2520Receptor-Associated%2520Kinases%2520%2528IRAK%2529%2520inhibitors%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Smith, G. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Altman, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andresen, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baker, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brubaker, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Childers, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donofrio, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferguson, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischer, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischmann, T. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gibeau, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hicks, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kattar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kleinschek, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leccese, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lesburg, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lim, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maclean, J. K. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mansoor, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moy, L. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mulrooney, E. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Necheva, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Presland, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rakhilina, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Torres, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang-Hoover, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Northrup, A.</span></span> <span> </span><span class="NLM_article-title">Identification of quinazoline based inhibitors of IRAK4 for the treatment of inflammation</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">2721</span>– <span class="NLM_lpage">2726</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2017.04.050</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01346&amp;key=10.1016%2Fj.bmcl.2017.04.050" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01346&amp;key=28501511" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01346&amp;key=1%3ACAS%3A528%3ADC%252BC2sXnslKhtrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2017&pages=2721-2726&author=G.+F.+Smithauthor=M.+D.+Altmanauthor=B.+Andresenauthor=J.+Bakerauthor=J.+D.+Brubakerauthor=H.+Chenauthor=Y.+Chenauthor=M.+Childersauthor=A.+Donofrioauthor=H.+Fergusonauthor=C.+Fischerauthor=T.+O.+Fischmannauthor=C.+Gibeauauthor=A.+Hicksauthor=S.+Jinauthor=S.+Kattarauthor=M.+A.+Kleinschekauthor=E.+Lecceseauthor=C.+Lesburgauthor=C.+Liauthor=J.+Limauthor=D.+Liuauthor=J.+K.+F.+Macleanauthor=F.+Mansoorauthor=L.+Y.+Moyauthor=E.+F.+Mulrooneyauthor=A.+S.+Nechevaauthor=J.+Preslandauthor=L.+Rakhilinaauthor=R.+Yangauthor=L.+Torresauthor=J.+Zhang-Hooverauthor=A.+Northrup&title=Identification+of+quinazoline+based+inhibitors+of+IRAK4+for+the+treatment+of+inflammation&doi=10.1016%2Fj.bmcl.2017.04.050"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of quinazoline based inhibitors of IRAK4 for the treatment of inflammation</span></div><div class="casAuthors">Smith, Graham F.; Altman, Michael D.; Andresen, Brian; Baker, James; Brubaker, Jason D.; Chen, Hongmin; Chen, Yiping; Childers, Matthew; Donofrio, Anthony; Ferguson, Heidi; Fischer, Christian; Fischmann, Thierry O.; Gibeau, Craig; Hicks, Alexander; Jin, Sue; Kattar, Sam; Kleinschek, Melanie A.; Leccese, Erica; Lesburg, Charles; Li, Chaomin; Lim, Jongwon; Liu, Duan; MacLean, John K. F.; Mansoor, Faruk; Moy, Lilly Y.; Mulrooney, Erin F.; Necheva, Antoaneta S.; Presland, Jeremy; Rakhilina, Larissa; Yang, Ruojing; Torres, Luis; Zhang-Hoover, Jie; Northrup, Alan</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2721-2726</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Interleukin-1 receptor assocd. kinase 4 (IRAK4) has been implicated in IL-1R and TLR based signaling.  Therefore selective inhibition of the kinase activity of this protein represents an attractive target for the treatment of inflammatory diseases.  Medicinal chem. optimization of high throughput screening (HTS) hits with the help of structure based drug design led to the identification of orally-bioavailable quinazoline based IRAK4 inhibitors with excellent pharmacokinetic profile and kinase selectivity.  These highly selective IRAK4 compds. show activity in vivo via oral dosing in a TLR7 driven model of inflammation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpQgzgP8TjUWbVg90H21EOLACvtfcHk0lilANl7Z-3cIQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXnslKhtrk%253D&md5=9a60520e66940d9d96859c6b77cb97a5</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2017.04.050&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2017.04.050%26sid%3Dliteratum%253Aachs%26aulast%3DSmith%26aufirst%3DG.%2BF.%26aulast%3DAltman%26aufirst%3DM.%2BD.%26aulast%3DAndresen%26aufirst%3DB.%26aulast%3DBaker%26aufirst%3DJ.%26aulast%3DBrubaker%26aufirst%3DJ.%2BD.%26aulast%3DChen%26aufirst%3DH.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DChilders%26aufirst%3DM.%26aulast%3DDonofrio%26aufirst%3DA.%26aulast%3DFerguson%26aufirst%3DH.%26aulast%3DFischer%26aufirst%3DC.%26aulast%3DFischmann%26aufirst%3DT.%2BO.%26aulast%3DGibeau%26aufirst%3DC.%26aulast%3DHicks%26aufirst%3DA.%26aulast%3DJin%26aufirst%3DS.%26aulast%3DKattar%26aufirst%3DS.%26aulast%3DKleinschek%26aufirst%3DM.%2BA.%26aulast%3DLeccese%26aufirst%3DE.%26aulast%3DLesburg%26aufirst%3DC.%26aulast%3DLi%26aufirst%3DC.%26aulast%3DLim%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DD.%26aulast%3DMaclean%26aufirst%3DJ.%2BK.%2BF.%26aulast%3DMansoor%26aufirst%3DF.%26aulast%3DMoy%26aufirst%3DL.%2BY.%26aulast%3DMulrooney%26aufirst%3DE.%2BF.%26aulast%3DNecheva%26aufirst%3DA.%2BS.%26aulast%3DPresland%26aufirst%3DJ.%26aulast%3DRakhilina%26aufirst%3DL.%26aulast%3DYang%26aufirst%3DR.%26aulast%3DTorres%26aufirst%3DL.%26aulast%3DZhang-Hoover%26aufirst%3DJ.%26aulast%3DNorthrup%26aufirst%3DA.%26atitle%3DIdentification%2520of%2520quinazoline%2520based%2520inhibitors%2520of%2520IRAK4%2520for%2520the%2520treatment%2520of%2520inflammation%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2017%26volume%3D27%26spage%3D2721%26epage%3D2726%26doi%3D10.1016%2Fj.bmcl.2017.04.050" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fensome, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ambler, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arnold, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banker, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chrencik, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clark, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dowty, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Efremov, I. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flick, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerstenberger, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gopalsamy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hayward, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hegen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hollingshead, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jussif, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knafels, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Limburg, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pierce, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saiah, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Symanowicz, P. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Telliez, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trujillo, J. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vajdos, F. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vincent, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wan, Z. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xing, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span> <span> </span><span class="NLM_article-title">Dual inhibition of TYK2 and JAK1 for the treatment of autoimmune diseases: discovery of ((S)-2,2-difluorocyclopropyl)((1R,5S)-3-(2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octan-8-yl)methanone (PF-06700841)</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">8597</span>– <span class="NLM_lpage">8612</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00917</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00917" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01346&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsFWgtLfI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=8597-8612&author=A.+Fensomeauthor=C.+M.+Amblerauthor=E.+Arnoldauthor=M.+E.+Bankerauthor=M.+F.+Brownauthor=J.+Chrencikauthor=J.+D.+Clarkauthor=M.+E.+Dowtyauthor=I.+V.+Efremovauthor=A.+Flickauthor=B.+S.+Gerstenbergerauthor=A.+Gopalsamyauthor=M.+M.+Haywardauthor=M.+Hegenauthor=B.+D.+Hollingsheadauthor=J.+Jussifauthor=J.+D.+Knafelsauthor=D.+C.+Limburgauthor=D.+Linauthor=T.+H.+Linauthor=B.+S.+Pierceauthor=E.+Saiahauthor=R.+Sharmaauthor=P.+T.+Symanowiczauthor=J.+B.+Telliezauthor=J.+I.+Trujilloauthor=F.+F.+Vajdosauthor=F.+Vincentauthor=Z.+K.+Wanauthor=L.+Xingauthor=X.+Yangauthor=X.+Yangauthor=L.+Zhang&title=Dual+inhibition+of+TYK2+and+JAK1+for+the+treatment+of+autoimmune+diseases%3A+discovery+of+%28%28S%29-2%2C2-difluorocyclopropyl%29%28%281R%2C5S%29-3-%282-%28%281-methyl-1H-pyrazol-4-yl%29amino%29pyrimidin-4-yl%29-3%2C8-diazabicyclo%5B3.2.1%5Doctan-8-yl%29methanone+%28PF-06700841%29&doi=10.1021%2Facs.jmedchem.8b00917"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Dual Inhibition of TYK2 and JAK1 for the Treatment of Autoimmune Diseases: Discovery of ((S)-2,2-Difluorocyclopropyl)((1R,5S)-3-(2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octan-8-yl)methanone (PF-06700841)</span></div><div class="casAuthors">Fensome, Andrew; Ambler, Catherine M.; Arnold, Eric; Banker, Mary Ellen; Brown, Matthew F.; Chrencik, Jill; Clark, James D.; Dowty, Martin E.; Efremov, Ivan V.; Flick, Andrew; Gerstenberger, Brian S.; Gopalsamy, Ariamala; Hayward, Matthew M.; Hegen, Martin; Hollingshead, Brett D.; Jussif, Jason; Knafels, John D.; Limburg, David C.; Lin, David; Lin, Tsung H.; Pierce, Betsy S.; Saiah, Eddine; Sharma, Raman; Symanowicz, Peter T.; Telliez, Jean-Baptiste; Trujillo, John I.; Vajdos, Felix F.; Vincent, Fabien; Wan, Zhao-Kui; Xing, Li; Yang, Xiaojing; Yang, Xin; Zhang, Liying</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">8597-8612</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Cytokine signaling is an important characteristic of autoimmune diseases.  Many pro-inflammatory cytokines signal through the Janus kinase (JAK)/Signal transducer and activator of transcription (STAT) pathway.  JAK1 is important for the γ-common chain cytokines, interleukin (IL)-6 and type-I interferon (IFN) family, while TYK2 in addn. to type-I IFN signaling also plays a role in IL-23 and IL-12 signaling.  Intervention with monoclonal antibodies (mAbs) or JAK1 inhibitors has demonstrated efficacy in Phase III psoriasis, psoriatic arthritis, inflammatory bowel disease and rheumatoid arthritis studies, leading to multiple drug approvals.  It is hypothesized that a dual JAK1/TYK2 inhibitor will provide addnl. efficacy, while managing risk by optimizing selectivity against JAK2 driven hematopoietic changes.  Our program began with a conformationally constrained piperazinyl-pyrimidine Type 1 ATP site inhibitor, subsequent work led to the discovery of PF-06700841 (compd. 23), which is in Phase II clin. development (NCT02969018, NCT02958865, NCT03395184, and NCT02974868).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqWNhVkNWDMq7Vg90H21EOLACvtfcHk0ljC8WoBEPK9xw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsFWgtLfI&md5=c321512f524560cba445d070b9639e55</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00917&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00917%26sid%3Dliteratum%253Aachs%26aulast%3DFensome%26aufirst%3DA.%26aulast%3DAmbler%26aufirst%3DC.%2BM.%26aulast%3DArnold%26aufirst%3DE.%26aulast%3DBanker%26aufirst%3DM.%2BE.%26aulast%3DBrown%26aufirst%3DM.%2BF.%26aulast%3DChrencik%26aufirst%3DJ.%26aulast%3DClark%26aufirst%3DJ.%2BD.%26aulast%3DDowty%26aufirst%3DM.%2BE.%26aulast%3DEfremov%26aufirst%3DI.%2BV.%26aulast%3DFlick%26aufirst%3DA.%26aulast%3DGerstenberger%26aufirst%3DB.%2BS.%26aulast%3DGopalsamy%26aufirst%3DA.%26aulast%3DHayward%26aufirst%3DM.%2BM.%26aulast%3DHegen%26aufirst%3DM.%26aulast%3DHollingshead%26aufirst%3DB.%2BD.%26aulast%3DJussif%26aufirst%3DJ.%26aulast%3DKnafels%26aufirst%3DJ.%2BD.%26aulast%3DLimburg%26aufirst%3DD.%2BC.%26aulast%3DLin%26aufirst%3DD.%26aulast%3DLin%26aufirst%3DT.%2BH.%26aulast%3DPierce%26aufirst%3DB.%2BS.%26aulast%3DSaiah%26aufirst%3DE.%26aulast%3DSharma%26aufirst%3DR.%26aulast%3DSymanowicz%26aufirst%3DP.%2BT.%26aulast%3DTelliez%26aufirst%3DJ.%2BB.%26aulast%3DTrujillo%26aufirst%3DJ.%2BI.%26aulast%3DVajdos%26aufirst%3DF.%2BF.%26aulast%3DVincent%26aufirst%3DF.%26aulast%3DWan%26aufirst%3DZ.%2BK.%26aulast%3DXing%26aufirst%3DL.%26aulast%3DYang%26aufirst%3DX.%26aulast%3DYang%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DL.%26atitle%3DDual%2520inhibition%2520of%2520TYK2%2520and%2520JAK1%2520for%2520the%2520treatment%2520of%2520autoimmune%2520diseases%253A%2520discovery%2520of%2520%2528%2528S%2529-2%252C2-difluorocyclopropyl%2529%2528%25281R%252C5S%2529-3-%25282-%2528%25281-methyl-1H-pyrazol-4-yl%2529amino%2529pyrimidin-4-yl%2529-3%252C8-diazabicyclo%255B3.2.1%255Doctan-8-yl%2529methanone%2520%2528PF-06700841%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D8597%26epage%3D8612%26doi%3D10.1021%2Facs.jmedchem.8b00917" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kettle, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grimster, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawatkar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Throner, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woessner, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bebernitz, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bell, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruston, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winter-Holt, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lyne, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vasbinder, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chuaqui, C.</span></span> <span> </span><span class="NLM_article-title">Abstract 979: Discovery of the JAK1 selective kinase inhibitor AZD4205</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>77</i></span>,  <span class="NLM_fpage">979</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=77&publication_year=2017&pages=979&author=J.+G.+Kettleauthor=Q.+Suauthor=N.+Grimsterauthor=S.+Kawatkarauthor=S.+Thronerauthor=R.+Woessnerauthor=H.+Chenauthor=G.+Bebernitzauthor=K.+Bellauthor=E.+Andersonauthor=L.+Rustonauthor=J.+Winter-Holtauthor=P.+Lyneauthor=M.+Vasbinderauthor=C.+Chuaqui&title=Abstract+979%3A+Discovery+of+the+JAK1+selective+kinase+inhibitor+AZD4205"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKettle%26aufirst%3DJ.%2BG.%26aulast%3DSu%26aufirst%3DQ.%26aulast%3DGrimster%26aufirst%3DN.%26aulast%3DKawatkar%26aufirst%3DS.%26aulast%3DThroner%26aufirst%3DS.%26aulast%3DWoessner%26aufirst%3DR.%26aulast%3DChen%26aufirst%3DH.%26aulast%3DBebernitz%26aufirst%3DG.%26aulast%3DBell%26aufirst%3DK.%26aulast%3DAnderson%26aufirst%3DE.%26aulast%3DRuston%26aufirst%3DL.%26aulast%3DWinter-Holt%26aufirst%3DJ.%26aulast%3DLyne%26aufirst%3DP.%26aulast%3DVasbinder%26aufirst%3DM.%26aulast%3DChuaqui%26aufirst%3DC.%26atitle%3DAbstract%2520979%253A%2520Discovery%2520of%2520the%2520JAK1%2520selective%2520kinase%2520inhibitor%2520AZD4205%26jtitle%3DCancer%2520Res.%26date%3D2017%26volume%3D77%26spage%3D979" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Soars, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grime, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sproston, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Webborn, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riley, R. J.</span></span> <span> </span><span class="NLM_article-title">Use of hepatocytes to assess the contribution of hepatic uptake to clearance in vivo</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>35</i></span>,  <span class="NLM_fpage">859</span>– <span class="NLM_lpage">865</span>, <span class="refDoi"> DOI: 10.1124/dmd.106.014464</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01346&amp;key=10.1124%2Fdmd.106.014464" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01346&amp;key=17344337" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01346&amp;key=1%3ACAS%3A528%3ADC%252BD2sXmt1ait7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2007&pages=859-865&author=M.+G.+Soarsauthor=K.+Grimeauthor=J.+L.+Sprostonauthor=P.+J.+Webbornauthor=R.+J.+Riley&title=Use+of+hepatocytes+to+assess+the+contribution+of+hepatic+uptake+to+clearance+in+vivo&doi=10.1124%2Fdmd.106.014464"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Use of hepatocytes to assess the contribution of hepatic uptake to clearance in vivo</span></div><div class="casAuthors">Soars, Matthew G.; Grime, Ken; Sproston, Joanne L.; Webborn, Peter J. H.; Riley, Robert J.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism and Disposition</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">859-865</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">0090-9556</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">The wealth of information that has emerged in recent years detailing the substrate specificity of hepatic transporters necessitates an investigation into their potential role in drug elimination.  Therefore, an assay in which the loss of parent compd. from the incubation medium into hepatocytes ("media loss" assay) was developed to assess the impact of hepatic uptake on unbound drug intrinsic clearance in vivo (CLint ub in vivo).  Studies using conventional hepatocyte incubations for a subset of 36 AstraZeneca new chem. entities (NCEs) resulted in a poor projection of CLint ub in vivo (r2 = 0.25, p = 0.002, av. fold error = 57).  This significant underestimation of CLint ub in vivo suggested that metab. was not the dominant clearance mechanism for the majority of compds. examd.  However, CLint ub in vivo was described well for this dataset using an initial compd. "disappearance" CLint obtained from media loss assays (r2 = 0.72, p = 6.3 × 10-11, av. fold error = 3).  Subsequent studies, using this method for the same 36 NCEs, suggested that the active uptake into human hepatocytes was generally slower (3-fold on av.) than that obsd. with rat hepatocytes.  The accurate prediction of human CLint ub in vivo (within 4-fold) for the marketed drug transporter substrates montelukast, bosentan, atorvastatin, and pravastatin confirmed further the utility of this assay.  This work has described a simple method, amenable for use within a drug discovery setting, for predicting the in vivo clearance of drugs with significant hepatic uptake.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo_EFTWIivbs7Vg90H21EOLACvtfcHk0ljC8WoBEPK9xw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXmt1ait7Y%253D&md5=3298ecc4f3a3e3109162c5ebbf89fda4</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1124%2Fdmd.106.014464&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.106.014464%26sid%3Dliteratum%253Aachs%26aulast%3DSoars%26aufirst%3DM.%2BG.%26aulast%3DGrime%26aufirst%3DK.%26aulast%3DSproston%26aufirst%3DJ.%2BL.%26aulast%3DWebborn%26aufirst%3DP.%2BJ.%26aulast%3DRiley%26aufirst%3DR.%2BJ.%26atitle%3DUse%2520of%2520hepatocytes%2520to%2520assess%2520the%2520contribution%2520of%2520hepatic%2520uptake%2520to%2520clearance%2520in%2520vivo%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2007%26volume%3D35%26spage%3D859%26epage%3D865%26doi%3D10.1124%2Fdmd.106.014464" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Camenisch, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alsenz, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van de Waterbeemd, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Folkers, G.</span></span> <span> </span><span class="NLM_article-title">Estimation of permeability by passive diffusion through Caco-2 cell monolayers using the drugs’ lipophilicity and molecular weight</span>. <i>Eur. J. Pharm. Sci.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">313</span>– <span class="NLM_lpage">319</span>, <span class="refDoi"> DOI: 10.1016/S0928-0987(97)10019-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01346&amp;key=10.1016%2FS0928-0987%2897%2910019-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01346&amp;key=1%3ACAS%3A528%3ADyaK1cXmtl2nsr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=1998&pages=313-319&author=G.+Camenischauthor=J.+Alsenzauthor=H.+van+de+Waterbeemdauthor=G.+Folkers&title=Estimation+of+permeability+by+passive+diffusion+through+Caco-2+cell+monolayers+using+the+drugs%E2%80%99+lipophilicity+and+molecular+weight&doi=10.1016%2FS0928-0987%2897%2910019-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Estimation of permeability by passive diffusion through Caco-2 cell monolayers using the drugs' lipophilicity and molecular weight</span></div><div class="casAuthors">Camenisch, Gian; Alsenz, Jochem; van de Waterbeemd, Han; Folkers, Gerd</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmaceutical Sciences</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">313-319</span>CODEN:
                <span class="NLM_cas:coden">EPSCED</span>;
        ISSN:<span class="NLM_cas:issn">0928-0987</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ireland Ltd.</span>)
        </div><div class="casAbstract">A recently developed, new theor. absorption model for passive diffusion through biol. membranes describing the dependency of membrane permeability on lipophilicity and mol. size, predicts different sigmoid-hyperbolic permeability-lipophilicity relationships for different mol. wt. ranges.  This model has been tested with exptl. in vitro cultured epithelial cell (Caco-2) permeability data for structurally diverse drugs differing in lipophilicity, ionization state and mol. size.  These data were pooled with literature values.  Using this simple physicochem. approach, the permeability of a compd. through Caco-2 cells by passive diffusion can be predicted from the compds.' distribution coeff. in 1-octanol/water (log Doct) and its mol. wt. (MW).  Deviations from this expected behavior may point to the involvement of biol. components in the transport process, which may require further investigations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrPZi9YD6wRi7Vg90H21EOLACvtfcHk0liFBZybkgDDDw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXmtl2nsr0%253D&md5=034f5764416eb407cc22d2119c1dce3c</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1016%2FS0928-0987%2897%2910019-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0928-0987%252897%252910019-7%26sid%3Dliteratum%253Aachs%26aulast%3DCamenisch%26aufirst%3DG.%26aulast%3DAlsenz%26aufirst%3DJ.%26aulast%3Dvan%2Bde%2BWaterbeemd%26aufirst%3DH.%26aulast%3DFolkers%26aufirst%3DG.%26atitle%3DEstimation%2520of%2520permeability%2520by%2520passive%2520diffusion%2520through%2520Caco-2%2520cell%2520monolayers%2520using%2520the%2520drugs%25E2%2580%2599%2520lipophilicity%2520and%2520molecular%2520weight%26jtitle%3DEur.%2520J.%2520Pharm.%2520Sci.%26date%3D1998%26volume%3D6%26spage%3D313%26epage%3D319%26doi%3D10.1016%2FS0928-0987%2897%2910019-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Abraham, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abraham, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Acree, W. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aliev, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leo, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whaley, W. L.</span></span> <span> </span><span class="NLM_article-title">An NMR method for the quantitative assessment of intramolecular hydrogen bonding; application to physicochemical, environmental, and biochemical properties</span>. <i>J. Org. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>79</i></span>,  <span class="NLM_fpage">11075</span>– <span class="NLM_lpage">11083</span>, <span class="refDoi"> DOI: 10.1021/jo502080p</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jo502080p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01346&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvVensLrM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=79&publication_year=2014&pages=11075-11083&author=M.+H.+Abrahamauthor=R.+J.+Abrahamauthor=W.+E.+Acreeauthor=A.+E.+Alievauthor=A.+J.+Leoauthor=W.+L.+Whaley&title=An+NMR+method+for+the+quantitative+assessment+of+intramolecular+hydrogen+bonding%3B+application+to+physicochemical%2C+environmental%2C+and+biochemical+properties&doi=10.1021%2Fjo502080p"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">An NMR Method for the Quantitative Assessment of Intramolecular Hydrogen Bonding; Application to Physicochemical, Environmental, and Biochemical Properties</span></div><div class="casAuthors">Abraham, Michael H.; Abraham, Raymond J.; Acree, William E.; Aliev, Abil E.; Leo, Al J.; Whaley, William L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Organic Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">79</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">11075-11083</span>CODEN:
                <span class="NLM_cas:coden">JOCEAH</span>;
        ISSN:<span class="NLM_cas:issn">0022-3263</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">1H NMR chem. shifts have been obtained in the solvents deuterochloroform and DMSO.  The difference in the chem. shifts of an OH or NH group in these two solvents, Δδ = δ(DMSO) - δ(CDCl3), can be converted into the hydrogen bond acidity, A, of the group using the equation A = 0.0065 + 0.133Δδ.  The NMR A value, ANMR, can be used as a quant. assessment of intramol. hydrogen bonding.  We list values of Δδ and ANMR for 55 compds. contg. an OH group and 60 compds. with an NH group.  For the hydroxy compds., if A > 0.5 then the OH group is not part of an intramol. hydrogen bond, but if A < 0.1 then the OH group forms part of an intramol. hydrogen bond.  For NH compds., if A > 0.16 the NH group is not part of an intramol. hydrogen bond, and if A < 0.05 the NH group is part of an intramol. hydrogen bond.  No comparison compds. are needed, and the method is extremely simple.  We further show how it is possible to relate intramol. hydrogen bonding to the actual effect on values of a no. of physicochem., environmental, and biochem. properties.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpS3GZXQi7robVg90H21EOLACvtfcHk0liFBZybkgDDDw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvVensLrM&md5=b5e9948a04237fadb3b4fc3237bde8b1</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1021%2Fjo502080p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo502080p%26sid%3Dliteratum%253Aachs%26aulast%3DAbraham%26aufirst%3DM.%2BH.%26aulast%3DAbraham%26aufirst%3DR.%2BJ.%26aulast%3DAcree%26aufirst%3DW.%2BE.%26aulast%3DAliev%26aufirst%3DA.%2BE.%26aulast%3DLeo%26aufirst%3DA.%2BJ.%26aulast%3DWhaley%26aufirst%3DW.%2BL.%26atitle%3DAn%2520NMR%2520method%2520for%2520the%2520quantitative%2520assessment%2520of%2520intramolecular%2520hydrogen%2520bonding%253B%2520application%2520to%2520physicochemical%252C%2520environmental%252C%2520and%2520biochemical%2520properties%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D2014%26volume%3D79%26spage%3D11075%26epage%3D11083%26doi%3D10.1021%2Fjo502080p" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lenz, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morin, P. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weston, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bayrakdarian, M.</span></span> <span> </span><span class="NLM_article-title">Reactive metabolite trapping screens and potential pitfalls: bioactivation of a homomorpholine and formation of an unstable thiazolidine adduct</span>. <i>Chem. Res. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">968</span>– <span class="NLM_lpage">980</span>, <span class="refDoi"> DOI: 10.1021/tx5000409</span> </span><div class="citationLinks">[<a href="/doi/10.1021/tx5000409" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01346&amp;key=1%3ACAS%3A528%3ADC%252BC2cXosFaisbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2014&pages=968-980&author=E.+M.+Lenzauthor=S.+Martinauthor=R.+Schmidtauthor=P.+E.+Morinauthor=R.+Smithauthor=D.+J.+Westonauthor=M.+Bayrakdarian&title=Reactive+metabolite+trapping+screens+and+potential+pitfalls%3A+bioactivation+of+a+homomorpholine+and+formation+of+an+unstable+thiazolidine+adduct&doi=10.1021%2Ftx5000409"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Reactive Metabolite Trapping Screens and Potential Pitfalls: Bioactivation of a Homomorpholine and Formation of an Unstable Thiazolidine Adduct</span></div><div class="casAuthors">Lenz, Eva. M.; Martin, Scott; Schmidt, Ralf; Morin, Pierre-Emmanuel; Smith, Robin; Weston, Daniel J.; Bayrakdarian, Malken</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Research in Toxicology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">968-980</span>CODEN:
                <span class="NLM_cas:coden">CRTOEC</span>;
        ISSN:<span class="NLM_cas:issn">0893-228X</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Successful early attrition of potential problematic compds. is of great importance in the pharmaceutical industry.  The lead compd. in a recent project targeting neuropathic pain was susceptible to metabolic bioactivation, which produced reactive metabolites and showed covalent binding to protein.  Therefore, as a part of the backup series for this compd. several structural modifications were explored to mediate the reactive metabolite and covalent binding risk.  A homomorpholine contg. series of compds. was identified without compromising potency.  However, when these compds. were incubated with human liver microsomes in the presence of GSH, Cys-Gly adducts were identified, instead of intact GSH conjugates.  This article examines the formation of the Cys-Gly adduct with AZX ([M+H]+ 486) as a representative compd. for this series.  The AZX-Cys-Gly-adduct ([M+H]+ 662) showed evidence of ring contraction by formation of a thiazolidine-glycine and was addnl. shown to be unstable.  During its isolation for structural characterization by 1H NMR spectroscopy, it was found to have decompd. to a product with [M+H]+ 446.  The characterization and identification of this labile GSH-derived adduct using LC-MS/MS and 1H NMR are described, along with observations around stability.  In addn., various structurally related trapping reagents were employed in an attempt to further investigate the reaction mechanism along with a methoxylamine trapping expt. to confirm the structure of the postulated reactive intermediate.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpPS272xX7pjbVg90H21EOLACvtfcHk0liFBZybkgDDDw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXosFaisbY%253D&md5=df277154a86526015e0cb770b75bf756</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1021%2Ftx5000409&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Ftx5000409%26sid%3Dliteratum%253Aachs%26aulast%3DLenz%26aufirst%3DE.%2BM.%26aulast%3DMartin%26aufirst%3DS.%26aulast%3DSchmidt%26aufirst%3DR.%26aulast%3DMorin%26aufirst%3DP.%2BE.%26aulast%3DSmith%26aufirst%3DR.%26aulast%3DWeston%26aufirst%3DD.%2BJ.%26aulast%3DBayrakdarian%26aufirst%3DM.%26atitle%3DReactive%2520metabolite%2520trapping%2520screens%2520and%2520potential%2520pitfalls%253A%2520bioactivation%2520of%2520a%2520homomorpholine%2520and%2520formation%2520of%2520an%2520unstable%2520thiazolidine%2520adduct%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D2014%26volume%3D27%26spage%3D968%26epage%3D980%26doi%3D10.1021%2Ftx5000409" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6RFI" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6RFI','PDB','6RFI'); return false;">PDB: 6RFI</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5T1T" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5T1T','PDB','5T1T'); return false;">PDB: 5T1T</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6RFJ" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6RFJ','PDB','6RFJ'); return false;">PDB: 6RFJ</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i44"><a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.9b01346">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_08725"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a class="ext-link" href="/">ACS Publications website</a> at DOI: <a class="ext-link" href="/doi/abs/10.1021/acs.jmedchem.9b01346">10.1021/acs.jmedchem.9b01346</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Assay statistical analyses; quantum mechanics calculations; crystallographic data (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.9b01346/suppl_file/jm9b01346_si_001.pdf">PDF</a>)</p></li><li><p class="inline">Molecular formula strings (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.9b01346/suppl_file/jm9b01346_si_002.csv">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b01346/suppl_file/jm9b01346_si_001.pdf">jm9b01346_si_001.pdf (242.47 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b01346/suppl_file/jm9b01346_si_002.csv">jm9b01346_si_002.csv (1.32 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.9b01346&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.9b01346%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2019.62.issue-21%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.9b01346" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                4MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"6799174129fa3d2a","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
